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Recently, we found upregulation of fibroblast growth factor receptor 4 (FGFR4) in a subset of 
hepatocellular carcinoma (HCC). Here, we provide mechanistic insight into the role of FGFR4-
mediated signaling for the aggressive behaviour of HCC cells.  
To overexpress FGFR4, hepatoma/hepatocarcinoma cells were transfected with a construct coding 
for FGFR4. For down-modulation of endogenous FGFR4 we used siRNA or adenoviral infection 
with dominant-negative FGFR4 constructs being either kinase dead (kdFGFR4) or coding for the 
auto-inhibitory soluble domain (solFGFR4).  
FGFR4 overexpression in non-tumourigenic hepatocarcinoma cells significantly reduced cell-matrix 
adhesion, enabled cells to grow anchorage-independently in soft agar, to disintegrate the lymph-
/blood-endothelial barrier for intra-/extravasation of tumour cells, and to form tumours in SCID mice. 
Transcriptome analysis revealed altered expression of genes involved in cell-matrix interactions. 
Conversely, in highly tumourigenic cell lines kdFGFR4 or solFGFR4 lowered the proportion of cells 
in S-phase of the cell cycle, enhanced the G0/G1 and G2/M-phase proportions, reduced anchorage-
independent growth in vitro, and attenuated disintegration of the lymph-/blood-endothelium and 
tumour formation in vivo. These findings were confirmed by altered expression profiles of genes 
being important for late stages of cell division.  
Deregulated FGFR4 expression appears to be one of the key drivers of the malignant phenotype of 
HCC cells. Accordingly, blockade of FGFR4-mediated signaling by soluble dominant-negative 
constructs, like solFGFR4, may be a feasible and promising therapeutic approach to antagonize 
aggressive behaviour of hepatoma/hepatocarcinoma cells.   
 
Summary:  Here, we found that deregulated FGFR4 expression appears to be one of the key drivers 
of the malignant phenotype of hepatoma/hepatocarcinoma cells. Accordingly, blockade of FGFR4-
mediated signalling may be a promising therapeutic approach to antagonize aggressive behaviour of 
the cells. 










































































Hepatocellular carcinoma (HCC) is among the five most common cancer entities  worldwide,  with  
about  half a  million  new  cases diagnosed  annually,  and an almost equal  number  of  deaths, 
mostly due to early metastatic spread. About 15% of HCC patients only are candidates for surgical 
resection or liver transplantation. Standard chemotherapy is not applicable due to the intrinsically 
high chemoresistance of this tumour type. New strategies offering improvements in therapeutic 
efficacy and disease outcome are eagerly sought (1-3).    
Upregulation of growth and survival factors is an important hallmark of hepatocarcinogenesis and a 
major driving force for tumour progression and dissemination (1-4). We have recently found over-
expression of fibroblast growth factor receptor 4 (FGFR4) in almost 50% of HCC cases investigated, 
which agrees with observations of another group (5,6). Also, FGFR4-ligands, like FGF2 and FGF8-
subfamily members were found to be upregulated in many HCC cases investigated (5-10). FGFR4 
belongs to a RTK family of genes with similar protein structures (FGFR1-4) (7-11). Upon ligand 
binding the phosphorylated and dimerized form of FGFR4 recruits several adapter proteins, like 
FRS2α, and activates several signaling pathways including mitogen-activated protein kinase and 
phosphoinositide 3-kinase cascades. In dependence on the ligand, a great variety of cell-biological 
and biochemical processes may be affected, like cell cycle regulation, survival, differentiation, 
migration, adhesion, and/or bile acid metabolism (8-12). There is some evidence that FGFR4 may 
contribute to the development and progression of HCC, e.g., siRNA against FGF19 or antibodies 
targeting the FGF19-FGFR4 axis impaired the tumourigenicity of Huh7-cells, while this approach 
lacked significant effects in HepG2, SNU182 and SNU423 hepatoma/hepatocarcinoma cells (13-16).  
Different FGFR ligands may impact in a specific way on one and the same receptor, as shown by the 
highly divergent molecular and biological effects of FGF7 and FGF10 on FGFR2b-mediated 
signaling (17). Also FGF19 exerts unique features with regard to FGFR4-activation and metabolic 
effects in hepatocytes, which are not shared by other FGFR4-ligands (8,11,12). We therefore used 
several hepatoma and recently established hepatocarcinoma cell lines which show inherent 
overexpression of FGF8-subfamily members, like 59% of the HCC cases studied (5,18). Since many 
FGFR4 ligands are upregulated in HCC, we targeted the receptor and applied not only siRNA and 
kinase-dead FGFR4-construct but also a soluble FGFR4-protein, which may be applicable in the near 
future, as exemplified by soluble decoy FGFR1c receptor being currently tested in a phase-1 clinical 
trial to treat solid tumours (19). In addition a novel, 3-dimensional bulk invasion assay was used to 
analyse the mechanism of tumour cell-mediated disruption of blood or lymphatic vessels (20). For 
the first time we show that FGFR4 over-expression reduced cell adhesion and enhanced anchorage-








































































independent growth, and disintegration of the lymph/blood-endothelial barrier. The boosted 
aggressive phenotype was confirmed by accelerated tumour formation of the HCC cells in SCID 
mice. In contrast, transfection with FGFR4-targeting siRNA or with kinase-deficient or soluble forms 
of FGFR4 impaired the malignant cell phenotype in vitro and tumour formation in vivo. Thus, use of 
soluble FGFR4-protein appeared as promising therapeutic option. In-depth investigations revealed 
that deregulations in FGFR4-mediated signaling affect genes involved in cell-matrix interactions, 
chromosome segregation, and/or cytokinesis. These findings together provide mechanistic insight 





Cells. HepG2 and CCl-13 were obtained from ATCC (Rockville, MD). HCC-1.2. and HCC-3 lines, 
and telomerase-immortalised human lymphendothelial cells (LEC) and blood endothelial cells (BEC) 
were recently established and characterized (18,21). Authentication of the lines was performed by 
short-tandem-repeat-analyses, parallel to in-vitro studies. Determination of cell proliferation and cell 
death followed previous descriptions (5).  
siRNA. SilencerSelect siRNA, targeting human FGFR4 and nonsilencing SilencerSelect 
scrambled siRNA (No AM4390843) were obtained from LifeTechnologies (Vienna/Austria). Further 
details see (5).   
Vectors and adenoviral constructs. pcDNA3.1-vectors with(out) human VSV-tagged FGFR4 were 
kindly provided by Axel Ullrich (Max Planck Institute, Martinsried/FRG). The constructs were 
introduced into HCC-1.2 cells via FuGene® (Roche, Graz/Austria). Neomycin (PAA Laboratories, 
Cölbe/FRG; 0.5mg/ml medium) served to generate clones.  
Adenoviral expression vectors for FGFRs have been described previously (22). Plasmids coding for 
human FGFR4 and solFGR4 were kindly provided by Shereen Ezzat (Ontario Cancer Institute, 
Canada) (23). The open reading frame was subcloned into pENTR1A (Invitrogen, Carlsbad/CA) with 
KpnI/XhoI. To generate a kinase-deficient variant (kdFGFR4), the kinase domain was removed by 
digestion with BglII/NotI and replaced by the Bg1II/NotI-digested sequence of cyan fluorescent 
protein (CFP).  The resulting FGFR4-CFP chimera and the solFGFR4 were transferred into 
pAd/CMV/V5-Dest by Gateway recombination (Invitrogen). Virus amplification was done as 
described and an adenovirus expressing GFP was used as control (24). Virus titers were determined 
with the Adeno-X Rapid Titer Kit (Clontech, Mountain View/CA). Cells were exposed to the 
constructs at the lowest multiplicity of infection (MOI) leading to 100% cell infection (titrated by a 









































































Clonogenicity. 48hrs after transfection cells were plated in medium containing 10% FCS. At clone 
appearance in controls, cells were fixed in acetone/methanol (v50:50) and stained with 0.01% of 
crystal violet.  
Soft agar assay. 48hrs after transfection cells were suspended in 20% FCS-RPMI containing 0.3% 
agar (Sigma) and were seeded onto 20% FCS-RPMI with 0.6% agar. Three-four weeks later the 
number of colonies (>10 cells) was determined.    
Cell adhesion assay. 96-well plates were coated with type 1 collagen or fibronectin (Sigma, 
St.Louis/MO). Cells were plated at a density of 5x103 per well. After incubation for 60, 90, or 
120min at 37°C, medium was removed and wells were washed twice with 1xPBS to eliminate non-
adherent cells. The number of adherent cells was determined by the EZ4U assay.  
CCID (circular chemorepellent-induced defects) assay. 1x103 cells were incubated in 150 µl 
EGM2-MV medium (Lonza, Walkersville/MD) containing 20% methylcellulose (M-0512, Sigma) in 
round bottom microtitre plates (BD-Biosciences) to allow spheroid formation within 48hrs. 
Spheroids were washed in PBS and transferred to confluent LEC/BEC monolayers, kept in EGM2-
MV medium and stained by cytotracker green (2µg/ml for1hr, Invitrogen); 4hrs later, the spheroid 
and the CCID area in the LEC/BEC monolayer underneath were photographed. For each condition, 
the size of >10 spheroids and appendant CCIDs was measured by Image-J-software. For details see 
suppl.figs.1 and 2. 
Gene expression analyses. For qRT-PCR, the extracted RNA was processed and measured by the 
ABI-Prism/7500 Sequence Detection System (Applied-Biosystems, Foster City/CA) using TaqMan-
based assays (Applied-Biosystems), as described (5).  
For whole genome expression analyses, the extracted RNA was subjected to quality control (2100 
Bioanalyzer-System, Agilent, StClara/CA) and prepared by “Low RNA Input Linear Amplification 
Kit Plus”, the “RNA Spike-In Kit” and the “Gene Expression Hybridization Kit” according to the 
manufacturer´s instructions (Agilent). The 4x44k microarray (Agilent) was used as a two-color array 
and was analysed by the G2505B-Microarray-Scanner (Agilent). Samples were analysed in triplicate 
in each individual experiment. Per run, data were processed by a combination of “Feature Extraction 
Software” and “GeneSpring-GX” (Agilent). Fold-change cutoffs (>2/<0.5) were used to select 
upregulated and downregulated genes, respectively. Differential gene expression was detected by t-
test and Benjamini-Hochberg correction for multiple testing to ensure a false discovery rate less than 
0.05. The functional annotation analysis on the selected lists was carried out using (i) gene set 
enrichment analysis (GSEA) to identify significantly enriched curated gene sets (version 3.0) among 
those included in the MSigDB database (http://www.broadinstitute.org/gsea/msigdb/index.jsp) and 








































































(ii) Ingenuity Pathway Analysis (IPA, version 8.8; Ingenuity Systems, Redwood City, CA; 
www.ingenuity.com) (24). Further details see suppl.tab.5 and 6.  
Immunoblotting. Protein purification, separation, and detection followed published protocols (5,18). 
Antibodies used: anti-VSV tag (eBioscience, San Diego/CA); anti-FGFR4 (sc-124 and sc-9006; 
Santa-Cruz Inc/CA), anti-ß-actin (Sigma, St Louis, MO), anti-phospho-PLCγ1(Tyr783) (Cell 
Signaling, Danvers, MA), anti-PLCγ1 (Cell Signaling), anti-phospho-p44/42 MAPK (ERK 1/2) 
(Thr202/Tyr204) (Cell Signaling), anti-ERK1/2 (Sigma), anti-phospho-AKT (Ser437) (Cell 
Signaling), anti-AKT (Cell Signaling). Band intensities were quantified by densitometry 
(ImageQuant 5.0-software; GE-Healthcare).  
Animal study. 1x106 cells were injected subcutaneously into both flanks of SCID/BALBc mice by 
standard procedures. HCC-1.2, HCC-3, and HepG2 cells were applied in serum-free medium 
containing 50% matrigel (Becton-Dickinson). The number and diameter of palpable tumours were 
determined thrice a week. When the local tumour affected the status of the host, the animal was 
sacrificed for necropsy. The experiments were performed according to the Austrian guidelines for 
animal care and protection.  









































































Upregulation of FGFR4 enhances the aggressive phenotype of hepatocarcinoma cells. We 
recently found upregulation of FGFR4 in a subset of HCC (5). We therefore asked whether FGFR4 
expression levels affect growth and aggressive phenotype of malignant hepatocytes. The 
hepatoma/hepatocarcinoma cell-lines used differ greatly in clonogenicity, anchorage-dependency in 
vitro, and tumourigenicity in vivo. Thus, CCl-13 cells are highly clonogenic in two different assays 
and tumourigenic in SCID mice, while HCC-1.2 cells are (almost) incapable of forming clones and 
tumours. HCC-3 and HepG2 cells rank in between these two extremes (fig.1). Spheroids of these 
hepatoma/hepatocarcinoma cells, attached to LEC or BEC monolayers, were used to simulate a 
critical step of metastasis, i.e., the gaps/CCID formed in the monolayer mimic entry gates for 
intravasating tumour emboli. The cell lines also vary in their capacity to disintegrate these lymph-
/blood-endothelial barriers and to form CCID, with CCl-13 being most aggressive in this respect and 
HCC-1.2 forming only moderate CCID in LEC/BEC monolayers (fig.1D, E, and F; suppl.figs.1 and 
2).  
We generated HCC-1.2 clones with stable overexpression of FGFR4 (Cl1-Cl4). The resulting cells 
showed considerably elevated levels of FGFR4 mRNA and protein and enhanced levels of 
phosphorylated ERK and phosphorylated phospholipase-Cγ1 (PLCG1), which indicates activation of 
the major FGFR-mediated pathways under our experimental conditions (suppl.fig.3) (8). When 
analysing the transcriptome profiles of clones 1 and 3, we found significant, >2-fold downregulations 
of 1295 and >2-fold upregulations of 1119 genes (suppl.tab.2). Gene set enrichment or Ingenuity 
showed that many of the deregulated genes are involved in bile acid- and phase I&II-metabolism as 
well as in lipid and carbohydrate metabolism, confirming that our cells show known, hepatocyte-
specific reaction patterns towards FGFR4-mediated signaling (suppl.tab.5 and 6) (11,12). 
Furthermore, many deregulations affected pathways being directly or indirectly involved in PLCG- 
and MAPK-mediated signaling. Similar alterations in the expression level of critical genes became 
evident in human HCC samples with high FGFR4 expression providing evidence that the 
hepatocarcinoma cells used are a relevant tool to study FGFR4-driven alterations in 
hepatocarcinogenesis (suppl.tab.7).  
In contrast to vector controls, FGFR4-overexpressing cells became capable to form tumours in SCID 
mice (fig.2C). Studies on the mechanisms confering tumourigenicity to HCC-1.2 cells revealed that 
FGFR4 upregulation had little effect on viability, cell-cycle, or apoptotic activity of the cells (data 
not shown), but enhanced dramatically the clone forming capacity of the cells at low density (fig.2A). 
Transcriptome analysis showed that many of the affected genes are involved in cell adhesion, e.g., 








































































several members of the collagen, integrin, laminin, lectin, cadherin or protocadherin family were 
found to be deregulated (tab.1). In line with this observation, adherence of most of the clones to 
polystyrene, collagen and to some extent also to fibronectin was significantly reduced and growth in 
soft-agar was greatly increased (fig.2B,E). We also found upregulation of genes involved in 
metastasis (suppl.tab.2 and 5). Accordingly, the capacity of clones to induce CCID in BEC 
monolayers was greatly increased (fig.2D). This may indicate that overexpressed FGFR4 confers the 
ability for anchorage-independent growth and for invasiveness into blood-/lymph-endothelium, one 
of the hallmarks of a malignant cell phenotype.  
 
Knock-down of FGFR4 reduces clone forming capacity of hepatocarcinoma cell lines. Next, we 
down-modulated the expression of FGFR4 by siRNA, which significantly reduced mRNA and 
protein levels in the cells investigated (fig. 3A and 3B). Viability (fig.3C) as well as cell cycle and 
apoptotic activity of the cells (not shown) was not altered, but the formation of clones at low density 
and in soft agar was significantly reduced (fig.3D and E). Scrambled siRNA (siSCR) did not impact 
on any of the test end points (not shown). These results provide further evidence that endogenous 
FGFR4 is essential for the pro-tumourigenic phenotype of hepatocarcinoma cells. 
 
Blockade of FGFR4-induced signaling antagonizes tumour formation. To further study the 
relevance of FGFR4 in malignant transformation we interfered with FGFR4-mediated signaling. 
Cells were infected with adenoviral constructs coding for (i) dominant negative FGFR4, in which the 
kinase domain had been replaced by CFP (kdFGFR4), or (ii) the soluble part of FGFR4 (solFGFR4) 
which is also considered to act dominant-negatively by interfering with receptor-ligand interactions 
(23). This resulted in high expression of the constructs at the protein level and lowered 
phosphorylation of the FGFR binding adaptor protein FRS2α (supplementary figs.4 and 5). Impaired 
FGFR4 signaling resulted in dramatic reduction of clonogenicity and anchorage-independent growth 
in all 4 cell lines (fig.4A, B) and lowered the cells´ capacity to induce gaps in LEC/BEC monolayers 
(fig.4G). Correspondingly, tumour forming capacity tested with the 2 most tumourigenic lines, 
HepG2 and CCl-13, was significantly attenuated (fig.4C). These findings suggest that blockade of 
FGFR4-mediated signaling is a promising approach to antagonize tumour formation by hepatoma 
/hepatocarcinoma cells.  
 
Blockade of FGFR4-mediated signaling may affect late stages of cell proliferation. Studies on 
the mechanisms underlying the reduced tumourigenicity of cell lines revealed that solFGFR4, and 
more strongly kdFGFR4, reduced the viability of the cells and increased the apoptotic activity 








































































(fig.4D,E). Coincidently a considerable percentage of cells was shifted from the S to the G0/G1 and 
G2/M phase of the cell cycle (fig.4F). Transcriptome profiles revealed that FGFR4 blockade affected 
mostly genes involved in the formation and/or function of the spindle apparatus or kinetochore 
complex, as outlined in detail in the discussion (tab.1, supplementary tabs.3 and 4). Furthermore, the 
transcripts of genes, which are involved in the initiation and propagation of DNA replication (e.g. 
CDC7, NOL8) were reduced, while negative regulators of cell cycle (e.g. C13ORF15) tended to be 
expressed at an enhanced level. Many of these alterations occurred in both, kdFGFR4 or solFGFR4-
transfected cells, indicating a similar consequence being more or less independent of the mode of 
FGFR4 blockade. 
To conclude, these findings strongly suggest that expression and function of FGFR4 is an important 
determinant of the aggressive phenotype of the hepatoma/hepatocarcinoma cell lines tested. 
Discussion 
Here we show that FGFR4 appears to be a key driver of the aggressive phenotype of 
hepatoma/hepatocarcinoma cells, as outlined in the following.  
For our mechanistic studies, we chose a panel of cell-lines, e.g. in barely aggressive HCC-1.2 cells 
upregulated FGFR4 expression elevated considerably clone formation, anchorage-independent and 
invasive growth and tumourigenicity. For proof of principle we chose the opposite approach and 
interfered in aggressive hepatoma/hepatocarcinoma cells with FGFR4 by (i) siRNA-mediated knock-
down, (ii) kinase-dead kdFGFR4 for non-functional dimers with endogenous FGFR4, and (iii) 
solFGFR4 which consists of the IgI-loop/acidic box, lacks ligand-binding domains, and nevertheless 
neutralizes the mitogenic effects of FGFR4 ligands (23). The IgI–IgII linker region of FGFR1-3 
serves as hinge allowing the IgI-loop/acidic box to auto-inhibit the ligand-binding domain (26). Since 
FGFR4 harbours the shortest IgI–IgII linker, solFGFR4 may compensate for this lack and compete 
with FGFs for binding (23,27). Here, solFGFR4 lowered phosphorylated FRS2α and altered the 
expression profiles to a similar extent as kdFGFR4 (suppl.fig.5). When compared to siRNA, 
solFGFR4 and kdFGFR4 caused more pronounced effects. The dominant-negative constructs 
decreased viability, anchorage-independent and invasive growth, and tumour formation in vivo. 
Thus, our data provide strong evidence that up- or downregulation of FGFR4 increases or decreases 
the aggressive phenotype of malignant hepatocytes, respectively. Furthermore, soluble FGFR4-
protein appears as a very promising approach in the therapy of HCC, similar to FP-1039, a soluble 
decoy FGFR1c receptor being currently applied in a phase-1 clinical trial to treat solid tumours (19; 
http://www.fiveprime.com/pipeline/fp-1039).  
 








































































An important hallmark of aggressive tumour cells is their capability to intravasate into the blood or 
lymphatic vasculature and to extravasate for metastasis formation. Since hepatocarcinoma cells 
preferably metastasize within the liver, which is hard to simulate in vivo, we established a 3-
dimensional co-culture model of hepatoma/hepatocarcinoma cells with LEC/BEC-monolayers. LEC 
or BEC retracted and generated CCID, which resembles entry gates for tumour emboli through the 
lymphatic/blood cell wall. CCID formation could be impaired by inhibitors of I-κBα 
phosphorylation, matrix-metalloproteases, and lipoxygenases 12/15-1 (suppl.tab.1). Thus, the activity 
of NF-κB and secretion of metalloproteases and 12/15-HETE appear to be critical for the 
disintegration of the lymph/hemangioendothelial barrier by hepatoma/hepatocarcinoma cells, as 
reported for MCF-7 cells (20). The CCID formation could be greatly enhanced by overexpressing 
FGFR4 and impaired by interfering with FGFR4-mediated signaling. Transcriptome analyses 
revealed upregulation of NFkB-dependent genes by FGFR4 overexpression, such as phospholipase 
A2, which releases arachidonic acid from the membranes to provide substrate for lipoxygenases-
12/15-1 (suppl.tab.2). 
The aggressive phenotype is also characterized by altered cell-cell and cell-matrix interactions to 
enable evasion from organized tissue structures. The increased cloning efficacy of cells 
overexpressing FGFR4 may indicate a reduced dependency on cell-cell contacts, while the reduced 
matrix adhesion and the enhanced growth in soft-agar reflect lower requirements on anchorage for 
survival and proliferation.  
In contrast to FGFR1-3 and mutant FGFR4, wildtype FGFR4 seems not to interact with NCAM (28-
30). Upregulated FGFR4 reduced the expression of several cadherins, proto-cadherins, and integrins, 
which serve as docking sites for collagens, vitronectin and/or thrombospondins (31,32). Furthermore, 
transcript encoding for several collagens, vitronectin and thrombospondins were lowered as well 
(tab.1). These alterations altogether may explain the reduced adhesion of FGFR4-overexpressing 
hepatocarcinoma cells to collagen, fibronectin, and polystyrene.  
It is becoming increasingly evident that cell-matrix interactions impact profoundly on several steps of 
cell division (33). At start of mitosis, cells loose attachments, disassemble focal adhesions, and adopt 
a round morphology. Cell-adhesion molecules, like ß-integrins, regulate centrosome function, spindle 
formation and orientation, and cytokinesis (34-36). In line with these findings is our observation that 
dominant negative FGFR4 constructs reduced the proportion of hepatoma/hepatocarcinoma cells in 
S-phase of the cell cycle and increased the proportion in G2/M. This was accompanied by changed 
transcription of genes involved in the formation and/or function of cohesins, chromosomal 
condensation, kinetochores, centrosome separation, the formation, stabilization and function of the 
spindles, and cytokinesis. Furthermore, impaired FGFR4-activity increased anchorage-dependency, 








































































induced apoptosis and impaired disintegration of the LEC/BEC barrier. On the other hand, 
overexpressed FGFR4 reduced anchorage-dependency and cell adhesion, facilitated proliferation and 
probably mitosis in the emerging clones, and affected also indirectly the interaction with LEC/BEC. 
Thus, disruption of FGFR4-mediated signaling seems to interfere with mechanisms linking cell 
matrix interactions with late stages of cell division and to impact on several important components of 
the malignant phenotype of hepatoma/hepatocarcinoma cells.  
 
To conclude, our mechanistic studies demonstrate the oncogenic impact of FGFR4 on the aggressive 
behaviour of HCC cells. Thus, great potential might lie in FGFR4 as a target for the treatment of this 
cancer entity and in the application of solFGFR4-protein as therapeutic tool.   
 
 
Abbreviations: FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; HCC, 
hepatocellular carcinoma; solFGFR4, soluble fibroblast growth factor receptor 4; kdFGFR4,  
dominant negative fibroblast growth factor receptor 4.  
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Figure 1. Cloning efficiency, invasive growth and tumourigenicity differ between 
hepatoma/hepatocarcinoma cell lines.  In (A) cell lines were plated at a low density of 240 cells/cm2 
(HCC-1.2), 100 cells/cm2 (HepG2, HCC-3), and of 60 cells/cm2 (CCl-13). Clone numbers were 
determined after 3 weeks (HCC-1.2, HCC-3, HepG2) or 7 days (CCl-13). In (B) cells were seeded in 
soft agar at a density of 540 cells/cm2 (HCC-1.2, HCC-3) or 180 cells/cm2 (HepG2, CCl-13). Clones 
were counted after 4 weeks. In (A) and (B) the cloning efficiency was determined as the percentage 
of the cells seeded that form a clone. In (C) 1x106 cells/100µl serum-free medium were injected into 
flanks of SCID/BALBc mice. In (D,E) 3x103 cells were used for spheroid formation (for details see 
Methods). 48hrs later the spheroids formed were placed on confluent monolayers of LEC or BEC and 
were incubated for 4hrs. Pictures of spheroids and gap areas underneath were taken and areas were 
measured by ImageJ software. (D), representative spheroids of untreated HCC-1.2 cells and (E) 
CCID formed beneath in LEC or BEC. (F) gives the ratio between CCID area and spheroid size. All 





Figure 2. Overexpression of FGFR4 enhances anchorage-independency, invasiveness, and 
tumourigenicity of HCC-1.2 cells. Experiments in (A)–(D) have been performed as described in 
fig.1. (D), CCID formation of FGFR4-overexpressing clones. For further details on clones see 
suppl.fig.3. In (E) cells were seeded to petri dishes (made of polystyrene), being uncoated or coated 
with collagen or fibronectin; 60, 90, or 120min later the number of attached cells was determined. 
Data are expressed as fold vector control (pcDNA3.1) in (A,B,E) and are given as mean + SD of >3 
independent experiments in (A,B,D,E). (C) shows tumour formation in individual animals for each 
treatment group. Statistics by t-test in (A,B,D) and by Kruskal-Wallis test in (C,E): a) p < 0.05; b) p < 
0.01; c) p < 0.001. 
 
 









































































Figure 3. FGFR4 knockdown in hepatocarcinoma/hepatoma cell lines lowers clonogenicity 
and colony formation in soft agar. Cells were transiently transfected with scrambled siRNA 
(siSCR) or siRNA targeting FGFR4 (siFGFR4) applying 20nM (HCC-1.2, HepG2) or 10nM 
(HCC-3, CCl-13) of each. (A), the FGFR4 expression level was determined by qRT-PCR. The 
level of FGFR4 protein was determined 48hrs after transfection by immunoblotting and bands 
obtained were subjected to densitometry in (B). In (C) cell viability was determined by the 
EZ4U assay (see Experimental Procedures). In (D) cells were allowed to grow for up to 48hrs 
after transfection, were re-seeded and cultivated until the formation of colonies. Further details 
see fig.1.  In (E) 48 hrs after transfection cells were replated in soft agar and were cultivated 
until the appearance of colonies. Further details are given in fig.1. Abbreviation: n.d., not 
determined. Data in (A-E) are means + SD of fold siSCR of 3 independent experiments. 
Statistical analyses were performed with the t-test for siFGFR4 vs. siSCR: a) p < 0.05; b) p < 
0.01; c) p < 0.001; d) p < 0.0001. 
 
Figure 4. Blockade of FGFR4-mediated signaling impairs growth of 
hepatoma/hepatocarcinoma cells. Adenoviral constructs were used to transfect cells with 
kdFGFR4 or solFGFR4 (see experimental procedures). Untransfected cells (Co) and cells 
transfected with the adenoviral construct expressing GFP only (Vector) served as controls. (A) 
gives the clonogenicity and (B) the clone forming capacity in soft agar of untreated and infected 
cells. In (C) cells were implanted subcutaneously into the flanks of SCID/BALBc mice. In (D) 
the viability was determined by the EZ4U assay (see Experimental Procedures). FACS analyses 
served to determine the frequency of apoptosis in (E) and of the relative cell cycle distribution of 
asynchronous cultures in (F). In (G), 24hrs after transfection, 3x103 cells were used for spheroid 
formation and were placed on BEC/LEC monolayers for CCID formation. In (A), (B), (D)-(G) 
the mean +/- SD of > 3 independent experiments are given. (C) shows the means of 2 
independent experiments each with 4 animals per treatment group. Statistics by t-test in (A,B,D-
G) and by  Kruskal-Wallis test in (C) for solFGFR4 or kdFGFR4 vs. vector: a) p < 0.05; b) p < 
0.01; c) p < 0.001; d) p < 0.0001.  
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Table 1. Selected genes being deregulated at least 2-fold by FGFR4 overexpression  or 
dominant negative FGFR4-constructs. Further information is given in Experimental 
Procedures. For the significance of gene deregulation see supplementary tabs. 2-4. Gene set 





HCC-1.2 expressing FGFR4  
 
HepG2 expressing  
solFGFR4  







Genes involved in the function of : G1/S and/or 
G2/M (CCAR1,CCNB3, CDKN1A, CLSPN), M-
phase: MPHOSPH10, cohesins (SMC1A), 
spindles (NEK1), kinetochore (CENPF,CENPJ), 
centrosome (CEP290, KIF15) 
Genes involved in 












Genes involved in the function of: 
G1/S-Phase (CDC7, DNA2, 
RB1CC1), M-phase (C14ORF106, 
MPHOSPH10, CUZD1,CDC40, 
NCAPG), cohesins (ESCO1,SGOL2, 
SMC2/6), kinetochore (CCDC99, 
CENPE, CENPK, CENPQ,CENPC1, 
MAD2L1, NDC80,NUF2,PLK4, 
ZWILCH), centrosome (KIF15), 
spindles (HMMR,DLGAP5,NEK7),   
cytokinesis (ANLN,SEPT7), Other: 
G2E3,NOL8, MORC3   
↑ G1/S and/or G2/M: CDKN1C, PPP2R1B, CCRK, 
Spindles (FEZ1, NEK6), cytokinesis (NEK6, 
SEPT4/5/6) 
G0/G1: G0S2, 
G1/S and G2/M: 
RRAD, 
C13ORF15  
G1/S and G2/M: RRAD 
Cell Adhesion/Extracellular Matrix 
↓ AHR, cadherins (CDH11/12 PCDH1), CADM4, 
CEACAM1/3,CLDN4, collagens (COL4A5/6, 
COL5A2/3,COL8A2,COL9A3,COL21A1), 
CTHRC1,DST,DTNA,FAT1,FLNC,FLRT3,GJA1,
GULP1,HPSE, ICAM5, integrins (ITGA1/2/V), 
KIRREL, laminins (LAMA4/B1), LGALS1, LPP, 
LUM, MMP15, MUC4/15,NRCAM,PARD6A, 
PECAM1, PPFIBP1,PLXND1,PNN,PRPH2, 
RELN,ROBO1,ROCK1/2,SSX2IP,STEAP1, 
thrombospondins(receptor) (THBS1/4,  THSD4, 
CD36) ,TRPM7, TSPAN8/13, UNC5B 
HMMR CUZD1,HMMR,SEPP1, TMEM87A,  
↑ cadherins (CDH16/17,PCDHA1, PCDH24, 
PCDHB2/5/12), CADM1,CLDN14, CLEC10A, 
COL4A2,FBLN7,FBN1,FLRT1,GJA3,GPC1/4/5 


















































































Studies on interactions of hepatoma/hepatocarcinoma cells with blood and 
lymphatic endothelium.  
Metastasis is one of the primary causes for human mortality by cancer, as is true also for 
hepatocellular carcinoma (HCC). In particular, HCC most frequently show intrahepatic 
colonization due to the dense hepatic vasculature in the liver microenvironment (Van Zijl et 
al., 2011). Blood circulation is considered the main route of metastatic spread of HCC cells 
although invasion into the lymphatic system is often observed as well (Mitsunobu et al., 
1996). In epithelial cancer entities, cells spontaneously form cohesive groups, which directly 
penetrate lymphatic vessel walls through large discontinuities (Kerjaschki et al., 2004; 
Christiansen et al., 2006; Friedl et al., 2010).  
To gain insight into the mechanisms underlying lymphatic bulk invasion, an in vitro assay 
was established mimicking some features of the in vivo situation (Kerjaschki et al., 2011). 
MCF-7 cells were used to form spheroids, which were placed on telomerase immortalized 
human lymphendothelial cells (LEC) grown to confluent monolayers. Co-cultivation of 
spheroids on LEC resulted in the formation of circular discontinuities in the monolayers 
precisely beneath the spheroids, termed as circular chemorepellent-induced defects (CCID). 
 
       
 
       
Supplementary Figure 1. Interaction of hepatoma/hepatocarcinoma cell lines with endothelial cells. 
1x103 CCl-13 cells were incubated in 150 µl EGM2-MV medium (Lonza, Walkersville, MD) 
containing 20% methyl cellulose (M-0512, Sigma Aldrich) in round bottom microtitre plates (BD 
Biosciences) to allow spheroid formation within 48hrs. Spheroids were washed in PBS and transferred 
to confluent LEC/BEC monolayers, kept in 24-well plates and EGM2-MV medium and stained by 
cytotracker green (2µg/ml for1hr, Invitrogen). After 4hrs of incubation, the spheroid size and the 
CCID area in the LEC/BEC monolayer underneath were photographed at the time points indicated. 
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Further, centrifugal migration (retraction) of LEC instead of apoptosis was defined as the 
mechanism for gap formation (Kerjaschki et al., 2011). 
  
We applied this assay to study the interaction of hepatoma/hepatocarcinoma cells with 
monolayers of telomerase immortalized LEC and blood endothelial cells (BEC) (Schoppmann 
et al., 2004). Generally, all cell lines used were able to form spheroids and CCID in 
endothelial cell monolayers. Pictures, taken at regular intervals, revealed centrifugal retraction 
of LEC and BEC beneath the spheroids, as has been shown before (suppl.fig.1).  
CCl-13 cells had the highest capacity to disintegrate the LEC/BEC barrier, followed by 
HepG2, HCC-3 and HCC-1.2 cells, which agrees with the highly differing aggressive 
phenotype of the cell lines (suppl.fig.2 and fig.1 in manuscript). HepG2 spheroids were larger 
and less compact than those of CCl-13, HCC-1.2, or HCC-3 cells, and tended to fall apart 
when being transferred to LEC/BEC monolayers. Consequently, we used CCl-13, HCC-1.2, 
and HCC-3 cells for further experimentation. 
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 Spheroid Mean 
spheroid size 
(mm2) 
CCID in LEC Mean area 
of CCID in 
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Supplementary Figure 2. Interaction of HCC model cell lines with endothelial cells. Methodical 
details see suppl.fig.1. After 4hrs of co-culture pictures of spheroids and CCID underneath were taken 
and the size of spheroids and the area of CCID underneath were measured by ImageJ software. Data 
are means ± SD of four independent experiments. Magnification x100.  
 








































































As shown by Honn et al. (1994) and Kerjaschki et al. (2011), the hypoxia-inducible enzymes 
lipoxygenases 12 (ALOX12) and ALOX15-1, which metabolize arachidonic acid to 12-
hydroxyeicosatetraenoic acid (12(S)-HETE), were identified as mediators of CCID formation 
by MCF-7 cells. LEC exposed to 12(S)-HETE transiently destabilize VE-cadherin resulting in 
focal disruption of inter-endothelial adhesions and induction of migration of these cells. NFkB 
activation and matrix-metalloproteases (MMP) were also found to enhance the process of 
CCID formation (Vonach et al., 2011). Flister et al. (2010) suggested that activation of NF-κB 
enhances the motility of LEC which is required for the retraction of the cells. MMP degrade 
components of the extracellular matrix, modulate cell-cell and cell-matrix interactions, and 
therefore assist tumour cell metastasis (Deryugina et al., 2006). Accordingly, gap formation 
by MCF-7 spheroids was decreased by inhibition of MMP, which was assigned to impaired 
degradation of the VE-cadherin meshwork at inter-endothelial junctions and matrix 
attachments (Kerjaschki et al., 2011;  Deryugina et al., 2006). 
 
To investigate the mechanisms underlying the effects of hepatoma/hepatocarcinama spheroids 
on endothelial cells, we applied inhibitors of I-κBα phosphorylation (BAY11-7082, Merck, 
Darmstadt, FRG), MMP (GM6001, Merck), or ALOX12/15-1 (baicalein, Merck) 1hr before 
spheroids were transferred to LEC or BEC (suppl.tab.1). These pretreatments of spheroids 
reduced the size of CCID in LEC and BEC, with the exception of baicalein-treated CCl13 
cells. Thus, the activity of NF-κB, MMP, and 12/15-HETE appear to be critical for the 
disintegration of the lymph/hemangioendothelial barrier by hepatoma/hepatocarcinoma cells. 
 
HCC‐1.2.  HCC‐3    CCL13   
LEC  BEC  LEC  BEC  LEC  BEC 
BAY  5 µM 99 + 2  100 + 11  90 + 5  80 + 8  97 + 7  96 + 15 
BAY  10 µM 73 + 3b  84 + 15  73 + 16  75 + 8a  89 + 1b  95 + 2a 
GM6001  10 µM 83 + 9  82 + 8  98 + 7  75 + 3b  97 + 11  94 + 1a 
GM6001  20 µM 86 + 7   83 + 6a  93 + 6   82 + 5a  87 + 5a  81 + 8 
GM6001  50 µM 83 + 5a  62 + 6b  85 + 7  80 + 2b  58 + 5b  77 + 2b 
Baicalein  10 µM 90 + 9  78 + 17  93 + 5  87 + 5  104 + 15  99 + 9 
Baicalein  20 µM 83 + 3a  73 + 10a  87 + 5a  78 + 6a  100 + 12  100 + 4 
Baicalein  50 µM 76 + 7a  65 + 12a  75 + 6a  67 + 4b  97 + 5  104 + 13 
 
Supplementary  Table 1. BAY 11-7082, GM6001, and baicalein impair spheroid-induced gap 
formation in  BEC and LEC monolayers. Methodical details see suppl.fig.1. Spheroids were treated 
with different concentrations of BAY11-7082, GM6001 and baicalein for 1h and were placed on 
confluent LEC or BEC monolayers for 4hrs. Pictures of spheroids and gap areas underneath were 
taken and areas were measured by ImageJ software. Results are shown as % of untreated control and 








































































are expressed as mean ± SD of 3 independent experiments. Significant differences to untreated 
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HCC-1.2. clones overexpress FGFR4 at the transcript and protein level and show 
enhanced phosphorylation of ERK and phospholipase CPLC.  
A C D 
FGFR4 mRNA

































































Supplementary Figure 3. We generated HCC-1.2 clones with stable overexpression of FGFR4 (Cl1-
Cl4). In (A) FGFR4 mRNA levels of clones 1-4 (Cl1-Cl4) were determined by qRT-PCR. In (B)- (D) 
cell lysates of the clones were subjected to immunoblotting to detect proteins. Antibodies used: anti-
FGFR4 (sc-124 and sc-9006; Santa-Cruz Inc/CA), anti-ß-actin (Sigma, St Louis, MO), anti-phospho-
PLCγ1(Tyr783) (Cell Signaling, Danvers, MA), anti-PLCγ1 (Cell Signaling), anti-phospho-p44/42 
MAPK (ERK 1/2) (Thr202/Tyr204) (Cell Signaling), anti-ERK1/2 (Sigma), anti-phospho-AKT 
(Ser437) (Cell Signaling), anti-AKT (Cell Signaling). Band intensities were quantified by densitometry 
(ImageQuant 5.0-software; GE-Healthcare). Band intensities were quantified by densitometry and 
normalized to the ß-actin level. Abbreviation: n.d., not detectable. Data are means + SD of >3 
independent (in A, B) and of >2 experiments in (D). Statistics by t-test: a) p < 0.05; b) p < 0.001. 
 








































































Expression of dominant negative FGFR4 constructs and interference with 
downstream signaling.  
Hepatoma/hepatocarcinoma cell lines were infected with dominant-negative FGFR4 
constructs. The high expression of the constructs is shown in suppl.fig.4.  
To investigate interference with FGFR4-mediated signaling, phosphorylation of the FGFR 
binding adaptor protein Frs2α was determined. On immunoblots signals were obtained at 60-
75kDa which conforms to the molecular weights known for Frs2 proteins (suppl.fig.5). The 
impact of stable FGFR4 overexpression on the amount of phosphorylated Frs2 is shown in 
suppl.fig.5A. In all three HCC cell lines, the expression of dominant-negative FGFR4 
constructs interfered with downstream signaling, as indicated by a reduced amount of 
phosphorylated Frs2α relative to total Frs2 protein (suppl.fig5B and 5C).  
 
Supplementary Figure 4. Expression of dominant-negative FGFR4-constructs in hepatoma/ 
hepatocarcinoma cell lines. Cells were infected with adenoviruses encoding for dn-FGFR4 or sol-
FGFR4. Untreated cells and cells infected with a GFP-adenovirus served as controls. Proteins were 
isolated 24 hrs after infection and determined by immunoblotting. Proteins in the cell supernatants 
were isolated by EtOH precipitation, as described by Gauglhofer et al (Hepatology, 2011;53:854-
864). For further details see Experimental Procedures. Lane 1, untreated; lane 2, GFP; lane 3, 
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Supplementary Figure 5. Effect of FGFR4 blockade on downstream signaling. (A), cell lysates of 
clones overexpressing the vector (control) or FGFR4 (Cl). (B), cell lysates of  untreated HCC-1.2 
cells (control) or 48hrs after infection with vector (GFP), solFGFR4, or kdFGFR4). Lysates were 
subjected to immunoblotting to detect total FRS2 and the phosphorylated form of FRS2. Antibodies: 
anti-FRS2 (Santa Cruz Biotechnology, St.Cruz, CA) anti-FRS2 (Tyr196) Cell Signaling Technology 
(Danvers, MA). (C), band intensities were quantified by densitometry and normalized to the ß-actin 
level. The values, obtained in untreated controls, were arbitrarily set 1. Means and SD of fold control 
values are given. Statistics by t-test for solFGFR4 or kdFGFR4 vs. GFP: a) p < 0.05. 
 








































































Impact of FGFR4 overexpression and of intereference with FGFR4-mediated 
signaling on transcriptome profiles of hepatoma/hepatocarcinoma cells.  
Supplementary Table 2. Genes being deregulated in FGFR4-overexpressing HCC-1.2. cells. Data 
were processed as described in Experimental Procedures and are means of fold-vector control values 
of two different clones (clone 1 and 3). Fold-change cutoffs of >2 and <0.5 were used to select 




A1BG up 8,3 6,7 0,1842 
A2BP1 down -2,8 0,1 0,0128 
A2M down -7,1 6,7 0,2091 
AADAC down -2,3 1,6 0,2313 
AASDH down -2,2 0,1 0,0269 
ABCA3 up 8,3 5,1 0,1454 
ABCC3 down -2,2 0,2 0,0420 
ABCD3 up 2,7 0,7 0,0934 
ABCE1 down -2,1 0,2 0,0466 
ABCG5 up 9,3 0,8 0,0209 
ABCG8 up 3,8 0,3 0,0248 
ABHD12 up 2,4 0,2 0,0334 
ABHD2 up 2,0 0,8 0,1548 
ACMSD up 23,9 20,8 0,1817 
ACPP down -6,3 2,1 0,0862 
ACSL3 down -3,2 0,3 0,0326 
ACSL5 up 3,0 0,3 0,0363 
ACSL6 down -9,5 7,6 0,1803 
ACSM1 down -5,3 4,8 0,2126 
ACSM3 up 2,5 0,8 0,1201 
ACSS1 up 6,7 0,1 0,0043 
ACSS2 up 2,5 0,1 0,0211 
ACSS3 down -3,4 1,7 0,1487 
ACTG2 down -3,2 2,2 0,1974 
ACVR1C up 3,1 0,9 0,0923 
ACYP1 down -2,1 0,3 0,0571 
ADAM21 up 2,0 0,8 0,1655 
ADAM23 down -2,9 0,6 0,0736 
ADAM6 down -2,6 0,8 0,1101 
ADAM8 up 2,8 0,1 0,0074 
ADAM9 down -2,2 0,0 0,0075 
ADAMTS2 down -12,4 4,6 0,0882 
ADAMTS9 up 2,8 1,2 0,1441 
ADARB1 up 2,3 0,4 0,0679 
ADC up 2,7 0,4 0,0525 
ADCY5 up 5,1 0,5 0,0277 
ADCY9 up 2,0 0,7 0,1364 
ADH1A up 14,7 14,2 0,2019 
ADH1C up 2,6 0,6 0,0906 
ADH4 up 15,7 16,0 0,2089 
ADORA1 up 2,9 1,3 0,1445 
ADPRHL1 up 2,1 0,1 0,0253 
ADRB2 up 6,3 3,7 0,1464 
ADRBK2 up 4,5 3,2 0,1849 
AFAP1L1 up 2,1 0,4 0,0784 
AFF1 down -2,0 0,4 0,0891 
AFM up 8,9 7,3 0,1857 
AFP up 29,8 35,3 0,2274 
AGAP2 up 2,9 0,4 0,0420 
AGBL2 up 2,7 1,0 0,1271 
AGGF1 down -2,4 0,4 0,0667 
AGK down -2,4 0,4 0,0646 
AGPAT2 up 2,9 0,4 0,0485 
AGPAT4 up 4,1 0,0 0,0013 
AGPS down -2,3 0,6 0,1111 
AGR2 down -7,0 1,6 0,0608 
AGTR1 down -2,2 0,5 0,0951 
AGXT up 2,2 0,5 0,0862 
AHCTF1 down -3,2 0,4 0,0452 
AHCY up 2,2 0,1 0,0182 
AHR down -3,2 1,3 0,1302 
AHRR up 2,3 0,0 0,0035 
AHSA2 down -2,0 0,3 0,0680 
AIF1 down -3,9 3,1 0,2076 
AIF1L up 12,0 4,1 0,0816 
AIFM3 down -2,6 0,5 0,0707 
AIMP1 down -2,0 0,4 0,0795 
AKAP11 down -2,3 0,6 0,0961 
AKAP12 up 3,2 2,6 0,2201 
AKAP14 up 9,6 3,4 0,0880 
AKAP9 down -3,8 1,0 0,0777 
AKD1 up 3,2 0,9 0,0871 
AKR1B10 down -2,4 1,3 0,1802 
AKR1C1 up 4,7 2,5 0,1417 
AKR1C3 up 2,1 0,1 0,0210 
AKR1D1 up 5,6 0,6 0,0280 
AKT1S1 up 2,0 0,1 0,0319 
ALAD up 2,2 0,0 0,0079 








































































ALB up 3,9 3,9 0,2442 
ALDH8A1 up 2,5 1,2 0,1660 
ALDOB down -2,4 0,6 0,0961 
ALKBH8 down -2,2 0,8 0,1495 
ALMS1 down -2,7 0,8 0,1005 
ALMS1P down -2,2 0,5 0,0980 
ALOX5AP up 7,1 0,5 0,0186 
ALPK1 down -2,6 1,4 0,1773 
ALX4 down -2,3 0,2 0,0391 
AMMECR1 down -2,1 0,0 0,0028 
AMOTL1 up 7,8 0,1 0,0031 
AMPD3 up 10,6 0,2 0,0042 
ANG up 2,2 0,7 0,1265 
ANGPT1 down -4,9 0,0 0,0007 
ANGPTL1 down -3,5 1,0 0,0895 
ANK3 down -2,2 1,0 0,1770 
ANKRD10 down -2,3 0,3 0,0570 
ANKRD12 down -3,7 0,6 0,0506 
ANKRD18B up 7,2 1,7 0,0594 
ANKRD20A2 up 5,1 0,8 0,0424 
ANKRD26 down -3,2 0,7 0,0715 
ANKRD32 down -2,4 0,4 0,0680 
ANKRD36 down -2,4 0,4 0,0728 
ANKRD36B down -2,6 0,5 0,0722 
ANKRD58 up 7,2 2,0 0,0729 
ANKRD6 up 16,8 7,3 0,1004 
ANKRD62 down -6,7 4,9 0,1751 
ANTXR1 up 3,7 1,2 0,0993 
ANTXR2 down -2,3 0,9 0,1366 
ANXA1 down -7,8 0,6 0,0196 
ANXA13 up 12,6 0,5 0,0088 
ANXA3 down -2,8 1,5 0,1678 
AP1AR down -2,3 0,2 0,0281 
APBA2 up 9,1 3,1 0,0842 
APBB1IP up 5,6 0,7 0,0321 
APBB2 down -2,2 0,2 0,0325 
APLF down -6,5 2,4 0,0951 
APLN up 4,7 1,0 0,0619 
APOA2 down -2,0 0,3 0,0711 
APOA4 up 3,2 0,0 0,0046 
APOA5 up 7,4 1,3 0,0468 
APOB down -3,4 0,6 0,0593 
APOBEC3C down -3,3 2,6 0,2139 
APOBEC3G up 6,4 2,8 0,1127 
APOC1 up 2,3 0,1 0,0144 
APOC3 up 6,6 2,4 0,0948 
APOL2 up 2,2 0,5 0,0811 
APOL4 up 2,2 0,6 0,1007 
APOLD1 up 2,5 0,6 0,0885 
AQP3 up 3,0 0,7 0,0795 
ARAP1 up 2,1 0,2 0,0431 
ARAP2 down -10,0 5,2 0,1221 
ARG2 down -2,5 0,4 0,0655 
ARGLU1 down -2,1 0,2 0,0415 
ARHGAP12 down -2,7 0,7 0,0868 
ARHGAP18 down -5,2 3,2 0,1587 
ARHGAP20 up 3,6 2,1 0,1641 
ARHGAP21 down -2,1 0,1 0,0118 
ARHGAP22 down -6,0 2,3 0,1011 
ARHGAP29 down -2,6 0,2 0,0310 
ARHGAP5 down -2,0 0,4 0,0892 
ARHGEF10 down -2,5 1,0 0,1369 
ARHGEF16 down -3,1 1,7 0,1643 
ARID4B down -2,5 0,1 0,0166 
ARID5B down -2,8 0,1 0,0184 
ARL10 up 3,0 0,1 0,0093 
ARL17 down -2,1 0,2 0,0464 
ARL17P1 down -2,5 0,7 0,1025 
ARL4C up 8,0 2,9 0,0921 
ARMC2 up 3,4 1,2 0,1098 
ARMC9 up 2,5 0,4 0,0653 
ARMCX1 down -4,7 2,1 0,1206 
ARMCX3 down -3,5 0,3 0,0314 
ARNTL2 down -3,6 1,1 0,0890 
ARRDC4 up 2,4 0,5 0,0790 
ARSJ down -39,8 46,0 0,2218 
ART5 up 3,2 0,4 0,0420 
ASB2 up 2,9 0,5 0,0558 
ASB9 down -2,3 1,2 0,1811 
ASH1L down -3,6 1,4 0,1126 
ASMT down -3,5 0,3 0,0308 
ASPA up 5,0 0,1 0,0043 
ASPG up 2,9 0,3 0,0345 
ASPH down -2,9 0,4 0,0431 
ASPHD1 down -3,8 0,3 0,0219 
ASPM down -2,6 0,1 0,0209 
ASS1 up 3,1 0,3 0,0320 
ATAD2 down -2,2 0,2 0,0280 
ATAD4 up 2,2 0,6 0,1000 
ATAD5 down -3,8 1,1 0,0838 
ATG16L2 down -2,5 0,4 0,0627 
ATOH7 up 2,5 1,0 0,1356 
ATOH8 down -5,1 1,1 0,0625 
ATP10D up 2,6 0,7 0,0928 








































































ATP13A3 down -2,1 0,3 0,0556 
ATP2B1 down -2,4 0,4 0,0597 
ATP7A down -2,1 0,6 0,1223 
ATR down -2,4 0,6 0,0876 
ATRNL1 up 5,0 4,0 0,1943 
ATRX down -2,9 0,2 0,0292 
AUTS2 up 23,9 1,5 0,0150 
AVIL up 4,3 3,3 0,1950 
AZGP1 up 3,9 1,8 0,1325 
AZI2 down -3,1 0,0 0,0034 
B3GALNT1 down -4,0 2,5 0,1676 
B4GALNT3 up 5,3 1,1 0,0546 
BACE1 down -2,4 0,7 0,1136 
BAGE down -3,4 0,5 0,0429 
BAT2D1 down -2,1 0,2 0,0334 
BATF down -10,6 9,1 0,1875 
BAZ1A down -2,5 1,0 0,1349 
BAZ2B down -2,8 0,9 0,1141 
BBOX1 up 3,8 0,2 0,0151 
BBS7 down -2,4 0,3 0,0404 
BCL2A1 up 2,0 0,3 0,0665 
BCL2L11 up 2,2 0,2 0,0373 
BCLAF1 down -2,1 0,8 0,1539 
BDKRB1 down -14,0 3,8 0,0655 
BDP1 down -2,5 0,4 0,0600 
BEND5 up 10,6 1,6 0,0384 
BEST1 down -3,2 0,7 0,0686 
BEX5 up 2,5 0,6 0,0893 
BICC1 down -4,5 3,4 0,1936 
BIN3 up 2,4 0,0 0,0009 
BIRC3 down -6,5 0,4 0,0155 
BIVM down -2,1 0,6 0,1137 
BMF up 4,7 1,4 0,0821 
BMP8B up 2,2 0,3 0,0665 
BNIP3L up 2,0 0,3 0,0706 
BOD1L down -5,3 1,6 0,0833 
BPI up 9,7 0,8 0,0210 
BRCA2 down -4,5 1,1 0,0716 
BRCC3 down -2,9 0,6 0,0673 
BRF1 down -2,3 0,7 0,1181 
BRIP1 down -2,4 0,5 0,0875 
BRUNOL4 down -3,5 0,5 0,0436 
BRWD1 down -4,5 0,8 0,0511 
BRWD3 down -2,3 0,1 0,0153 
BTBD9 up 2,8 0,2 0,0276 
BTD up 2,3 0,3 0,0487 
BTG1 up 2,3 0,2 0,0345 
C10orf10 down -5,5 0,7 0,0368 
C10orf116 down -3,7 0,9 0,0756 
C10orf118 down -2,8 0,8 0,0996 
C10orf82 up 10,4 10,3 0,2102 
C10orf90 down -2,3 0,0 0,0043 
C10orf93 up 8,3 6,9 0,1864 
C11orf60 up 3,2 0,5 0,0508 
C11orf63 up 7,2 6,7 0,2073 
C11orf82 down -2,0 0,2 0,0361 
C11orf86 up 2,6 1,0 0,1366 
C11orf92 down -2,3 0,9 0,1454 
C11orf93 down -2,2 0,9 0,1499 
C12orf34 up 2,2 0,5 0,0831 
C12orf35 down -2,8 0,0 0,0003 
C12orf39 down -6,9 0,7 0,0257 
C12orf42 up 2,2 0,1 0,0122 
C12orf70 down -3,0 0,0 0,0028 
C13orf15 down -7,5 0,6 0,0217 
C13orf29 down -2,9 0,5 0,0617 
C13orf31 down -2,6 0,9 0,1173 
C14orf106 down -2,3 0,7 0,1221 
C14orf132 up 7,8 1,9 0,0613 
C14orf145 down -2,3 0,0 0,0076 
C15orf27 up 9,1 2,2 0,0605 
C15orf41 down -2,8 0,6 0,0730 
C15orf48 up 15,3 6,0 0,0920 
C15orf59 up 4,7 1,9 0,1114 
C16orf45 up 8,4 1,9 0,0578 
C16orf74 up 5,3 2,4 0,1188 
C17orf108 up 2,1 0,3 0,0626 
C17orf97 up 6,1 0,7 0,0295 
C18orf1 up 79,6 2,4 0,0070 
C19orf18 up 4,1 1,5 0,1062 
C19orf69 down -11,4 10,3 0,1949 
C1orf114 down -3,9 0,7 0,0529 
C1orf115 up 2,2 0,4 0,0698 
C1orf161 down -2,8 0,5 0,0659 
C1orf162 down -2,1 0,2 0,0328 
C1orf21 up 6,7 2,2 0,0837 
C1orf210 up 3,7 2,0 0,1546 
C1orf226 up 2,5 0,3 0,0486 
C1orf27 down -3,3 0,6 0,0581 
C1orf89 down -2,2 0,3 0,0620 
C1orf9 down -3,8 0,7 0,0528 
C1R up 2,3 0,2 0,0337 
C20orf132 up 2,8 0,4 0,0472 
C20orf29 up 2,3 0,0 0,0013 








































































C20orf3 up 2,2 0,4 0,0720 
C20orf94 down -100,9 102,1 0,1991 
C21orf122 up 2,6 0,8 0,1091 
C21orf129 down -2,3 1,3 0,1962 
C21orf34 down -11,6 0,0 0,0001 
C22orf41 up 2,6 0,1 0,0124 
C2CD2 down -2,2 0,0 0,0002 
C2orf60 down -2,1 0,5 0,1025 
C2orf63 down -2,1 0,7 0,1285 
C2orf77 down -5,5 0,9 0,0428 
C2orf88 up 2,0 0,4 0,0805 
C3 up 2,4 0,4 0,0626 
C3orf14 down -2,5 0,8 0,1143 
C3orf15 down -6,9 0,0 0,0015 
C3orf32 down -2,6 0,9 0,1125 
C3orf57 down -4,1 2,6 0,1704 
C3orf63 down -2,4 0,4 0,0675 
C4B up 5,5 2,6 0,1240 
C4orf21 down -4,2 1,5 0,0978 
C4orf41 down -2,1 0,0 0,0003 
C4orf49 down -2,5 0,3 0,0407 
C5orf24 up 2,5 0,0 0,0013 
C5orf32 down -13,5 12,4 0,1950 
C5orf42 down -3,2 0,1 0,0075 
C6 down -5,0 3,9 0,1927 
C6orf114 up 2,1 0,3 0,0684 
C6orf132 up 4,9 0,1 0,0073 
C6orf134 down -4,7 0,0 0,0006 
C6orf141 down -11,4 10,5 0,1971 
C6orf145 up 2,0 0,3 0,0691 
C6orf154 up 2,3 0,1 0,0181 
C6orf168 up 3,1 1,7 0,1618 
C6orf208 up 2,5 0,6 0,0842 
C6orf225 up 2,9 0,8 0,0922 
C6orf26 down -2,5 0,0 0,0075 
C6orf59 up 4,2 0,5 0,0344 
C7orf10 up 2,5 0,6 0,0932 
C7orf53 down -2,9 1,3 0,1444 
C7orf58 down -7,3 1,2 0,0417 
C8B up 4,1 2,0 0,1320 
C8orf38 down -2,0 0,1 0,0134 
C8orf4 down -20,8 0,3 0,0031 
C8orf47 up 2,7 0,7 0,0930 
C8orf58 up 2,1 0,2 0,0512 
C9orf109 up 3,0 0,0 0,0006 
C9orf114 up 2,0 0,1 0,0141 
C9orf122 up 3,6 1,3 0,1086 
C9orf123 up 2,2 0,5 0,0996 
C9orf125 down -3,5 1,4 0,1190 
C9orf130 up 2,2 0,3 0,0639 
C9orf150 down -4,9 0,5 0,0261 
C9orf167 up 2,8 0,8 0,1022 
C9orf3 up 2,0 0,0 0,0003 
C9orf43 up 2,9 0,4 0,0443 
C9orf5 up 2,3 0,2 0,0259 
C9orf57 down -7,4 0,5 0,0167 
C9orf9 up 3,0 0,2 0,0265 
CA13 up 16,2 10,3 0,1431 
CA14 down -2,0 0,1 0,0317 
CA5A up 2,2 0,4 0,0669 
CA9 down -2,9 0,5 0,0575 
CACHD1 up 4,8 2,3 0,1281 
CACNA1D down -2,7 0,2 0,0223 
CACNG1 down -4,1 0,2 0,0166 
CACNG4 down -3,0 0,7 0,0759 
CADM1 up 2,3 0,7 0,1235 
CADM4 down -2,6 0,3 0,0361 
CADPS2 down -3,2 1,1 0,1055 
CALR3 up 2,0 0,5 0,1053 
CAMK2D down -2,1 0,5 0,0995 
CAMKK1 up 2,9 1,2 0,1366 
CAMSAP1L1 down -2,3 0,2 0,0311 
CAMTA1 down -2,8 0,1 0,0158 
CAMTA2 down -2,1 0,1 0,0127 
CAPN2 up 4,6 3,0 0,1672 
CASC5 down -2,2 0,6 0,1095 
CASK down -2,2 0,1 0,0273 
CASP8 down -3,3 0,7 0,0637 
CASP8AP2 down -2,6 0,6 0,0868 
CCAR1 down -2,1 0,5 0,1032 
CCBL2 down -2,1 0,2 0,0367 
CCDC11 down -8,0 1,9 0,0611 
CCDC116 up 2,1 0,2 0,0501 
CCDC122 down -2,0 0,3 0,0604 
CCDC125 down -2,2 0,3 0,0595 
CCDC132 down -2,0 0,1 0,0201 
CCDC135 up 3,6 1,1 0,0891 
CCDC144A up 2,3 0,6 0,0964 
CCDC150 down -2,9 0,4 0,0423 
CCDC151 up 2,9 0,1 0,0102 
CCDC155 up 5,7 2,8 0,1279 
CCDC28B down -2,1 0,5 0,1042 
CCDC34 down -2,2 0,2 0,0370 
CCDC36 up 4,8 0,0 0,0007 








































































CCDC41 down -2,1 0,4 0,0747 
CCDC46 down -2,9 1,5 0,1612 
CCDC47 down -2,0 0,3 0,0706 
CCDC50 down -2,0 0,1 0,0188 
CCDC55 down -2,4 0,7 0,1039 
CCDC66 down -3,1 0,0 0,0006 
CCDC68 down -3,8 1,0 0,0784 
CCDC69 up 5,6 1,3 0,0612 
CCDC74B down -2,9 0,2 0,0248 
CCDC82 down -2,9 0,2 0,0213 
CCDC88A down -3,6 1,3 0,1085 
CCL20 down -3,1 0,8 0,0854 
CCL27 up 2,9 0,2 0,0199 
CCL28 down -4,2 1,2 0,0838 
CCNB3 down -2,9 0,1 0,0122 
CCNJL down -2,4 1,5 0,2001 
CCNL1 down -2,7 0,0 0,0053 
CCNT2 down -2,0 0,6 0,1196 
CCPG1 down -2,5 0,2 0,0260 
CCR6 down -2,6 0,7 0,0986 
CCRK up 3,0 0,1 0,0096 
CD163 down -10,4 7,8 0,1696 
CD163L1 down -3,8 0,3 0,0247 
CD2 up 3,0 1,8 0,1773 
CD244 up 3,8 2,8 0,1920 
CD36 down -21,4 19,2 0,1866 
CD72 up 3,3 0,5 0,0440 
CD83 down -2,1 0,1 0,0206 
CD86 up 4,0 0,8 0,0621 
CD8A up 7,0 3,3 0,1190 
CD9 up 5,1 2,1 0,1081 
CD99L2 up 3,6 0,9 0,0746 
CDC42BPA down -2,7 0,7 0,0954 
CDCA7L up 8,2 3,6 0,1101 
CDH11 down -3,6 0,0 0,0005 
CDH12 down -6,9 0,3 0,0114 
CDH16 up 3,0 1,9 0,1881 
CDH17 up 23,5 8,8 0,0861 
CDKN1A down -2,1 0,6 0,1205 
CDKN1C up 4,2 1,2 0,0849 
CDS1 down -6,7 2,4 0,0904 
CDYL2 up 4,6 0,7 0,0437 
CEACAM1 down -3,1 0,2 0,0208 
CEACAM3 down -2,5 0,2 0,0314 
CEBPB up 2,0 0,3 0,0571 
CEBPE up 2,3 0,2 0,0296 
CEBPZ down -2,3 0,5 0,0836 
CECR2 up 2,9 0,1 0,0094 
CECR6 up 4,5 0,3 0,0167 
CENPC1 down -2,7 0,8 0,0983 
CENPE down -4,8 1,7 0,0999 
CENPF down -3,2 0,3 0,0356 
CENPJ down -2,7 0,7 0,0905 
CEP110 down -2,3 0,2 0,0318 
CEP120 down -2,1 0,0 0,0029 
CEP135 down -2,3 0,5 0,0881 
CEP152 down -2,4 0,3 0,0481 
CEP170 down -3,5 0,4 0,0328 
CEP192 down -2,1 0,4 0,0784 
CEP290 down -4,6 1,6 0,0995 
CEP350 down -2,6 0,1 0,0193 
CEP63 down -2,1 0,3 0,0645 
CES4 down -4,6 2,9 0,1632 
CFB up 6,4 3,8 0,1473 
CHAC2 down -2,0 0,5 0,1034 
CHADL up 2,4 0,4 0,0620 
CHD1 down -3,3 0,4 0,0418 
CHD2 down -2,6 0,6 0,0797 
CHD9 down -3,0 0,9 0,0950 
CHIC1 down -2,6 0,4 0,0559 
CHM down -2,2 0,3 0,0477 
CHML down -3,1 1,1 0,1125 
CHMP7 up 2,2 0,0 0,0063 
CHN1 up 2,1 0,6 0,1083 
CHP2 up 2,2 0,6 0,1039 
CHPT1 up 2,2 0,4 0,0786 
CHRDL2 down -2,2 0,2 0,0279 
CHRM3 up 10,2 1,3 0,0307 
CHST14 up 2,1 0,2 0,0440 
CHST7 up 2,3 1,5 0,2193 
CIDEB up 2,0 0,1 0,0231 
CIDEC up 2,1 0,6 0,1218 
CIZ1 up 2,1 0,1 0,0260 
CKMT1A up 2,3 0,4 0,0709 
CLDN14 up 2,2 0,4 0,0649 
CLDN4 down -3,7 2,0 0,1585 
CLEC10A up 2,3 0,4 0,0761 
CLK1 up 3,7 0,0 0,0024 
CLMN up 4,0 0,8 0,0612 
CLOCK down -2,3 0,7 0,1105 
CLRN3 up 2,1 0,1 0,0198 
CLSPN down -2,6 0,4 0,0581 
CMAH down -2,1 0,6 0,1183 
CNNM2 up 3,3 0,2 0,0165 








































































CNTNAP3 up 8,4 3,6 0,1053 
COBLL1 down -2,1 0,7 0,1331 
COG6 down -2,1 0,3 0,0685 
COL21A1 down -66,0 30,2 0,1011 
COL4A2 up 2,3 0,6 0,0972 
COL4A5 down -3,9 0,1 0,0099 
COL4A6 down -3,3 0,1 0,0141 
COL5A2 down -8,0 0,0 0,0013 
COL5A3 down -10,5 8,0 0,1710 
COL8A2 down -5,5 0,2 0,0095 
COL9A3 down -9,6 8,8 0,1987 
COLEC11 down -2,3 0,2 0,0288 
COQ10A up 2,1 0,2 0,0332 
COQ9 down -2,1 0,5 0,0967 
CPE up 6,5 1,7 0,0700 
CPM up 3,0 0,7 0,0793 
CPN1 up 2,4 1,1 0,1604 
CPNE2 up 5,2 0,7 0,0385 
CPNE7 down -2,4 0,2 0,0350 
CPNE8 down -2,1 0,4 0,0769 
CPS1 down -4,8 3,5 0,1854 
CREB3L3 up 2,8 0,0 0,0025 
CREB5 down -3,4 0,8 0,0707 
CREG1 up 2,2 0,8 0,1424 
CRIM1 down -2,3 0,3 0,0498 
CRIP3 down -5,7 4,9 0,2007 
CROCCL2 down -2,3 0,1 0,0128 
CRYM up 2,4 0,7 0,1040 
CSNK2A2 up 2,1 0,5 0,1045 
CSPP1 down -2,2 0,5 0,1013 
CSRNP3 down -2,7 0,9 0,1144 
CSRP1 down -2,7 1,6 0,1939 
CSTF2T up 2,0 0,3 0,0703 
CTBP2 down -3,5 1,2 0,1087 
CTDSP2 up 2,2 0,2 0,0450 
CTDSPL down -2,0 0,1 0,0318 
CTHRC1 down -5,4 2,3 0,1118 
CTNNBIP1 down -2,7 0,7 0,0893 
CTSD up 2,2 0,4 0,0689 
CUBN up 2,5 0,1 0,0152 
CUL5 up 2,2 0,0 0,0085 
CUX2 up 2,1 0,3 0,0531 
CWC22 down -2,1 0,3 0,0677 
CX3CL1 up 2,9 0,4 0,0451 
CX3CR1 up 6,4 3,1 0,1228 
CXADR down -2,1 0,0 0,0052 
CXCL1 down -3,3 2,7 0,2204 
CXCL2 down -7,1 4,5 0,1533 
CXCL3 down -12,3 3,4 0,0676 
CXCL5 down -14,1 3,8 0,0647 
CXCR7 up 122,0 152,7 0,2319 
CXorf15 down -2,4 0,9 0,1421 
CXorf48 up 2,5 0,3 0,0413 
CXorf61 up 9,5 8,3 0,1918 
CXorf65 down -13,9 0,4 0,0077 
CYFIP2 up 4,0 0,8 0,0577 
CYP17A1 up 3,7 0,6 0,0498 
CYP19A1 up 2,1 0,0 0,0032 
CYP1B1 up 24,5 14,3 0,1289 
CYP21A2 up 3,8 1,4 0,1058 
CYP26B1 down -4,2 1,1 0,0791 
CYP27A1 up 2,8 0,2 0,0268 
CYP2A13 up 2,9 1,5 0,1665 
CYP2A6 up 3,1 2,5 0,2171 
CYP2A7 up 3,0 2,4 0,2217 
CYP2B6 up 2,1 0,8 0,1515 
CYP2C9 up 3,3 2,1 0,1787 
CYP2D6 up 2,3 0,7 0,1071 
CYP2E1 up 6,9 4,0 0,1413 
CYP2U1 up 2,2 0,7 0,1223 
CYP3A4 down -2,3 0,3 0,0492 
CYP3A5 down -2,8 0,2 0,0260 
CYP3A7 down -2,1 0,4 0,0813 
CYP4A11 up 2,8 1,2 0,1451 
CYP4F12 up 2,3 0,1 0,0172 
CYP4F2 up 2,3 0,1 0,0247 
CYP7A1 up 6,9 0,9 0,0356 
CYR61 down -3,4 2,4 0,1946 
CYTSB up 6,3 0,1 0,0048 
DAB2 down -2,1 0,0 0,0050 
DAB2IP up 12,5 8,5 0,1537 
DAPK1 up 2,3 0,4 0,0638 
DCDC2 down -5,9 0,8 0,0387 
DCLK3 up 3,2 0,5 0,0480 
DCP2 down -2,1 0,4 0,0890 
DDAH1 up 2,0 0,4 0,0849 
DDO up 2,8 0,5 0,0588 
DDX10 down -2,1 0,0 0,0073 
DDX17 down -2,3 0,6 0,0911 
DDX26B up 9,4 4,2 0,1083 
DDX52 down -2,1 0,6 0,1192 
DDX60 up 5,6 3,2 0,1441 
DENND1B down -2,7 0,1 0,0078 
DENND2A up 8,6 2,2 0,0647 








































































DENND2C up 2,2 0,5 0,0893 
DENND4A down -2,8 0,0 0,0040 
DES down -2,9 0,9 0,1028 
DFNB59 down -2,5 0,5 0,0662 
DGCR8 down -2,8 0,2 0,0281 
DGKB down -14,5 1,1 0,0182 
DGKG down -8,7 4,5 0,1255 
DHCR24 up 2,0 0,2 0,0426 
DHDPSL up 5,4 1,4 0,0696 
DHRS2 up 3,3 0,1 0,0088 
DIAPH2 down -2,4 0,1 0,0110 
DIAPH3 down -3,1 0,0 0,0039 
DICER1 down -2,3 0,1 0,0250 
DIO1 up 2,9 0,4 0,0512 
DIP2C up 57,2 22,4 0,0875 
DIS3 down -2,6 0,1 0,0164 
DISC1 down -6,7 4,1 0,1510 
DISP2 up 6,5 1,7 0,0674 
DKFZP434L187 up 6,2 0,4 0,0168 
DKFZP547L112 up 14,3 7,3 0,1170 
DKFZP564C152 down -2,6 0,5 0,0703 
DKFZp667E0512 down -3,0 0,4 0,0438 
DKK4 down -10,6 0,1 0,0015 
DLC1 up 2,2 0,2 0,0396 
DLG3 up 6,3 0,5 0,0231 
DLK2 up 3,1 0,4 0,0475 
DLX1 down -6,6 3,9 0,1432 
DLX2 down -2,6 0,7 0,0916 
DMKN up 3,0 1,5 0,1523 
DMTF1 down -2,2 0,6 0,1151 
DNA2 down -2,3 0,4 0,0691 
DNAH14 down -2,2 0,2 0,0474 
DNAJA4 up 5,3 4,7 0,2101 
DNAJB14 down -2,3 0,5 0,0803 
DNAJB2 up 2,1 0,3 0,0726 
DNAJC2 down -3,0 0,6 0,0660 
DNAJC25 up 2,1 0,3 0,0526 
DNAJC3 down -2,1 0,3 0,0710 
DNM1L down -2,4 0,5 0,0835 
DNMBP up 2,2 0,1 0,0245 
DNMT3B up 3,1 0,3 0,0300 
DNMT3L up 3,6 2,3 0,1772 
DNTTIP2 down -2,5 0,5 0,0721 
DOCK7 down -2,3 0,1 0,0152 
DOK1 up 3,0 0,7 0,0760 
DOK3 up 2,9 0,5 0,0594 
DOLPP1 up 2,2 0,3 0,0615 
DPF3 up 2,6 0,4 0,0578 
DPY19L1P1 down -2,6 0,4 0,0582 
DPY19L2P4 down -2,7 0,1 0,0119 
DPYD up 2,1 0,3 0,0537 
DPYS down -8,6 8,5 0,2133 
DPYSL2 up 2,3 0,1 0,0110 
DPYSL5 up 13,4 12,4 0,1957 
DQX1 down -5,2 1,3 0,0699 
DSE up 2,9 1,2 0,1383 
DST down -2,3 0,0 0,0053 
DTNA down -3,8 0,5 0,0396 
DUSP26 up 16,8 5,9 0,0819 
DUSP6 down -3,8 1,9 0,1405 
DYDC2 up 2,8 0,2 0,0241 
DYNLT3 down -2,6 0,2 0,0257 
DZIP1L up 7,7 1,3 0,0425 
EBF3 down -3,2 2,7 0,2300 
ECE1 up 2,2 0,2 0,0371 
ECHDC3 down -4,0 2,0 0,1409 
EDEM3 down -2,0 0,3 0,0720 
EDNRB down -4,0 3,0 0,1974 
EEA1 down -2,2 0,2 0,0283 
EEF1E1 down -2,0 0,1 0,0307 
EFEMP1 down -35,6 47,7 0,2461 
EFHD1 up 2,5 0,6 0,0919 
EFR3B up 13,9 6,5 0,1084 
EFTUD1 down -2,7 0,3 0,0435 
EGFL7 up 2,0 0,1 0,0204 
EGR1 down -2,3 0,6 0,1006 
EHBP1 down -2,2 0,1 0,0222 
EHD3 up 4,2 2,0 0,1310 
EIF3A down -2,3 0,7 0,1200 
EIF4EBP2 up 2,0 0,2 0,0409 
EIF5 down -2,9 0,9 0,1093 
EIF5B down -2,5 0,8 0,1213 
ELOVL6 down -3,1 1,3 0,1290 
ELOVL7 up 2,8 1,3 0,1476 
EMID1 up 3,0 0,2 0,0269 
EMILIN2 up 2,2 1,3 0,2078 
EML1 up 2,7 1,2 0,1453 
EML4 down -4,2 0,2 0,0174 
EMP2 up 9,2 4,9 0,1285 
EMR1 up 10,4 7,5 0,1649 
ENAH down -2,5 0,2 0,0241 
ENC1 down -6,5 2,8 0,1091 
ENDOD1 up 6,5 4,7 0,1734 
ENPP4 down -3,5 2,8 0,2116 








































































ENPP6 down -9,5 0,0 0,0008 
ENTPD8 up 2,9 0,2 0,0192 
EP400 up 2,2 0,3 0,0567 
EPB41L1 up 5,1 1,6 0,0868 
EPB41L3 up 19,2 16,6 0,1819 
EPB41L4B up 2,1 0,4 0,0870 
EPCAM down -8,1 8,8 0,2286 
EPHA10 up 4,0 0,4 0,0279 
EPM2AIP1 down -2,5 1,1 0,1567 
EPN3 down -2,8 0,8 0,1017 
EPRS down -2,0 0,2 0,0524 
EPS8 down -3,1 0,1 0,0131 
EPSTI1 up 4,4 1,2 0,0784 
ERAP1 down -4,9 0,0 0,0005 
ERAP2 down -3,4 0,0 0,0019 
EREG down -2,2 0,0 0,0038 
ERMAP up 2,8 0,1 0,0185 
ESPN up 2,4 0,3 0,0419 
ESPNL up 2,4 0,2 0,0243 
ETAA1 down -2,4 0,5 0,0731 
ETNK2 up 2,5 0,5 0,0681 
ETS1 down -2,9 0,3 0,0338 
ETS2 down -2,2 0,1 0,0190 
ETV1 down -3,7 0,8 0,0622 
ETV4 down -4,3 0,3 0,0220 
ETV5 down -3,2 0,2 0,0206 
EVC2 down -3,1 0,3 0,0280 
EVI5 down -2,0 0,2 0,0418 
EXOC5 down -2,0 0,5 0,1114 
EXPH5 up 2,8 0,2 0,0285 
EXT1 down -2,4 0,1 0,0201 
EYA3 down -2,7 0,0 0,0046 
EYA4 down -10,5 0,7 0,0158 
F9 up 89,3 105,2 0,2229 
FAAH up 2,4 0,4 0,0673 
FABP6 up 2,3 0,6 0,1112 
FADS1 up 2,6 0,1 0,0128 
FADS6 up 3,5 1,1 0,0951 
FAM105A down -10,0 10,0 0,2115 
FAM111B down -3,7 1,5 0,1161 
FAM129A down -2,6 0,1 0,0193 
FAM133A down -68,5 26,6 0,0865 
FAM133B down -2,0 0,1 0,0274 
FAM135A down -3,9 0,1 0,0106 
FAM13A down -2,5 0,8 0,1124 
FAM13AOS down -3,1 0,0 0,0016 
FAM150A down -2,9 0,0 0,0044 
FAM153A down -2,4 0,1 0,0183 
FAM153B down -2,9 0,1 0,0114 
FAM155B down -2,3 0,7 0,1126 
FAM167A up 5,1 1,1 0,0590 
FAM171A1 up 7,3 4,2 0,1412 
FAM171B down -5,4 3,8 0,1761 
FAM174B down -3,4 1,8 0,1594 
FAM178A down -2,1 0,8 0,1485 
FAM183A up 3,5 1,5 0,1225 
FAM184A down -2,0 0,6 0,1251 
FAM188B down -8,9 8,3 0,2030 
FAM189A1 up 8,7 5,3 0,1435 
FAM20A up 7,9 2,0 0,0654 
FAM20C up 8,5 1,6 0,0479 
FAM22A up 2,2 0,5 0,0940 
FAM22D up 5,0 1,5 0,0804 
FAM38B down -9,5 5,5 0,1365 
FAM3B down -3,1 2,7 0,2392 
FAM40B down -2,3 0,1 0,0231 
FAM50B up 2,3 0,3 0,0427 
FAM60A down -2,1 0,2 0,0380 
FAM78A up 4,1 0,4 0,0290 
FAM81A down -2,2 0,2 0,0365 
FAM9B down -186,7 108,2 0,1244 
FAM9C down -31,3 0,5 0,0041 
FANCB down -2,9 0,4 0,0493 
FANCD2 down -2,3 0,3 0,0520 
FANCI down -2,0 0,4 0,0822 
FANCL down -3,0 0,6 0,0711 
FANCM down -2,7 0,4 0,0573 
FAR1 down -2,0 0,2 0,0545 
FAR2 up 3,2 1,6 0,1491 
FASTKD1 down -2,5 0,2 0,0258 
FAT1 down -2,6 0,1 0,0167 
FBLN7 up 3,7 2,3 0,1717 
FBN1 up 2,3 0,4 0,0630 
FBP1 up 5,8 1,0 0,0470 
FBXL17 up 2,3 0,5 0,0893 
FBXL21 up 11,2 1,3 0,0293 
FBXL7 up 9,5 4,0 0,1021 
FBXO38 down -2,2 0,6 0,1077 
FBXO4 down -2,8 1,3 0,1459 
FBXW10 down -2,8 1,0 0,1199 
FBXW2 up 2,9 0,0 0,0057 
FCGBP up 2,5 1,1 0,1553 
FCGR2A up 2,4 0,3 0,0401 
FCGR3A up 22,6 14,5 0,1409 








































































FCRLA up 7,1 2,1 0,0758 
FCRLB up 4,4 1,5 0,0937 
FER down -2,0 0,7 0,1391 
FER1L4 up 4,3 2,5 0,1547 
FES up 5,8 1,0 0,0474 
FEZ1 up 8,0 3,7 0,1126 
FGD5 up 3,8 0,9 0,0709 
FGF13 down -7,3 6,3 0,1967 
FGF19 down -10,7 7,8 0,1645 
FGF2 up 11,0 4,8 0,1044 
FGF9 down -4,5 1,8 0,1117 
FGFR4 up 7,7 7,1 0,2050 
FGR up 3,6 0,2 0,0163 
FHL1 up 10,6 8,6 0,1793 
FHOD3 up 5,4 2,1 0,1037 
FILIP1 down -4,0 0,3 0,0255 
FLI1 down -59,3 31,6 0,1166 
FLJ11235 up 2,0 0,3 0,0584 
FLJ13744 down -2,2 0,1 0,0285 
FLJ23834 down -3,5 0,1 0,0132 
FLJ36031 up 2,2 0,1 0,0219 
FLJ37644 down -4,0 0,1 0,0108 
FLJ40330 down -6,6 0,9 0,0365 
FLJ40852 up 3,4 0,5 0,0493 
FLJ42875 up 3,0 1,2 0,1261 
FLJ45244 down -2,4 0,2 0,0303 
FLNC down -13,8 13,1 0,1996 
FLRT1 up 2,5 0,2 0,0242 
FLRT3 down -8,1 6,9 0,1900 
FLYWCH2 up 2,0 0,6 0,1274 
FMNL1 down -4,2 2,5 0,1575 
FMO1 up 15,7 10,7 0,1511 
FMO3 down -20,5 2,6 0,0301 
FMO4 up 3,4 1,0 0,0919 
FMO5 down -3,9 0,3 0,0224 
FNBP1L down -2,8 0,5 0,0644 
FNIP2 down -2,7 0,5 0,0646 
FOLR1 up 3,6 1,7 0,1381 
FOXC1 down -2,1 0,3 0,0520 
FOXG1 down -2,3 0,0 0,0067 
FOXN4 up 4,8 0,1 0,0053 
FOXO1 down -2,1 0,4 0,0782 
FOXO3 up 2,0 0,4 0,0896 
FRAS1 down -2,1 0,8 0,1488 
FRMD3 down -3,7 2,0 0,1549 
FRMD6 down -3,1 0,1 0,0116 
FRRS1 down -2,7 0,1 0,0082 
FRY down -2,1 0,5 0,1007 
FRYL down -2,5 0,6 0,0829 
FST down -3,6 0,7 0,0593 
FSTL5 down -18,0 13,6 0,1639 
FUT8 down -2,3 0,3 0,0444 
FUZ down -3,8 0,2 0,0166 
FZD2 up 2,0 0,2 0,0330 
FZD3 down -2,4 0,8 0,1155 
FZD4 down -2,1 1,4 0,2316 
FZD7 up 2,6 0,8 0,1084 
G0S2 up 2,1 0,8 0,1559 
G6PC up 3,6 1,2 0,0981 
GABARAPL1 up 2,0 0,8 0,1633 
GABRA5 up 4,6 2,8 0,1603 
GABRE down -3,5 0,4 0,0367 
GABRG2 down -2,2 0,9 0,1577 
GAD1 up 2,4 0,3 0,0498 
GADD45B up 2,5 0,0 0,0061 
GAFA3 down -4,7 0,1 0,0079 
GALNS up 5,5 1,9 0,0913 
GALNT6 up 6,7 3,0 0,1128 
GALNTL1 up 13,8 6,6 0,1121 
GARNL3 up 5,7 0,3 0,0142 
GAS5 down -2,1 0,1 0,0258 
GATA3 down -3,3 1,5 0,1355 
GATM up 3,8 2,0 0,1510 
GBA3 up 6,2 5,0 0,1907 
GBP2 down -2,7 0,7 0,0829 
GBP3 down -2,8 0,5 0,0591 
GCNT4 down -3,3 2,3 0,1940 
GCOM1 up 5,6 1,3 0,0644 
GDA down -3,3 0,1 0,0062 
GDF1 up 2,5 0,8 0,1184 
GDF10 up 20,0 8,0 0,0923 
GDF15 down -2,5 0,3 0,0381 
GDPD3 down -2,2 0,7 0,1261 
GEM up 2,6 0,0 0,0061 
GEN1 down -2,1 0,2 0,0465 
GGT8P down -2,2 0,2 0,0355 
GHR down -2,1 0,4 0,0812 
GIGYF2 down -2,1 0,4 0,0892 
GIMAP7 up 3,4 0,6 0,0596 
GIPC2 down -2,2 1,2 0,1915 
GJA1 down -7,4 0,1 0,0047 
GJA3 up 8,9 4,8 0,1298 
GLA down -2,2 0,1 0,0268 
GLE1 up 2,1 0,0 0,0063 








































































GLI1 up 5,2 2,1 0,1097 
GLIPR1 down -2,1 0,0 0,0027 
GLIPR2 down -4,0 3,9 0,2368 
GLS down -3,8 0,1 0,0117 
GLT1D1 up 6,7 5,7 0,1971 
GLT8D3 down -2,4 0,6 0,0994 
GLT8D4 up 2,7 0,0 0,0028 
GLUD1 up 2,0 0,3 0,0639 
GLUD2 up 2,4 0,4 0,0695 
GM2A up 2,1 0,1 0,0239 
GNB4 up 9,2 0,2 0,0049 
GNGT1 down -5,2 0,3 0,0168 
GNPDA2 down -2,2 0,3 0,0524 
GNRH1 down -2,3 0,6 0,1054 
GNS up 2,7 0,0 0,0043 
GOLGA2LY1 down -2,3 0,7 0,1164 
GOLGA4 down -4,7 0,8 0,0491 
GOLGA6A down -2,3 0,1 0,0120 
GOLGA6L10 down -2,2 0,7 0,1359 
GOLGA6L9 down -2,2 0,5 0,0866 
GOLGA8A down -2,4 0,0 0,0067 
GOLGA8F down -2,1 0,8 0,1515 
GOLGB1 down -2,4 0,6 0,0958 
GOLM1 down -8,8 9,2 0,2217 
GON4L down -2,1 0,0 0,0081 
GOT1 down -2,2 0,0 0,0055 
GPATCH4 down -2,3 0,3 0,0548 
GPBP1 down -2,1 0,3 0,0658 
GPC1 up 3,4 0,1 0,0140 
GPC4 up 5,1 1,9 0,1022 
GPC5 up 8,3 6,9 0,1863 
GPD1 up 2,4 0,5 0,0709 
GPD1L down -2,5 0,8 0,1171 
GPR109B down -2,7 1,4 0,1681 
GPR110 down -5,4 2,7 0,1310 
GPR126 down -3,4 0,3 0,0243 
GPR128 up 2,2 0,6 0,1007 
GPR133 up 2,3 0,4 0,0636 
GPR146 up 2,1 0,3 0,0530 
GPR158 down -2,4 0,5 0,0858 
GPR176 up 2,8 0,1 0,0071 
GPR177 down -3,1 0,6 0,0610 
GPR68 up 6,8 0,0 0,0008 
GPR81 down -2,7 0,5 0,0695 
GPRC5B up 2,8 1,6 0,1767 
GPRIN1 up 2,0 0,1 0,0172 
GPSM1 up 3,7 1,8 0,1374 
GPX7 down -8,8 0,1 0,0017 
GPX8 up 3,5 0,8 0,0702 
GRAMD3 down -2,1 0,1 0,0268 
GRB14 down -3,3 1,3 0,1175 
GREM1 down -4,5 2,8 0,1597 
GSN up 6,7 0,3 0,0109 
GSTA1 up 16,0 6,4 0,0932 
GSTA2 up 14,2 4,1 0,0696 
GSTA3 up 12,8 4,2 0,0787 
GSTA5 up 13,2 4,6 0,0826 
GSTO2 up 2,7 0,5 0,0718 
GTDC1 up 2,7 1,7 0,1997 
GTF2H5 down -2,1 0,5 0,0925 
GTF2IRD2 up 5,5 1,3 0,0659 
GUCA1B down -2,2 0,1 0,0148 
GUCY2C up 2,8 2,1 0,2219 
GULP1 down -4,1 0,0 0,0005 
H2AFY2 up 6,5 2,7 0,1074 
HAO2 up 7,9 6,5 0,1855 
HAUS6 down -2,1 0,2 0,0415 
HAVCR2 down -5,6 1,9 0,0889 
HBE1 down -4,9 2,1 0,1140 
HBG1 down -5,0 2,0 0,1089 
hCG_1817306 down -2,1 0,0 0,0041 
hCG_1993592 down -2,0 0,1 0,0209 
HCG27 down -2,5 1,3 0,1651 
HCP5 up 2,7 0,1 0,0116 
HDAC6 down -2,3 0,4 0,0661 
HDGFRP3 up 36,9 22,7 0,1342 
HDHD3 up 2,3 0,3 0,0468 
HEATR1 down -2,1 0,4 0,0830 
HECA up 3,5 0,6 0,0537 
HERC2P2 down -2,1 0,3 0,0637 
HERC6 up 3,2 0,8 0,0783 
HERV-FRD down -2,5 0,0 0,0018 
HEY1 up 2,7 0,9 0,1161 
HEY2 down -4,0 2,9 0,1922 
HEYL up 7,0 1,2 0,0461 
HHAT up 3,7 0,1 0,0119 
HIBCH down -2,1 0,1 0,0297 
HIST2H2BE up 2,6 0,2 0,0332 
HK2 down -2,6 0,7 0,0907 
HLA-DQB1 up 8,7 4,1 0,1145 
HLTF down -3,0 0,8 0,0845 
HMGCS2 up 3,0 1,0 0,1074 
HMGN1 down -3,8 0,8 0,0642 
HMGN5 down -3,3 0,2 0,0212 








































































HNRNPA3 down -2,2 0,3 0,0646 
HNRNPU down -2,5 0,1 0,0210 
HOMER2 up 5,0 0,5 0,0251 
HOOK1 down -3,2 0,2 0,0167 
HOXA13 up 2,6 2,1 0,2436 
HOXB5 down -12,0 2,0 0,0402 
HOXC13 down -7,5 2,7 0,0914 
HOXD10 down -2,4 0,0 0,0058 
HOXD8 down -2,4 0,6 0,0966 
HP up 2,8 1,1 0,1307 
HPGD down -3,5 0,9 0,0825 
HPR up 3,9 1,9 0,1354 
HPSE down -5,2 0,5 0,0265 
HRASLS up 8,3 3,1 0,0923 
HRC down -4,4 0,9 0,0592 
HRCT1 down -2,2 0,4 0,0767 
HRG up 2,5 0,7 0,0998 
HSD17B11 down -2,4 0,1 0,0231 
HSD17B12 down -2,0 0,2 0,0389 
HSD17B6 up 3,5 2,2 0,1727 
HSD3B1 up 4,6 3,5 0,1892 
HSP90AA1 down -2,2 0,1 0,0253 
HSP90B1 down -2,4 0,4 0,0723 
HSPA12A up 9,2 7,4 0,1802 
HSPA12B up 24,1 14,3 0,1318 
HSPA4L down -3,3 0,5 0,0517 
HSPA6 up 2,5 1,1 0,1481 
HSPH1 down -2,0 0,6 0,1279 
HTRA1 up 7,3 0,9 0,0328 
HYAL4 down -5,6 3,7 0,1657 
HYLS1 up 2,6 0,1 0,0099 
ICA1 up 2,0 0,3 0,0576 
ICA1L down -2,2 1,2 0,1896 
ICAM5 down -2,4 0,0 0,0032 
IDS down -2,3 0,0 0,0046 
IER3 down -4,2 0,5 0,0358 
IER5L down -2,3 0,4 0,0656 
IFI16 up 2,4 1,0 0,1425 
IFRD1 down -2,7 0,2 0,0303 
IFT80 down -2,4 0,2 0,0331 
IFT81 down -2,3 0,5 0,0758 
IFT88 down -2,3 0,3 0,0477 
IGFBP2 up 6,2 6,5 0,2298 
IGFBP3 up 2,5 0,2 0,0377 
IGFBP4 up 5,9 1,7 0,0766 
IGFBPL1 down -2,1 0,3 0,0610 
IGSF1 up 2,1 0,8 0,1530 
IGSF11 up 6,9 0,1 0,0028 
IGSF9 up 6,4 2,1 0,0873 
IKBKAP up 3,2 1,2 0,1148 
IL11RA up 2,2 0,1 0,0159 
IL13RA2 down -8,0 0,1 0,0023 
IL18 down -13,3 16,0 0,2369 
IL18R1 up 21,4 5,6 0,0615 
IL1F7 up 2,4 0,7 0,1101 
IL1R2 up 2,4 0,0 0,0027 
IL1RAP down -2,3 0,1 0,0236 
IL1RN up 6,0 0,7 0,0317 
IL22RA1 up 2,2 0,6 0,1058 
IL23R down -10,2 6,4 0,1449 
IL2RB down -5,2 4,0 0,1864 
IL2RG down -5,2 1,1 0,0591 
IL6ST down -2,4 0,4 0,0723 
IL8 down -6,1 4,4 0,1734 
IMPA2 up 2,3 1,0 0,1568 
INHBE up 5,4 0,7 0,0377 
INPP1 down -2,9 0,5 0,0518 
INPP5D up 17,9 5,7 0,0747 
INPP5K up 2,1 0,3 0,0546 
INTS6 down -2,2 0,1 0,0127 
IPO7 down -2,0 0,5 0,1042 
IPW down -3,1 1,5 0,1474 
IQCA1 up 30,2 5,7 0,0438 
IQCK up 2,8 0,2 0,0289 
IQGAP2 down -2,8 1,5 0,1672 
IQSEC2 up 2,2 0,6 0,1055 
IRF8 up 3,6 2,1 0,1609 
IRF9 up 2,6 0,3 0,0471 
IRS2 up 2,2 0,8 0,1313 
IRX3 up 5,2 3,8 0,1807 
ISCA1 up 2,1 0,3 0,0555 
ISX up 4,1 0,7 0,0525 
ITGA1 down -2,3 0,1 0,0119 
ITGA2 down -6,7 0,1 0,0023 
ITGA3 up 4,0 2,7 0,1779 
ITGAM up 4,0 3,5 0,2212 
ITGAV down -2,7 0,2 0,0301 
ITGB1BP2 up 2,2 0,7 0,1278 
ITGB2 up 9,0 9,5 0,2220 
ITIH1 up 7,5 4,5 0,1463 
ITIH3 up 3,4 2,6 0,2069 
ITIH4 up 3,3 1,9 0,1675 
ITLN1 up 2,0 0,4 0,0861 
ITPR3 up 6,1 2,0 0,0841 








































































ITPRIPL1 down -2,2 0,5 0,0957 
ITSN2 down -2,5 0,9 0,1255 
IYD up 8,7 1,3 0,0373 
JAG1 down -5,0 4,2 0,2041 
JAZF1 up 5,4 0,3 0,0163 
JMJD1C down -2,7 0,4 0,0573 
JUN down -3,0 0,7 0,0749 
KALRN down -8,4 2,2 0,0674 
KANK1 up 2,1 0,4 0,0773 
KANK3 up 2,0 0,5 0,1087 
KANK4 up 54,9 26,3 0,1059 
KBTBD11 up 40,0 24,9 0,1347 
KCNC1 up 6,1 0,5 0,0237 
KCNC3 up 3,4 0,3 0,0247 
KCNE1L down -3,1 1,2 0,1165 
KCNE3 up 10,6 5,8 0,1293 
KCNJ15 down -2,7 0,1 0,0171 
KCNJ16 up 187,5 13,2 0,0159 
KCNJ8 up 2,4 0,7 0,1014 
KCNK10 up 6,3 2,9 0,1163 
KCNK5 up 7,4 2,0 0,0681 
KCNQ1OT1 down -2,4 0,4 0,0621 
KCTD5 up 2,1 0,1 0,0136 
KCTD7 down -2,1 0,5 0,0926 
KDM4D up 2,1 0,2 0,0432 
KHDC1 up 2,7 0,3 0,0354 
KIAA0040 up 5,6 2,8 0,1290 
KIAA0125 up 2,6 0,5 0,0708 
KIAA0232 down -2,3 0,8 0,1303 
KIAA0319 up 5,3 4,2 0,1909 
KIAA0564 down -2,2 0,1 0,0161 
KIAA0802 down -2,8 1,6 0,1804 
KIAA0907 down -2,2 0,1 0,0135 
KIAA0947 down -2,7 0,4 0,0510 
KIAA1009 down -2,8 0,6 0,0725 
KIAA1107 down -2,3 1,0 0,1632 
KIAA1109 down -4,1 0,4 0,0261 
KIAA1147 down -2,4 0,3 0,0550 
KIAA1161 up 3,8 0,6 0,0498 
KIAA1199 up 18,8 23,2 0,2366 
KIAA1377 up 5,5 3,1 0,1443 
KIAA1430 down -2,3 0,0 0,0023 
KIAA1549 down -3,0 0,4 0,0479 
KIAA1656 up 3,7 0,6 0,0482 
KIAA1683 down -2,1 0,0 0,0052 
KIAA1712 down -2,6 0,0 0,0008 
KIAA1731 down -3,4 0,5 0,0449 
KIAA1804 down -2,6 0,5 0,0737 
KIAA1908 up 2,4 0,0 0,0045 
KIAA1967 up 2,5 0,3 0,0498 
KIF14 down -3,1 0,5 0,0533 
KIF15 down -3,8 0,1 0,0115 
KIF20B down -2,6 0,6 0,0822 
KIF21A down -2,1 0,5 0,0973 
KIF3A down -2,5 0,8 0,1081 
KIF6 up 2,5 1,0 0,1370 
KIRREL down -2,2 1,0 0,1668 
KLC4 up 2,4 0,0 0,0038 
KLF2 up 2,8 0,6 0,0701 
KLHL24 up 3,0 1,5 0,1606 
KLHL3 up 2,2 0,3 0,0661 
KLHL34 down -5,7 2,0 0,0947 
KLHL5 down -2,3 0,6 0,1067 
KNG1 up 10,5 0,0 0,0001 
KRAS down -2,1 0,0 0,0097 
KRCC1 down -3,3 0,9 0,0852 
KREMEN1 up 3,3 0,0 0,0035 
KRT222 down -2,3 0,9 0,1489 
KRT23 down -15,1 13,6 0,1897 
KRT6A up 10,9 3,9 0,0871 
KRT86 down -2,0 0,1 0,0283 
KRTAP19-1 down -3,1 1,2 0,1215 
KRTCAP3 down -2,0 0,3 0,0601 
KRTDAP up 4,9 2,2 0,1232 
KTN1 down -3,2 0,9 0,0882 
KYNU down -2,9 0,3 0,0324 
L3MBTL3 up 3,5 0,8 0,0739 
LAMA4 down -19,9 22,9 0,2255 
LAMB1 down -4,9 2,1 0,1174 
LAMB3 up 2,3 0,1 0,0234 
LANCL2 up 2,7 0,3 0,0431 
LARGE up 10,3 1,9 0,0457 
LARP1B down -2,5 0,6 0,0846 
LARP7 down -3,0 0,8 0,0826 
LARS down -2,3 0,7 0,1161 
LAT2 up 2,1 0,4 0,0737 
LBP up 9,0 6,7 0,1695 
LCA5 down -4,1 2,6 0,1745 
LCAT up 2,9 0,2 0,0256 
LCORL down -2,5 0,5 0,0782 
LCP1 down -10,3 3,0 0,0707 
LDHD up 2,0 0,0 0,0079 
LDLRAD1 up 8,7 3,2 0,0894 
LDOC1L up 2,1 0,2 0,0456 








































































LEF1 up 20,9 14,2 0,1490 
LEFTY1 up 5,2 3,5 0,1710 
LEO1 down -2,2 0,3 0,0564 
LEPR up 2,9 0,5 0,0620 
LFNG down -6,5 2,7 0,1075 
LGALS1 down -2,2 0,0 0,0083 
LGALS2 up 2,8 0,1 0,0100 
LHPP up 2,4 0,0 0,0077 
LHX1 down -4,9 0,9 0,0529 
LHX2 up 4,7 2,4 0,1353 
LHX6 up 5,4 1,6 0,0794 
LIFR up 13,7 7,1 0,1207 
LIG4 down -2,2 0,0 0,0009 
LILRB3 down -2,3 0,2 0,0294 
LIMA1 down -3,8 1,8 0,1345 
LIMCH1 down -2,1 0,1 0,0232 
LIMD2 up 2,2 0,4 0,0700 
LIN54 down -2,5 0,2 0,0252 
LINGO1 down -40,6 11,1 0,0620 
LIPG down -2,1 1,1 0,1970 
LITAF up 23,3 9,9 0,0967 
LMBRD2 down -2,1 0,4 0,0812 
LNPEP down -2,4 0,6 0,0997 
LNX1 down -2,0 0,2 0,0349 
LOC100127983 down -3,5 1,4 0,1205 
LOC100128164 up 10,8 9,4 0,1893 
LOC100128842 down -2,1 0,6 0,1158 
LOC100129104 down -2,5 0,4 0,0570 
LOC100129291 down -4,5 1,5 0,0940 
LOC100129488 down -3,4 0,3 0,0253 
LOC100130506 down -2,1 0,2 0,0513 
LOC100130967 up 3,2 1,0 0,1008 
LOC100131067 up 2,5 0,2 0,0246 
LOC100131504 up 4,4 2,5 0,1524 
LOC100131564 down -2,1 0,5 0,1070 
LOC100131646 up 2,3 0,4 0,0741 
LOC100131929 down -2,4 0,3 0,0488 
LOC100132247 down -2,4 0,1 0,0138 
LOC100134228 down -2,0 0,3 0,0747 
LOC100134229 up 2,1 0,6 0,1265 
LOC100170939 down -2,2 0,7 0,1243 
LOC100286895 down -2,1 0,7 0,1346 
LOC100286909 down -2,4 0,7 0,1100 
LOC100287412 up 2,0 0,0 0,0037 
LOC100287869 up 2,2 0,6 0,1102 
LOC100288367 down -3,0 0,6 0,0713 
LOC100288671 down -2,1 0,1 0,0149 
LOC100288846 up 3,2 0,3 0,0275 
LOC100289058 down -2,5 0,3 0,0395 
LOC100289169 down -2,7 0,9 0,1074 
LOC100289490 up 2,9 0,3 0,0360 
LOC100289574 down -2,0 0,7 0,1378 
LOC100292427 up 2,3 0,3 0,0434 
LOC100293208 down -2,4 0,0 0,0037 
LOC134466 down -2,6 1,0 0,1350 
LOC145783 down -4,0 0,1 0,0068 
LOC150759 down -4,2 1,8 0,1201 
LOC151438 up 4,9 1,6 0,0883 
LOC157562 down -2,2 0,5 0,0897 
LOC221442 down -7,8 4,9 0,1492 
LOC283352 up 2,9 0,8 0,0944 
LOC283663 down -2,6 0,2 0,0262 
LOC283788 down -3,0 0,3 0,0320 
LOC284232 up 2,9 0,0 0,0009 
LOC284542 down -2,2 1,1 0,1804 
LOC284561 up 2,1 0,6 0,1104 
LOC285216 down -2,6 0,7 0,0900 
LOC285441 down -2,9 0,0 0,0040 
LOC338620 down -3,3 1,2 0,1089 
LOC339240 down -2,9 0,3 0,0353 
LOC339524 down -4,2 1,6 0,1088 
LOC340888 down -2,4 1,2 0,1752 
LOC344887 down -6,7 0,9 0,0359 
LOC346887 down -3,1 1,2 0,1200 
LOC348751 up 4,5 0,0 0,0031 
LOC374491 down -2,2 0,5 0,0822 
LOC387895 down -3,3 1,7 0,1506 
LOC388242 down -2,1 0,5 0,0958 
LOC388630 down -2,8 1,8 0,1990 
LOC389634 up 4,8 0,7 0,0405 
LOC389831 down -2,1 0,1 0,0300 
LOC399815 down -2,6 0,5 0,0642 
LOC400027 up 2,2 0,2 0,0375 
LOC400987 down -2,1 0,2 0,0387 
LOC439949 up 7,7 0,7 0,0243 
LOC440173 up 2,0 0,2 0,0402 
LOC441208 up 3,5 0,1 0,0066 
LOC441601 down -2,1 0,0 0,0074 
LOC441666 down -4,5 0,8 0,0514 
LOC552889 up 12,1 3,4 0,0687 
LOC642413 up 2,1 0,2 0,0313 
LOC644662 up 3,0 0,1 0,0081 
LOC646509 up 2,1 0,1 0,0160 
LOC646936 down -4,6 2,3 0,1333 








































































LOC646976 up 2,1 0,4 0,0717 
LOC650226 up 2,1 0,6 0,1160 
LOC723809 down -17,9 0,3 0,0035 
LOC727758 down -2,2 0,0 0,0093 
LOC727916 up 2,4 0,3 0,0502 
LOC729683 up 2,3 0,1 0,0136 
LOC729806 down -3,9 1,9 0,1347 
LOC729817 down -2,4 0,1 0,0226 
LOC730098 up 3,0 0,7 0,0744 
LOC84740 down -4,1 3,9 0,2298 
LOH3CR2A down -2,1 0,5 0,0984 
LONRF1 down -2,0 0,1 0,0110 
LOXL1 up 9,5 7,7 0,1805 
LOXL2 up 27,6 15,6 0,1252 
LOXL4 up 5,4 1,4 0,0689 
LPA up 3,1 0,8 0,0787 
LPAL2 up 3,4 0,3 0,0283 
LPCAT3 up 2,7 0,3 0,0420 
LPGAT1 down -2,2 0,4 0,0718 
LPP down -2,0 0,0 0,0057 
LRFN5 down -4,2 0,0 0,0013 
LRMP up 4,1 2,0 0,1369 
LRP11 up 2,5 0,4 0,0655 
LRP12 down -3,9 0,0 0,0031 
LRP4 up 2,3 1,3 0,1911 
LRRC16A up 7,0 4,4 0,1503 
LRRC27 up 4,5 2,3 0,1362 
LRRC31 up 4,5 0,6 0,0355 
LRRC39 down -3,7 1,2 0,0933 
LRRC4 down -2,1 0,5 0,0900 
LRRC47 up 2,5 0,0 0,0031 
LRRC48 up 2,3 0,1 0,0114 
LRRC6 up 12,0 1,1 0,0231 
LRRCC1 down -3,5 0,6 0,0560 
LRRFIP1 down -2,2 0,6 0,1083 
LSAMP down -2,1 0,0 0,0057 
LTB down -2,8 2,1 0,2203 
LTBP1 up 137,0 2,8 0,0047 
LUC7L3 down -3,6 0,8 0,0652 
LUM down -6,8 3,5 0,1296 
LUZP4 up 8,5 1,2 0,0371 
LY6G5C up 3,1 0,6 0,0641 
LY6K up 2,1 0,2 0,0313 
LY75 down -8,2 4,3 0,1274 
LY96 down -6,2 0,7 0,0307 
LYG1 down -2,4 0,5 0,0791 
LYNX1 down -2,8 0,6 0,0713 
LYPD1 up 8,2 4,4 0,1297 
LYSMD3 down -2,9 0,6 0,0649 
LYST down -3,2 0,1 0,0129 
LYZ down -4,8 0,3 0,0182 
MACF1 down -2,2 0,5 0,0981 
MACROD2 down -12,1 0,4 0,0078 
MAF up 2,7 0,4 0,0536 
MAFB up 3,6 0,2 0,0207 
MAFF down -2,9 0,8 0,0987 
MAG up 2,1 0,5 0,0971 
MAGEA10 up 9,6 0,8 0,0204 
MAGEA9 up 12,1 4,4 0,0863 
MAGEB2 up 17,7 2,4 0,0325 
MAGEC1 up 20,7 10,3 0,1130 
MAGEC2 up 6,1 0,6 0,0272 
MALAT1 down -4,4 1,7 0,1125 
MAN1C1 up 5,6 3,0 0,1386 
MANBA down -2,1 0,2 0,0472 
MAP3K8 down -2,1 0,9 0,1711 
MAP4K3 down -2,2 0,2 0,0396 
MAPK13 up 3,4 0,2 0,0175 
MAPKAP1 up 2,1 0,1 0,0226 
MAPT down -2,8 0,6 0,0681 
MARCO up 8,5 7,7 0,1986 
MARK1 up 2,6 0,5 0,0639 
MARVELD1 up 12,6 0,9 0,0172 
MASP2 up 2,6 0,8 0,1032 
MAT2A down -2,5 0,3 0,0429 
MATN2 up 2,0 0,6 0,1319 
MBD2 up 2,7 0,2 0,0288 
MBL2 up 2,1 0,1 0,0232 
MBNL1 down -2,5 0,1 0,0128 
MBNL2 down -2,8 1,4 0,1644 
MBOAT2 up 4,7 2,0 0,1182 
MBP down -15,3 12,8 0,1799 
MBTPS1 up 2,0 0,1 0,0111 
MCC down -10,5 1,4 0,0330 
MCM3APAS down -2,8 0,1 0,0128 
MCTS1 down -3,3 1,7 0,1547 
ME3 down -2,1 0,9 0,1747 
MEG3 down -2,0 0,1 0,0126 
MEIS2 down -2,1 0,3 0,0676 
MESP1 up 3,3 0,2 0,0211 
MET down -2,4 0,4 0,0646 
METTL7A up 3,5 2,0 0,1626 
MFAP2 up 3,2 1,0 0,0994 
MFGE8 up 2,4 0,0 0,0002 








































































MFNG up 2,4 0,9 0,1276 
MFSD8 down -2,4 0,7 0,1013 
MGC23270 up 2,3 0,2 0,0290 
MGC24125 down -2,7 0,9 0,1097 
MGC70870 down -3,2 0,8 0,0808 
MIB2 up 3,3 0,2 0,0191 
MID2 down -2,6 0,4 0,0512 
MIPOL1 down -2,0 0,7 0,1391 
MIR17HG down -2,6 1,1 0,1459 
MKKS down -2,0 0,2 0,0335 
MKLN1 down -3,2 0,7 0,0720 
MLF1 down -2,1 0,4 0,0867 
MLH3 down -3,1 0,7 0,0744 
MLLT11 down -2,8 0,6 0,0796 
MLLT3 down -2,0 0,3 0,0631 
MLXIP up 2,8 0,5 0,0674 
MMD down -2,1 0,6 0,1175 
MMP11 up 2,1 0,3 0,0511 
MMP15 down -2,9 1,3 0,1402 
MMP23B down -2,1 0,6 0,1172 
MNS1 down -2,2 0,7 0,1271 
MOBKL1A down -2,2 0,6 0,1082 
MOBKL2B up 3,0 1,1 0,1207 
MOGAT2 down -3,2 0,0 0,0018 
MORC3 down -2,4 0,4 0,0732 
MORC4 down -2,3 0,3 0,0438 
MOSPD2 down -2,2 0,8 0,1405 
MOXD1 up 5,1 2,0 0,1061 
MPDZ down -2,2 0,4 0,0704 
MPHOSPH10 down -2,7 0,5 0,0691 
MPP1 up 3,2 1,4 0,1294 
MPP7 up 6,0 1,7 0,0764 
MPV17L up 2,5 1,1 0,1550 
MRC1L1 down -3,5 0,4 0,0368 
MRPL30 up 2,3 0,3 0,0567 
MRPL42P5 up 2,0 0,3 0,0733 
MSH2 down -2,0 0,2 0,0416 
MSH3 down -2,0 0,2 0,0391 
MSRA up 2,7 0,2 0,0227 
MST1R down -5,3 2,7 0,1318 
MT1B up 2,1 0,1 0,0214 
MT1F up 4,1 0,1 0,0048 
MT1G up 2,2 0,0 0,0031 
MT1H up 2,1 0,0 0,0067 
MT1X up 2,2 0,1 0,0107 
MTBP down -2,5 0,1 0,0181 
MTHFD2 down -2,6 0,5 0,0634 
MTMR11 up 2,4 1,4 0,1976 
MTMR6 down -2,0 0,1 0,0290 
MTMR8 down -3,8 0,5 0,0419 
MTMR9L down -4,4 0,9 0,0575 
MUC15 down -2,1 0,1 0,0122 
MUC4 down -2,0 0,2 0,0440 
MVK up 2,3 0,2 0,0387 
MVP up 3,7 0,1 0,0105 
MXRA8 down -2,8 1,3 0,1485 
MYCBP2 down -3,8 1,3 0,0971 
MYCN down -95,7 112,8 0,2228 
MYH10 down -2,0 0,3 0,0547 
MYH3 down -2,0 0,4 0,0843 
MYL5 up 2,6 0,6 0,0865 
MYO10 down -2,2 0,1 0,0151 
MYO1D up 4,9 0,9 0,0485 
MYO5A down -2,4 1,2 0,1683 
MYO5C down -2,2 0,3 0,0511 
MYO6 down -2,6 0,3 0,0415 
MYO9A down -2,9 0,3 0,0350 
MYOM2 up 6,3 3,9 0,1526 
MYSM1 down -3,1 0,9 0,0943 
N4BP2 down -2,7 0,5 0,0610 
N4BP2L2 down -2,5 0,1 0,0181 
NAAA down -2,2 0,7 0,1357 
NARG1 down -2,5 0,2 0,0241 
NARG1L down -2,2 0,7 0,1253 
NAT8 down -2,7 1,0 0,1276 
NAT8L up 2,1 0,8 0,1597 
NBN down -2,1 0,1 0,0285 
NCALD up 3,2 1,7 0,1548 
NCAPG down -2,2 0,5 0,0951 
NCOA7 down -3,9 1,4 0,1052 
NCRNA00087 up 2,0 0,2 0,0409 
NCRNA00164 down -2,5 1,6 0,2062 
NDRG1 up 4,4 0,3 0,0221 
NDRG4 up 3,5 1,1 0,0997 
NEAT1 down -2,2 0,7 0,1263 
NEBL up 3,5 0,5 0,0408 
NECAB1 down -5,0 3,3 0,1700 
NEK1 down -2,5 0,5 0,0761 
NEK6 up 2,2 0,3 0,0560 
NES down -4,4 0,3 0,0225 
NETO2 up 3,8 0,4 0,0351 
NEURL1B up 3,0 0,1 0,0150 
NEXN down -2,7 0,4 0,0566 
NFASC up 6,4 5,9 0,2091 








































































NFATC4 up 2,1 0,5 0,1082 
NFIB down -2,4 0,1 0,0103 
NFKBIE down -2,3 0,8 0,1347 
NHS down -16,3 5,4 0,0773 
NIN down -2,1 0,6 0,1283 
NIPBL down -2,3 0,3 0,0495 
NKTR down -3,2 0,7 0,0688 
NKX2-1 up 2,2 0,2 0,0413 
NLGN2 up 3,1 0,6 0,0632 
NLRC5 up 2,6 0,1 0,0144 
NLRP2 up 2,1 0,1 0,0111 
NLRP5 down -5,2 3,7 0,1783 
NNMT down -2,4 0,7 0,1091 
NOC3L down -2,4 0,6 0,0930 
NOL8 down -2,1 0,7 0,1322 
NOM1 down -2,2 0,1 0,0136 
NOSTRIN down -3,1 0,8 0,0846 
NOTCH1 up 2,6 1,5 0,1912 
NPAS1 down -2,2 0,5 0,0876 
NPEPPS down -2,0 0,2 0,0468 
NPHP1 up 3,2 1,7 0,1532 
NPM2 down -2,7 1,0 0,1273 
NPNT up 16,7 11,6 0,1529 
NR0B2 down -8,9 5,5 0,1455 
NR1I3 up 3,8 0,7 0,0591 
NR2E3 down -3,0 0,2 0,0229 
NRCAM down -2,0 0,5 0,1049 
NRG4 up 4,4 1,0 0,0651 
NRIP1 down -2,4 0,0 0,0053 
NRXN3 up 21,4 15,8 0,1597 
NSD1 up 2,5 0,1 0,0131 
NT5E down -2,9 1,4 0,1545 
NTN5 up 4,6 2,4 0,1430 
NUAK2 down -2,9 1,7 0,1778 
NUDT13 down -3,4 0,0 0,0003 
NUDT9 down -2,7 0,1 0,0150 
NUFIP2 down -2,6 0,7 0,0946 
NUP205 down -2,2 0,4 0,0842 
NXF2 up 6,0 2,9 0,1232 
NXF5 up 6,0 2,8 0,1215 
NXN up 2,2 0,0 0,0017 
NYNRIN up 2,3 0,7 0,1210 
OASL up 3,6 1,6 0,1353 
OAT up 2,1 0,2 0,0518 
OBFC1 up 2,3 0,3 0,0582 
OBSCN up 2,2 0,4 0,0801 
OCA2 up 2,8 0,4 0,0518 
ODF2L down -2,8 1,1 0,1309 
OFD1 down -2,2 0,6 0,1121 
ONECUT1 up 2,1 0,6 0,1177 
ONECUT2 down -3,1 0,8 0,0811 
OPHN1 down -3,5 0,3 0,0251 
OPN3 down -4,1 1,6 0,1145 
OR2A9P down -2,0 0,2 0,0463 
OR51B4 down -4,0 2,8 0,1847 
ORM2 up 2,4 0,2 0,0333 
OSBPL10 down -3,6 3,2 0,2273 
OSBPL3 down -2,2 0,7 0,1287 
OSBPL6 up 2,6 1,2 0,1530 
OSCAR up 3,3 1,5 0,1394 
OTC down -2,1 0,2 0,0317 
OTUD4 down -2,2 0,5 0,0825 
OTUD7B down -2,9 0,3 0,0312 
OXCT1 up 3,7 0,2 0,0167 
OXT up 7,2 1,4 0,0495 
OXTR down -2,5 0,6 0,0940 
P2RX5 down -2,6 1,1 0,1469 
P2RY2 up 2,0 0,2 0,0350 
PABPC1L down -7,3 0,5 0,0180 
PABPC4L down -4,1 1,3 0,0919 
PAGE4 up 3,4 1,8 0,1561 
PAICS down -2,3 0,2 0,0273 
PAIP2B up 3,7 1,4 0,1090 
PAK6 up 5,7 0,2 0,0117 
PALLD down -2,1 0,6 0,1203 
PALMD down -6,1 3,8 0,1542 
PAM down -2,0 0,6 0,1282 
PAQR8 down -3,1 1,3 0,1285 
PARD3B down -3,8 3,5 0,2267 
PARD6A down -2,3 0,3 0,0507 
PARP11 up 2,5 0,7 0,0987 
PARP14 down -2,1 0,6 0,1183 
PARVA up 4,7 1,9 0,1101 
PAX3 down -2,0 0,2 0,0451 
PBRM1 down -2,0 0,5 0,1127 
PBX3 up 2,0 0,3 0,0635 
PBX4 down -3,0 1,9 0,1836 
PC up 2,0 0,1 0,0218 
PCDH1 down -3,6 0,1 0,0110 
PCDH24 up 4,5 0,9 0,0548 
PCDHA1 up 2,5 0,1 0,0092 
PCDHB12 up 2,8 0,2 0,0229 
PCDHB2 up 2,1 0,1 0,0179 
PCDHB5 up 3,2 0,7 0,0679 








































































PCID2 down -5,1 1,6 0,0865 
PCK1 up 2,5 0,6 0,0827 
PCM1 down -2,3 1,2 0,1804 
PCP4L1 up 2,4 0,6 0,0974 
PCSK1N up 2,3 0,7 0,1213 
PCSK7 up 2,0 0,3 0,0741 
PDCD7 down -2,1 0,0 0,0023 
PDE4D down -12,5 9,4 0,1668 
PDE4DIP down -2,2 0,3 0,0594 
PDE5A down -6,1 4,3 0,1716 
PDE6A up 11,9 0,0 0,0008 
PDE6B up 43,4 5,1 0,0268 
PDGFRL up 2,1 0,6 0,1114 
PDK4 up 9,6 2,2 0,0566 
PDLIM3 down -3,1 1,2 0,1213 
PDLIM4 up 3,3 0,4 0,0366 
PDS5B down -2,4 0,1 0,0226 
PDZD3 up 3,9 0,2 0,0127 
PDZRN3 up 11,9 6,4 0,1254 
PECAM1 down -4,7 0,2 0,0141 
PFKFB2 down -2,7 0,5 0,0676 
PFN3 up 2,6 0,3 0,0444 
PGC down -4,0 1,8 0,1241 
PGLYRP2 up 3,6 1,3 0,1046 
PGRMC1 up 2,9 0,0 0,0010 
PHF11 down -2,4 0,7 0,1120 
PHF6 down -2,4 0,6 0,0959 
PHIP down -4,9 0,7 0,0389 
PHLDA1 down -2,6 0,8 0,1061 
PHLDA2 down -2,8 0,3 0,0341 
PHTF2 down -2,6 0,3 0,0383 
PI4K2A up 2,0 0,1 0,0273 
PI4K2B down -2,1 0,6 0,1205 
PIBF1 down -2,5 0,4 0,0551 
PIGA down -2,3 0,2 0,0255 
PIK3C2A down -2,3 0,1 0,0225 
PIK3CA down -2,1 0,1 0,0144 
PIK3IP1 up 2,2 0,3 0,0657 
PINK1 up 2,1 0,4 0,0892 
PION down -2,3 0,4 0,0612 
PIPOX up 2,2 0,5 0,0996 
PITPNC1 up 4,2 0,9 0,0644 
PITX2 down -4,5 3,4 0,1929 
PIWIL4 down -89,0 102,3 0,2191 
PKD2 up 4,7 2,4 0,1339 
PKHD1L1 down -2,4 1,1 0,1609 
PKIB down -4,5 1,7 0,1029 
PKIG up 2,2 0,2 0,0425 
PKN2 down -2,1 0,9 0,1680 
PLA2G1B up 4,5 0,1 0,0041 
PLAC2 up 3,8 1,0 0,0768 
PLAC8 down -6,4 3,0 0,1200 
PLAGL1 up 3,5 0,1 0,0115 
PLCB1 down -2,7 0,6 0,0747 
PLCD1 up 2,1 0,1 0,0199 
PLCG2 up 25,8 11,7 0,1024 
PLCH1 down -3,1 0,0 0,0013 
PLD1 down -2,9 0,0 0,0050 
PLD6 down -2,1 0,3 0,0569 
PLEKHA1 down -2,1 0,3 0,0662 
PLEKHA6 down -2,1 0,6 0,1116 
PLEKHG1 up 4,3 3,4 0,2015 
PLEKHG6 up 2,3 0,4 0,0741 
PLEKHN1 down -2,2 0,4 0,0639 
PLG up 3,5 1,2 0,1001 
PLGLB1 up 2,7 1,4 0,1642 
PLIN1 up 6,2 2,1 0,0871 
PLK3 down -3,4 0,4 0,0337 
PLOD2 down -2,7 0,1 0,0194 
PLXND1 down -2,9 1,6 0,1690 
PMFBP1 down -2,2 0,1 0,0164 
PML up 2,1 0,0 0,0005 
PMS1 down -2,5 0,4 0,0600 
PNMA2 up 2,9 0,2 0,0264 
PNMAL1 up 2,8 1,4 0,1662 
PNN down -4,1 0,6 0,0445 
PNPLA7 up 3,5 0,4 0,0345 
PNPLA8 down -2,4 1,0 0,1524 
PODXL down -2,4 0,9 0,1349 
POF1B down -2,1 0,0 0,0020 
POLK down -2,8 0,6 0,0799 
POLQ down -2,3 0,7 0,1145 
POP1 down -2,0 0,0 0,0106 
POU2AF1 down -3,8 1,6 0,1258 
POU6F1 up 2,7 0,7 0,0880 
PPARGC1A up 7,1 7,6 0,2302 
PPFIBP1 down -2,5 0,0 0,0058 
PPIG down -2,2 0,2 0,0358 
PPIL6 up 3,9 1,2 0,0923 
PPM1E up 11,4 6,9 0,1396 
PPM1K down -2,7 0,2 0,0228 
PPM1L down -6,0 0,7 0,0313 
PPP1R14A up 7,4 2,9 0,0994 
PPP1R1A up 2,1 0,9 0,1752 








































































PPP1R3B down -2,8 0,5 0,0634 
PPP1R3C up 3,2 0,6 0,0629 
PPP1R3F up 3,3 0,2 0,0195 
PPP1R9A down -2,9 0,0 0,0022 
PPP2R1B up 3,7 1,3 0,1074 
PPP2R2B down -2,6 0,6 0,0787 
PPP2R2C down -3,7 0,1 0,0078 
PPP4R2 down -2,1 0,1 0,0132 
PPWD1 down -2,2 0,2 0,0326 
PQLC3 down -2,0 0,6 0,1245 
PRAGMIN down -2,5 1,1 0,1584 
PRAME up 2,2 0,1 0,0143 
PRAP1 up 3,0 0,4 0,0417 
PRDM13 up 2,6 0,3 0,0421 
PRDM6 up 13,2 3,1 0,0560 
PRDXDD1P down -3,1 1,0 0,1012 
PRELID2 down -2,5 0,1 0,0083 
PREX1 down -5,6 3,6 0,1604 
PRG4 up 3,4 0,5 0,0436 
PRKAA1 down -2,2 0,1 0,0244 
PRKAB1 up 2,1 0,2 0,0314 
PRKAB2 down -2,6 0,5 0,0692 
PRKAG2 up 3,6 1,7 0,1383 
PRKD1 up 3,9 1,8 0,1328 
PROM1 down -9,2 9,2 0,2139 
PRPF39 down -3,1 0,2 0,0200 
PRPF4B down -3,1 1,2 0,1220 
PRPH up 2,2 1,0 0,1726 
PRPH2 down -6,5 2,9 0,1118 
PRR13 up 2,1 0,0 0,0081 
PRR15 up 18,1 0,2 0,0027 
PRR22 up 2,1 0,0 0,0072 
PRR5-ARHGAP8 up 3,3 1,1 0,1040 
PRSS16 up 3,9 0,1 0,0076 
PRSS23 down -2,7 1,9 0,2131 
PRSS7 down -10,6 2,2 0,0504 
PRTG up 3,1 0,0 0,0050 
PSKH2 up 3,1 0,4 0,0442 
PSMD9 up 2,4 0,4 0,0593 
PTGIS up 4,9 1,2 0,0697 
PTK6 up 5,0 1,6 0,0878 
PTK7 up 4,5 1,0 0,0637 
PTPN22 down -2,7 0,1 0,0184 
PTPN4 down -6,0 0,5 0,0222 
PVRL1 up 5,7 2,8 0,1259 
PYGO1 up 15,4 5,5 0,0835 
PYY2 up 2,1 0,2 0,0458 
QKI up 2,0 0,0 0,0090 
QSER1 down -2,2 0,2 0,0297 
R3HCC1 up 2,2 0,2 0,0419 
RAB11FIP2 down -2,1 0,8 0,1528 
RAB11FIP4 up 3,1 1,8 0,1792 
RAB26 down -2,0 0,3 0,0697 
RAB27B down -7,7 1,6 0,0549 
RAB28 down -2,0 0,6 0,1207 
RAB31 down -4,6 3,9 0,2078 
RAB37 up 5,1 0,8 0,0428 
RAB3B down -3,9 0,2 0,0157 
RAB3D down -7,6 1,5 0,0517 
RAB7B down -2,4 0,1 0,0094 
RAB8B down -3,0 0,9 0,1004 
RABEP1 down -2,3 1,0 0,1552 
RAC2 up 2,1 0,6 0,1233 
RAD50 down -2,4 0,2 0,0364 
RAD54B down -2,6 0,4 0,0555 
RADIL up 3,4 0,6 0,0560 
RAG1 up 3,8 1,9 0,1427 
RALGPS1 up 22,6 1,5 0,0158 
RAMP1 down -2,3 1,0 0,1588 
RANBP2 down -2,2 0,5 0,0994 
RAPGEF5 down -3,0 1,6 0,1641 
RAPGEF6 down -2,5 0,3 0,0479 
RAPH1 up 2,2 0,1 0,0230 
RASA2 down -3,0 0,6 0,0698 
RASD1 down -4,2 1,3 0,0929 
RASD2 down -4,0 1,4 0,1055 
RASEF up 6,2 1,0 0,0443 
RASGEF1B down -3,4 0,1 0,0064 
RASL11A up 3,2 1,5 0,1414 
RASL12 down -13,0 9,9 0,1675 
RASSF5 up 2,9 0,1 0,0089 
RASSF8 down -2,4 0,7 0,1103 
RAVER2 up 17,3 2,9 0,0403 
RB1CC1 down -2,1 0,7 0,1367 
RBBP6 down -2,4 0,7 0,1028 
RBBP8 down -2,0 0,3 0,0645 
RBM25 down -2,1 0,3 0,0559 
RBM27 down -2,1 0,4 0,0722 
RBM41 down -3,1 0,1 0,0094 
RBMS1 up 6,6 0,4 0,0164 
RBP1 up 4,7 1,6 0,0969 
RBP2 up 6,7 0,2 0,0071 
RBP5 up 2,9 0,7 0,0759 
RCN1 down -2,6 1,4 0,1771 








































































RDH12 down -4,6 1,3 0,0796 
RDH16 up 2,5 0,7 0,0965 
RDH5 up 2,5 0,5 0,0754 
RDX down -2,6 0,1 0,0202 
RELN down -2,3 0,9 0,1442 
RENBP down -4,0 0,0 0,0008 
REPS2 up 6,9 5,3 0,1788 
REV3L down -2,2 0,3 0,0656 
RFC1 down -2,2 0,5 0,0921 
RFK up 2,2 0,0 0,0018 
RFTN1 up 18,4 3,6 0,0461 
RFX3 down -3,2 1,5 0,1401 
RGAG4 up 5,7 4,2 0,1788 
RGNEF down -2,1 0,1 0,0226 
RGP1 up 2,2 0,2 0,0299 
RGPD5 down -2,4 0,6 0,0975 
RGS20 down -5,1 3,1 0,1544 
RGS3 down -2,9 0,1 0,0174 
RHBG down -2,9 1,6 0,1681 
RHOBTB1 down -2,9 2,1 0,2102 
RHOF up 2,3 0,1 0,0191 
RHOH down -4,3 0,6 0,0389 
RHOV up 4,4 0,0 0,0031 
RHPN1 up 5,0 1,3 0,0728 
RIC3 up 4,1 1,2 0,0850 
RICH2 up 5,0 2,0 0,1051 
RICTOR down -2,4 1,0 0,1475 
RIF1 down -2,4 0,1 0,0130 
RILPL2 up 2,0 0,0 0,0090 
RIMBP3 up 2,0 0,0 0,0069 
RIMKLB up 2,7 0,2 0,0218 
RIMS3 up 2,8 0,4 0,0435 
RIN1 down -7,7 5,7 0,1726 
RIN2 up 2,3 0,1 0,0255 
RIPK2 down -2,1 0,1 0,0116 
RNASE2 up 12,9 1,8 0,0330 
RNASE4 up 2,4 0,9 0,1328 
RND1 up 2,6 0,6 0,0814 
RND3 down -7,7 4,7 0,1459 
RNF148 down -3,9 3,2 0,2102 
RNF152 up 4,2 0,9 0,0634 
RNF160 down -2,8 0,3 0,0316 
RNF17 down -3,8 0,0 0,0014 
RNF217 up 7,6 0,4 0,0121 
RNF6 down -2,1 0,4 0,0773 
RNLS up 5,0 0,5 0,0256 
RNU12 up 2,0 0,3 0,0711 
ROBO1 down -4,6 3,1 0,1756 
ROCK1 down -2,7 0,2 0,0248 
ROCK2 down -2,2 0,7 0,1328 
ROR1 down -4,7 3,4 0,1838 
RPGRIP1L down -2,3 0,7 0,1229 
RPL10 down -4,4 1,0 0,0659 
RPL27A up 2,1 0,3 0,0690 
RPRML up 2,5 1,1 0,1476 
RPS6KA3 down -2,7 0,8 0,1018 
RPS6KA5 up 3,8 1,3 0,1047 
RPS6KB1 down -2,1 0,9 0,1734 
RRAGD up 31,2 9,0 0,0662 
RRP15 down -2,1 0,2 0,0505 
RSF1 down -2,5 0,2 0,0265 
RTDR1 up 2,7 0,1 0,0072 
RTKN2 down -2,4 0,5 0,0841 
RTN1 up 10,6 6,8 0,1482 
RTN4RL1 up 3,3 0,6 0,0586 
RTP3 up 15,2 15,2 0,2058 
RTP4 up 2,1 0,6 0,1129 
RUFY2 down -2,4 0,7 0,1103 
RUFY3 down -2,3 0,1 0,0220 
RUNDC2B down -2,8 0,3 0,0403 
RUNX1 down -2,4 0,4 0,0675 
RXRA up 2,2 0,1 0,0114 
S100P down -3,9 1,5 0,1109 
S1PR1 up 10,6 0,2 0,0046 
SAA4 up 5,1 0,2 0,0122 
SACS down -3,3 0,9 0,0883 
SAGE1 down -2,0 0,4 0,0768 
SAMD12 down -5,4 0,0 0,0019 
SAMD9 down -3,0 1,7 0,1733 
SAPS2 down -2,2 0,1 0,0245 
SBF2 down -2,3 0,1 0,0235 
SC5DL down -2,0 0,0 0,0037 
SCCPDH down -2,1 0,1 0,0308 
SCD5 up 8,8 2,2 0,0618 
SCLT1 down -2,9 0,9 0,1008 
SCN9A down -2,1 0,3 0,0532 
SDAD1 down -2,7 0,8 0,0998 
SDCBP2 up 6,1 0,1 0,0033 
SDCCAG1 down -3,3 0,5 0,0460 
SEC31A down -4,3 0,3 0,0201 
SECTM1 up 4,8 1,4 0,0833 
SEL1L3 down -5,3 1,7 0,0845 
SELV up 4,3 1,9 0,1244 
SEMA3B down -3,4 1,7 0,1486 








































































SEMA3D down -3,9 3,8 0,2365 
SEMA3G down -2,1 0,2 0,0419 
SEMA6A down -3,4 2,6 0,2066 
SENP3 down -2,1 0,4 0,0804 
SENP7 down -2,7 0,3 0,0388 
SEPP1 down -2,4 0,0 0,0001 
SEPT4 up 4,2 2,9 0,1807 
SEPT5 up 2,5 0,0 0,0058 
SEPT6 up 2,6 0,2 0,0326 
SERINC2 up 2,0 0,0 0,0054 
SERINC5 up 2,5 0,9 0,1193 
SERPINA10 up 2,5 0,5 0,0749 
SERPINA11 up 2,0 0,8 0,1617 
SERPINA4 up 2,7 0,0 0,0053 
SERPINA5 up 2,1 0,4 0,0745 
SERPINA6 up 2,0 0,3 0,0557 
SERPINA7 up 3,9 2,6 0,1821 
SERPINB9 up 8,6 4,4 0,1242 
SERPING1 up 3,7 1,3 0,1045 
SERPINI1 up 2,0 0,8 0,1617 
SESN1 up 2,7 0,2 0,0314 
SETBP1 down -5,3 4,0 0,1861 
SETD8 up 2,0 0,0 0,0002 
SETX down -2,1 0,6 0,1229 
SF1 down -2,3 0,1 0,0111 
SFMBT2 up 6,7 1,0 0,0400 
SFN down -2,5 0,5 0,0726 
SFRP4 up 2,2 0,3 0,0522 
SFRS11 down -2,2 0,3 0,0582 
SFRS12 down -2,9 0,4 0,0498 
SFRS18 down -2,6 0,3 0,0462 
SGK2 up 2,0 0,4 0,0895 
SGMS1 up 2,1 0,4 0,0802 
SGOL1 down -2,0 0,3 0,0575 
SGOL2 down -2,4 0,4 0,0647 
SGSM1 down -3,6 2,8 0,2071 
SH3BGRL down -2,4 0,5 0,0703 
SH3GLB1 down -2,3 1,0 0,1622 
SH3RF1 down -2,6 0,9 0,1173 
SH3TC1 down -2,5 0,0 0,0009 
SHPRH down -2,2 0,6 0,1060 
SHROOM2 up 12,6 6,0 0,1116 
SIK2 up 2,2 0,2 0,0290 
SIX2 up 2,4 0,6 0,0996 
SKAP1 up 4,1 2,2 0,1457 
SLC10A1 up 4,2 1,5 0,0999 
SLC12A2 down -2,2 0,1 0,0208 
SLC13A3 up 10,2 0,2 0,0037 
SLC13A4 down -14,7 0,5 0,0086 
SLC13A5 up 2,0 0,4 0,0793 
SLC16A10 up 3,8 0,7 0,0523 
SLC16A12 up 6,6 4,3 0,1590 
SLC16A2 up 9,4 1,7 0,0454 
SLC16A3 down -3,9 1,6 0,1180 
SLC17A1 up 6,2 1,8 0,0763 
SLC17A2 up 7,5 1,3 0,0453 
SLC1A2 up 32,5 29,2 0,1849 
SLC1A3 up 8,0 0,2 0,0068 
SLC1A7 up 2,4 1,2 0,1754 
SLC22A15 down -2,1 0,2 0,0320 
SLC22A4 up 2,5 1,0 0,1419 
SLC22A7 up 5,0 2,7 0,1409 
SLC22A9 up 2,4 0,2 0,0262 
SLC23A3 up 7,6 2,4 0,0799 
SLC25A12 down -2,8 0,5 0,0633 
SLC25A18 up 2,7 0,4 0,0544 
SLC25A36 down -2,1 0,3 0,0534 
SLC25A42 up 2,1 0,6 0,1087 
SLC2A10 up 2,1 0,8 0,1613 
SLC2A13 down -2,4 0,8 0,1192 
SLC2A2 up 2,8 0,2 0,0218 
SLC2A3 up 2,4 0,5 0,0731 
SLC30A1 up 2,4 0,5 0,0811 
SLC30A3 up 2,3 1,3 0,1985 
SLC30A4 up 22,2 0,1 0,0011 
SLC30A8 up 2,8 1,0 0,1221 
SLC35F2 up 3,8 1,2 0,0899 
SLC38A1 up 2,1 0,2 0,0437 
SLC38A11 down -3,5 2,1 0,1713 
SLC38A2 down -2,7 0,7 0,0911 
SLC38A5 down -3,3 1,2 0,1133 
SLC39A14 up 2,3 0,1 0,0138 
SLC39A5 up 2,2 0,5 0,0957 
SLC41A1 up 2,5 0,8 0,1159 
SLC44A3 down -2,1 0,7 0,1324 
SLC44A5 down -3,6 0,4 0,0320 
SLC45A4 down -4,0 0,9 0,0660 
SLC4A4 down -5,9 2,3 0,1034 
SLC4A7 down -6,3 0,3 0,0147 
SLC5A11 down -2,6 0,8 0,1090 
SLC5A3 down -2,5 0,7 0,1065 
SLC6A11 down -2,5 0,1 0,0211 
SLC6A13 up 2,1 0,2 0,0382 
SLC6A20 down -3,5 0,8 0,0697 








































































SLC6A6 down -3,3 1,5 0,1398 
SLC7A11 down -4,0 0,1 0,0040 
SLCO2B1 up 2,8 0,2 0,0272 
SLCO4C1 up 2,1 0,3 0,0558 
SLFN11 down -22,3 17,2 0,1656 
SLK down -2,0 0,6 0,1242 
SLPI up 7,8 3,3 0,1036 
SLTM down -2,5 0,5 0,0746 
SMAD9 down -2,1 1,0 0,1875 
SMARCA1 down -2,5 0,9 0,1239 
SMARCAD1 down -2,4 0,9 0,1398 
SMC1A down -3,5 0,1 0,0097 
SMC2 down -2,1 0,3 0,0676 
SMC4 down -2,5 0,5 0,0749 
SMC5 down -2,3 0,2 0,0306 
SMC6 down -3,3 0,9 0,0821 
SMCHD1 down -2,2 0,4 0,0746 
SMG1 down -2,3 0,5 0,0871 
SMO down -2,6 0,6 0,0783 
SMS down -2,1 0,6 0,1159 
SMYD1 up 3,9 0,2 0,0190 
SNAP25 down -2,4 1,0 0,1518 
SNHG1 down -3,1 0,6 0,0571 
SNORD123 up 2,2 0,2 0,0292 
SNRK down -2,2 0,1 0,0166 
SNRPN down -3,0 2,3 0,2130 
SNURF down -2,2 0,4 0,0692 
SNX13 down -2,6 0,7 0,0969 
SNX25 down -2,2 0,5 0,0964 
SOCS1 down -3,1 1,4 0,1429 
SOCS3 up 2,0 0,2 0,0361 
SOHLH2 down -2,2 0,4 0,0684 
SORBS2 down -2,1 0,8 0,1517 
SORCS3 up 4,5 1,4 0,0866 
SORD up 2,2 0,1 0,0143 
SOX2 up 11,4 0,1 0,0012 
SOX4 down -2,2 0,9 0,1540 
SOX5 down -3,5 1,2 0,1042 
SOX6 down -15,4 16,9 0,2199 
SOX9 down -6,6 3,2 0,1208 
SP4 down -2,1 0,1 0,0128 
SP5 up 18,2 0,2 0,0020 
SPAG8 down -2,4 0,1 0,0132 
SPARC up 8,9 1,8 0,0520 
SPG20 down -3,6 0,8 0,0717 
SPINK4 down -6,9 2,4 0,0886 
SPINK5 down -2,1 0,9 0,1651 
SPINK5L3 down -3,7 0,6 0,0523 
SPINT1 up 2,2 1,4 0,2106 
SPINT2 up 2,1 0,4 0,0859 
SPOCK2 up 2,2 0,8 0,1369 
SPP2 up 36,8 42,4 0,2218 
SPRED1 down -2,0 0,5 0,1102 
SPRY1 down -3,5 2,1 0,1682 
SPRY2 down -3,1 2,0 0,1937 
SPRY4 down -6,9 1,9 0,0727 
SPTBN5 up 2,7 0,0 0,0037 
SRC up 2,4 0,0 0,0032 
SRCRB4D up 3,7 2,4 0,1794 
SRGN down -11,9 6,5 0,1263 
SRP72 down -2,2 0,5 0,0861 
SRPX up 9,1 3,2 0,0876 
SSB down -2,0 0,4 0,0873 
SSBP2 up 8,4 1,4 0,0418 
SSFA2 down -2,8 0,1 0,0080 
SSTR1 up 5,7 2,1 0,0959 
SSTR2 down -25,2 2,9 0,0268 
SSTR5 down -6,3 0,1 0,0046 
SSX1 down -9,6 8,9 0,2006 
SSX2IP down -2,6 0,4 0,0623 
SSX8 down -6,8 3,0 0,1122 
ST6GAL1 up 2,4 0,6 0,0924 
STAG2 down -3,3 0,8 0,0724 
STARD6 up 3,7 2,5 0,1815 
STAT3 up 2,0 0,5 0,1080 
STEAP1 down -2,0 0,2 0,0484 
STEAP2 down -2,6 0,3 0,0385 
STEAP3 up 2,2 0,4 0,0710 
STH down -2,6 0,6 0,0792 
STK39 down -8,4 1,3 0,0399 
STOM up 2,7 0,3 0,0407 
STRN down -2,4 1,0 0,1450 
STX11 up 2,0 0,8 0,1542 
STXBP1 up 18,9 6,2 0,0768 
STXBP4 down -2,1 0,1 0,0150 
STXBP5 down -2,2 0,2 0,0360 
STXBP5L down -2,7 0,0 0,0064 
SUCLA2 down -2,2 0,4 0,0792 
SUGT1L1 down -2,6 0,1 0,0104 
SULF2 up 209,5 121,3 0,1243 
SULT2A1 up 3,6 0,1 0,0078 
SUOX up 2,0 0,0 0,0073 
SUZ12 down -2,5 0,1 0,0143 
SUZ12P down -2,1 0,2 0,0458 








































































SV2B up 6,0 1,0 0,0435 
SVOP up 5,4 1,4 0,0718 
SVOPL up 2,3 0,4 0,0638 
SYDE2 down -2,6 0,2 0,0248 
SYNC down -2,0 0,2 0,0525 
SYNM down -2,9 0,1 0,0153 
SYT1 down -3,4 1,3 0,1172 
SYT13 up 13,8 6,9 0,1162 
SYT15 up 2,2 0,0 0,0065 
SYT7 up 2,9 0,3 0,0401 
SYTL1 down -2,6 1,3 0,1679 
SYTL3 up 3,2 0,5 0,0539 
SYTL5 down -2,6 1,4 0,1759 
TACC1 down -3,0 0,0 0,0003 
TAF15 down -2,1 0,3 0,0690 
TAF1A down -2,2 0,5 0,0913 
TAF2 down -2,7 0,4 0,0459 
TAF5L down -2,0 0,8 0,1601 
TAF7 up 2,5 0,7 0,0981 
TANC2 up 5,6 4,4 0,1887 
TANK down -2,1 0,2 0,0413 
TAS2R14 down -2,9 0,9 0,0999 
TBC1D12 down -2,9 0,8 0,0907 
TBC1D2 up 3,3 0,9 0,0825 
TBC1D4 down -6,2 3,5 0,1409 
TBC1D8B down -3,0 0,5 0,0543 
TBX18 down -3,9 0,4 0,0350 
tcag7.1307 up 10,5 3,3 0,0763 
TCEA2 up 5,4 1,0 0,0521 
TCEAL3 down -3,5 0,6 0,0528 
TCEAL5 down -2,4 1,3 0,1852 
TCEAL6 down -3,8 0,7 0,0559 
TCF12 down -2,3 0,1 0,0114 
TCF25 up 2,0 0,5 0,0997 
TCIRG1 down -2,1 1,0 0,1864 
TCTEX1D2 up 2,3 0,3 0,0578 
TDH up 8,2 6,2 0,1736 
TDO2 down -3,9 0,3 0,0237 
TDRD10 up 3,9 1,9 0,1378 
TERF1 down -2,2 0,1 0,0277 
TESC down -5,6 3,5 0,1590 
TEX11 down -15,7 7,3 0,1082 
TEX15 down -6,5 0,0 0,0019 
TEX19 up 3,0 1,8 0,1833 
TFCP2 down -52,9 0,9 0,0037 
TFEB down -4,1 0,1 0,0056 
TFPI down -14,5 3,1 0,0519 
TFR2 up 2,3 0,4 0,0621 
TGFB3 down -3,0 1,4 0,1436 
TGM2 up 2,2 0,4 0,0661 
TH1L up 2,1 0,2 0,0318 
THAP5 down -2,3 0,3 0,0450 
THBS1 down -3,9 0,8 0,0586 
THBS4 down -2,1 0,8 0,1472 
THG1L up 2,2 0,2 0,0293 
THOC2 down -3,7 0,9 0,0721 
THSD4 down -4,2 1,6 0,1058 
THUMPD2 down -2,3 0,4 0,0752 
TIA1 down -2,2 0,6 0,1112 
TIMD4 down -3,4 0,8 0,0788 
TLE2 up 3,9 2,4 0,1682 
TLE4 down -5,1 3,6 0,1794 
TLL2 up 3,9 1,3 0,0993 
TLR2 up 3,4 1,7 0,1498 
TLR4 down -2,2 0,9 0,1524 
TM4SF1 down -7,9 7,0 0,1992 
TM4SF4 up 2,4 0,5 0,0763 
TMBIM1 up 2,2 0,4 0,0691 
TMC6 down -5,2 0,8 0,0414 
TMCC3 up 8,2 1,1 0,0338 
TMEM108 up 4,4 1,8 0,1134 
TMEM127 up 2,1 0,2 0,0429 
TMEM150C up 9,5 4,6 0,1161 
TMEM159 up 8,8 4,9 0,1325 
TMEM19 up 2,1 0,5 0,1100 
TMEM2 down -2,7 0,1 0,0180 
TMEM200A up 2,8 0,0 0,0051 
TMEM217 up 2,6 0,4 0,0504 
TMEM220 down -15,1 8,9 0,1341 
TMEM30B down -2,1 0,5 0,0936 
TMEM42 down -5,7 1,8 0,0862 
TMEM45A up 11,1 0,2 0,0053 
TMEM45B up 6,1 6,3 0,2291 
TMEM47 down -19,1 18,3 0,1978 
TMEM55A down -2,9 0,1 0,0169 
TMEM8B up 4,6 0,3 0,0174 
TMF1 down -2,3 0,1 0,0196 
TMOD1 up 2,5 0,3 0,0469 
TMPRSS2 up 5,1 0,9 0,0470 
TMPRSS6 up 4,8 0,3 0,0204 
TMSB4X down -5,1 2,1 0,1099 
TMSL3 down -8,3 8,4 0,2163 
TMX3 down -2,0 0,4 0,0925 
TNC up 3,5 1,4 0,1239 








































































TNF down -8,7 7,1 0,1846 
TNFAIP8 down -2,3 0,4 0,0617 
TNFRSF11A up 3,9 0,3 0,0256 
TNFRSF11B down -15,1 0,4 0,0066 
TNFRSF25 up 5,7 0,6 0,0290 
TNFSF11 down -21,5 5,4 0,0581 
TNFSF13B down -4,1 1,1 0,0747 
TNFSF4 down -2,2 1,1 0,1862 
TNIK down -2,8 1,7 0,1827 
TNK1 down -2,2 0,1 0,0157 
TNN up 2,7 0,2 0,0222 
TNNC1 down -5,7 3,4 0,1493 
TNPO1 down -2,7 0,8 0,1089 
TNPO2 down -5,7 0,3 0,0128 
TNS1 up 3,9 0,1 0,0109 
TNS3 up 2,0 0,4 0,0852 
TOX2 up 4,6 0,7 0,0426 
TP53I3 up 2,2 0,5 0,0999 
TP53INP2 up 2,9 0,2 0,0235 
TP53TG3 up 2,0 0,6 0,1240 
TP73 up 3,2 0,1 0,0105 
TPBG up 2,1 0,6 0,1209 
TPD52L1 up 11,9 8,5 0,1603 
TPK1 down -2,8 1,9 0,2034 
TPP2 down -2,1 0,3 0,0634 
TPR down -2,6 0,5 0,0747 
TPTE down -2,3 0,3 0,0521 
TRAF3IP2 up 3,1 0,4 0,0456 
TRAF5 down -3,0 0,3 0,0309 
TRANK1 up 2,3 0,4 0,0678 
TRAPPC2L up 2,3 0,6 0,0966 
TRAPPC6A up 2,6 0,2 0,0220 
TRIB2 up 6,0 0,7 0,0304 
TRIM13 down -2,9 0,2 0,0189 
TRIM14 up 2,3 0,1 0,0213 
TRIM2 down -2,1 0,3 0,0491 
TRIM31 up 2,1 0,4 0,0753 
TRIM32 up 2,2 0,1 0,0162 
TRIM34 down -2,6 1,2 0,1540 
TRIM35 up 2,1 0,2 0,0485 
TRIM36 up 2,4 0,1 0,0133 
TRIM5 down -2,7 1,7 0,1887 
TRIM59 up 3,3 1,0 0,0997 
TRIM60 up 6,2 0,5 0,0226 
TRIM74 up 2,5 0,4 0,0584 
TRIM9 down -3,8 2,2 0,1610 
TRIP11 down -2,5 0,3 0,0474 
TRNP1 down -2,0 0,0 0,0030 
TRNT1 down -2,1 0,1 0,0133 
TRO up 17,0 5,7 0,0792 
TRPM7 down -2,4 0,1 0,0174 
TRPV2 down -7,1 3,5 0,1210 
TSNARE1 up 2,3 0,2 0,0424 
TSPAN13 down -2,4 0,2 0,0385 
TSPAN3 up 2,4 0,1 0,0172 
TSPAN8 down -2,2 0,7 0,1314 
TSPAN9 up 2,0 0,1 0,0325 
TSPYL1 up 2,1 0,1 0,0186 
TSPYL4 up 2,8 0,3 0,0421 
TTC13 down -2,6 0,4 0,0616 
TTC14 down -2,1 0,4 0,0781 
TTC21B down -2,1 0,4 0,0874 
TTC22 down -12,1 13,1 0,2210 
TTC3 down -3,2 1,0 0,0978 
TTC37 down -2,6 0,8 0,1051 
TTC39C up 2,0 0,1 0,0285 
TTC7B up 3,5 0,4 0,0317 
TTC9 up 3,1 0,9 0,0931 
TTLL11 up 2,3 0,3 0,0481 
TTLL2 down -5,6 1,1 0,0508 
TTR down -2,4 1,5 0,2091 
TUB up 2,9 0,5 0,0544 
TUBAL3 down -11,8 11,7 0,2071 
TUBB2B up 3,7 1,5 0,1197 
TUBB4 up 2,0 0,1 0,0240 
TUSC3 up 4,8 0,8 0,0490 
TWISTNB down -2,1 0,4 0,0756 
TXLNA up 2,0 0,0 0,0080 
TXNDC11 up 2,1 0,1 0,0279 
TXNL4B up 2,0 0,3 0,0644 
TYMP up 3,9 0,8 0,0598 
TYW3 down -2,1 0,6 0,1194 
UAP1L1 up 2,1 0,4 0,0788 
UBA6 down -3,6 0,7 0,0610 
UBR1 down -2,1 0,5 0,1045 
UCHL5 down -2,2 0,4 0,0715 
UCP2 up 2,0 0,4 0,0924 
UGGT2 down -3,1 0,9 0,0985 
UGT1A6 down -4,7 3,2 0,1735 
UGT2B11 down -3,0 0,8 0,0905 
UGT2B4 down -3,4 0,7 0,0645 
UGT2B7 down -3,6 2,0 0,1571 
ULK1 up 2,5 0,8 0,1067 
ULK2 up 17,0 4,5 0,0620 








































































UNC13C down -3,7 0,1 0,0058 
UNC5B down -8,3 9,6 0,2374 
UNC93A up 2,9 0,5 0,0650 
UNG up 2,2 0,1 0,0226 
UPF2 down -3,0 0,4 0,0412 
UPF3B down -4,1 0,9 0,0641 
USHBP1 down -4,0 2,3 0,1606 
USO1 down -2,1 0,7 0,1450 
USP16 down -2,4 0,7 0,0996 
USP25 down -2,5 0,1 0,0187 
USP46 down -2,0 0,4 0,0938 
USP47 down -2,3 0,3 0,0515 
USP48 down -2,4 0,0 0,0052 
USP53 down -3,1 1,2 0,1203 
USP6NL down -2,3 0,6 0,0975 
UTP14A down -2,0 0,0 0,0012 
UTP15 down -2,0 0,3 0,0615 
UTP20 down -2,2 0,7 0,1277 
UTRN down -2,0 0,2 0,0512 
UTS2 down -5,9 6,1 0,2308 
VAMP4 down -2,6 0,5 0,0754 
VASH1 up 3,5 0,4 0,0313 
VAV2 up 2,0 0,1 0,0227 
VCX up 8,4 3,1 0,0910 
VCX2 up 5,4 1,7 0,0848 
VCX3A up 10,0 4,1 0,1007 
VCY up 5,8 2,0 0,0902 
VDR up 10,5 3,0 0,0696 
VPS13A down -5,3 0,5 0,0276 
VPS13B down -2,1 0,7 0,1267 
VPS13C down -2,6 1,0 0,1312 
VPS54 down -2,3 0,2 0,0410 
VSNL1 down -2,2 0,1 0,0267 
VTN up 2,3 0,3 0,0435 
VWCE up 2,1 0,2 0,0399 
VWF up 2,2 0,7 0,1317 
WBP5 down -2,0 0,6 0,1306 
WDHD1 down -2,4 0,3 0,0495 
WDR66 up 5,0 1,5 0,0827 
WDR67 down -2,2 0,3 0,0606 
WDR72 down -3,0 0,2 0,0208 
WFIKKN1 up 2,4 0,6 0,0983 
WFS1 down -2,0 0,2 0,0434 
WHSC1 down -2,5 0,1 0,0220 
WIPF1 up 2,8 0,0 0,0005 
WNK2 down -9,2 0,0 0,0000 
WNK3 up 10,5 1,4 0,0341 
WNK4 down -2,5 0,2 0,0321 
WNT5A up 5,5 0,1 0,0035 
WRN down -2,2 0,1 0,0268 
WSCD1 up 2,1 0,1 0,0272 
WWOX up 2,2 0,0 0,0084 
XAF1 down -2,9 2,0 0,2002 
XBP1 down -2,3 0,6 0,1046 
XIAP down -2,3 0,2 0,0420 
XIST down -55,6 22,7 0,0911 
XK up 4,9 0,2 0,0140 
XKR6 up 7,8 2,2 0,0722 
XPR1 down -2,3 0,1 0,0171 
XRCC2 down -2,4 0,0 0,0039 
XYLB up 3,1 0,4 0,0411 
YIF1B up 5,2 2,2 0,1136 
YPEL1 up 2,6 0,7 0,0937 
YPEL2 up 2,2 0,0 0,0044 
YTHDC2 down -3,0 0,7 0,0764 
ZADH2 down -2,0 0,4 0,0936 
ZBTB20 down -2,8 0,2 0,0216 
ZBTB41 down -2,6 0,3 0,0422 
ZC3H10 up 2,1 0,0 0,0004 
ZC3H11A down -2,0 0,0 0,0043 
ZC3H12C up 35,9 0,1 0,0006 
ZC3H13 down -3,9 1,0 0,0747 
ZC3H6 down -3,9 0,0 0,0007 
ZCCHC3 up 2,4 0,6 0,0922 
ZDHHC2 up 5,8 0,1 0,0036 
ZDHHC8P up 2,1 0,5 0,0946 
ZEB1 down -2,9 1,3 0,1390 
ZER1 up 2,7 0,3 0,0441 
ZFAND2A up 2,0 0,2 0,0522 
ZFC3H1 down -2,1 0,4 0,0832 
ZFHX4 down -2,2 0,1 0,0178 
ZFYVE16 down -2,1 0,0 0,0016 
ZIC5 down -2,6 1,3 0,1683 
ZIM2 up 2,0 1,2 0,2154 
ZMYM5 down -2,2 0,1 0,0180 
ZMYM6 down -2,1 0,3 0,0667 
ZMYND12 up 2,2 0,1 0,0195 
ZNF100 down -2,6 1,1 0,1500 
ZNF107 down -3,6 0,4 0,0326 
ZNF138 down -2,5 0,3 0,0395 
ZNF146 down -2,2 0,1 0,0138 
ZNF148 down -2,2 0,3 0,0519 
ZNF177 up 2,4 1,0 0,1421 
ZNF182 down -2,1 0,3 0,0680 








































































ZNF195 down -2,1 0,0 0,0072 
ZNF207 down -2,6 0,7 0,0992 
ZNF215 down -2,0 0,1 0,0300 
ZNF229 up 2,3 0,3 0,0561 
ZNF248 down -3,0 0,1 0,0070 
ZNF25 down -2,8 1,5 0,1699 
ZNF254 down -2,2 0,2 0,0295 
ZNF267 down -2,4 0,1 0,0240 
ZNF273 down -2,3 0,1 0,0229 
ZNF280C down -2,1 0,2 0,0340 
ZNF280D down -2,7 0,4 0,0521 
ZNF292 down -2,8 0,5 0,0685 
ZNF323 down -2,0 0,1 0,0263 
ZNF326 down -2,5 0,3 0,0430 
ZNF37B down -2,3 0,5 0,0780 
ZNF385A up 2,2 0,5 0,0994 
ZNF395 up 2,0 0,0 0,0047 
ZNF41 down -2,0 0,0 0,0076 
ZNF449 down -2,1 0,7 0,1391 
ZNF451 down -2,1 0,0 0,0012 
ZNF488 up 2,8 0,5 0,0614 
ZNF492 down -2,2 0,3 0,0513 
ZNF493 down -2,8 1,0 0,1176 
ZNF502 down -3,3 1,0 0,0987 
ZNF513 up 5,4 0,8 0,0407 
ZNF518B down -2,6 0,2 0,0349 
ZNF519 down -2,0 0,2 0,0487 
ZNF541 up 4,9 2,5 0,1360 
ZNF560 down -2,9 0,0 0,0041 
ZNF599 up 2,4 0,6 0,0905 
ZNF608 down -2,1 0,4 0,0704 
ZNF614 down -2,2 0,1 0,0239 
ZNF615 down -2,2 0,6 0,1098 
ZNF618 up 12,8 0,4 0,0068 
ZNF619 up 2,9 0,9 0,0964 
ZNF624 down -2,0 0,3 0,0582 
ZNF630 down -2,6 0,9 0,1188 
ZNF638 down -2,6 0,7 0,0956 
ZNF644 down -2,3 0,6 0,0945 
ZNF660 down -6,9 1,4 0,0515 
ZNF670 down -2,3 0,2 0,0437 
ZNF678 down -2,4 0,7 0,1036 
ZNF702P up 2,6 1,5 0,1811 
ZNF711 down -2,7 0,8 0,1041 
ZNF718 down -3,7 0,6 0,0501 
ZNF721 down -3,1 0,9 0,0958 
ZNF726 down -2,0 0,7 0,1452 
ZNF747 up 2,0 0,1 0,0250 
ZNF783 down -2,2 0,1 0,0228 
ZNF800 down -2,7 0,5 0,0602 
ZNF876P down -18,7 12,4 0,1465 
ZNF92 down -2,2 0,1 0,0262 
ZNF99 down -2,0 0,5 0,1116 
ZRANB2 down -2,1 0,6 0,1132 
ZSCAN18 up 2,1 0,4 0,0790 
ZSCAN5A up 2,1 0,2 0,0398 
     
     
     
     
     
     
    
    
    
    
    
    
 








































































Supplementary Table 3. Genes being deregulated in HepG2-cells expressing solFGFR4. Data were 
processed as described in Experimental Procedures and are means of fold-vector control values of 2 
different experiments. Fold-change cutoffs of >2 and <0.5 were used to select upregulated and 





Control S.D. p-value 
ABLIM3 up 2,24 0,39 0,070 
ABTB1 up 2,80 0,19 0,024 
ACAD10 up 20,14 2,21 0,026 
ADC up 5,34 2,91 0,141 
ADH4 down -2.03 0.22 0.047 
AKAP9 down -2.02 0.72 0.147 
ALB down -2.34 0.97 0.150 
ALG10B down -2.07 0.32 0.066 
ANGPTL1 down -2.51 0.64 0.093 
ANGPT2 up 3,81 2,95 0,203 
ANKRD32 down -2.33 0.12 0.020 
AQP3 up 2,37 0,84 0,130 
BRCA2 down -2.19 0.66 0.119 
C12orf60 down -2.02 0.63 0.132 
C6orf167 down -2.03 0.00 0.000 
C13orf15 up 2,07 0,89 0,169 
C14orf72 up 2,13 0,49 0,095 
C7orf58 down -2.20 0.56 0.101 
CASP8AP2 down -2.11 0.49 0.096 
CCDC150 down -2.05 0.48 0.098 
CCDC41 down -2.06 0.35 0.073 
CENPC1 down -2.36 0.21 0.035 
CENPE down -2,39 1,03 0,154 
CEP290 down -2,01 0,63 0,131 
CHMP4B up 2,43 1,17 0,167 
COG6 down -2,31 0,21 0,035 
CUL5 down -2,21 0,09 0,017 
CYB561 up 2,03 0,21 0,046 
CYTH4 up 2,08 0,00 0,000 
DLEU2 down -2,09 1,11 0,199 
DLGAP5 down -2,01 0,30 0,066 
DNAJB4 down -2,08 0,45 0,091 
EGR2 up 2,91 1,70 0,179 
EIF4A2 down -2,01 0,23 0,051 
 
FANCM down -2,04 0,50 0,104 
FLNB up 2,00 0,71 0,148 
FPGT down -2,09 0,66 0,129 
FUT1 up 3,79 2,11 0,157 
GNPDA2 down -2,02 0,40 0,086 
G0S2 up 4,76 0,80 0,048 
GPAM down -2,00 0,70 0,146 
HLTF down -2,52 0,24 0,036 
HMMR down -2,10 0,46 0,092 
HSPA6 down -2,29 0,14 0,024 
IER3IP1 down -2,13 0,17 0,034 
IFIT1 down -2,56 0,89 0,121 
IGF2 up 2,97 1,36 0,145 
IGFBP1 up 2,04 0,19 0,041 
IGFBP3 up 2,24 0,21 0,039 
INHBE up 2,41 0,51 0,079 
IQCG up 2,44 0,53 0,082 
ITGB3BP down -2,05 0,89 0,171 
KLHDC7B up 2,18 0,56 0,103 
KLHL29 up 4,56 0,41 0,026 
LARP6 up 4,13 2,46 0,162 
LENG8 up 9,72 1,11 0,029 
LOC10012911
3 up 4,12 1,77 0,121 
LOC401397 down -2,11 0,68 0,130 
LRRC47 up 2,09 0,13 0,026 
MANEA down -2,34 0,22 0,037 
MEI1 up 2,41 0,09 0,014 
NDC80 down -2,04 0,47 0,098 
NUP107 down -2,04 0,72 0,145 
NXT2 down -2,07 0,39 0,081 
OSCAR up 2,25 0,06 0,011 
PAEP up 2,00 0,01 0,002 
PHIP down -2,00 0,64 0,136 
PI4K2B down -2,04 0,08 0,018 
PIGK down -2,28 0,45 0,078 
PLXND1 up 2,38 0,61 0,097 
PSG2 up 4,06 2,40 0,161 
RAB39B up 10,47 1,26 0,030 
RAC2 up 2,08 0,14 0,029 
RAD54B down -2,09 0,22 0,046 
RASD1 up 2,04 0,04 0,008 








































































RNF160 down -2,40 0,17 0,028 
ROBO3 up 3,62 0,23 0,020 
RRAD up 2,55 0,96 0,131 
SERPINE1 up 2,01 0,03 0,007 
SFRS12IP1 down -2,14 0,47 0,089 
SGOL2 down -2,40 0,38 0,060 
SLC25A36 down -2,05 0,46 0,096 
SLCO4C1 down -2,25 0,48 0,085 
SNORD22 down -2,26 0,09 0,015 
SPRR2C up 3,57 1,23 0,104 
SPRR2D up 6,51 4,20 0,157 
SSTR3 up 12,74 2,33 0,044 
TBL1XR1 down -2,01 0,21 0,047 
TNFRSF10D up 2,05 0,51 0,105 
TNPO1 down -2,08 0,42 0,086 
TTK down -2,13 0,11 0,021 
UNC5B up 4,25 0,49 0,034 
USP15 down -2,29 0,43 0,074 
ZDHHC14 up 2,64 1,67 0,199 
ZNF267 down -2,02 0,08 0,018 
ZNF292 down -2,09 0,67 0,130 
ZNF418 up 2,25 0,11 0,020 








































































 Supplementary Table 4. Genes being deregulated in HepG2-cells expressing kdFGFR4. Data were 
processed as described in Experimental Procedures and are means of fold-vector control values of 2 
different experiments. Fold-change cutoffs of >2 and <0.5 were used to select upregulated and 
downregulated genes, respectively.  
Gene reg. 
mean x 
Control S.D. p-value 
ACADM down -2.02 0.16 0.035 
AIMP1 down -2.02 0.36 0.078 
AKAP9 down -2.75 1.48 0.171 
ANKRD12 down -3.03 1.63 0.164 
ANKRD32 down -2.67 0.34 0.045 
ANLN down -2.15 0.48 0.092 
ARHGAP18 down -2.04 0.16 0.035 
ARL6IP1 down -2.17 0.43 0.081 
ASNSD1 down -2.13 0.28 0.055 
BDP1 down -2.51 1.17 0.159 
BLZF1 down -2.18 0.20 0.039 
BRIX1 down -2.06 0.05 0.011 
C12orf4 down -2.15 0.67 0.125 
C12orf60 down -2.07 0.69 0.137 
C14orf106 down -2.36 0.85 0.132 
C1orf156 down -2.10 0.22 0.045 
C5 down -2.17 0.92 0.161 
C6orf211 down -2.10 0.26 0.052 
CASP8AP2 down -2.61 0.85 0.113 
CCDC41 down -2.36 0.41 0.066 
CCDC77 down -2.13 0.08 0.016 
CCDC99 down -2.06 0.57 0.115 
CCNL1 down -2.99 2.43 0.227 
CCPG1 down -2.08 0.06 0.012 
CDC40 down -2.14 0.36 0.071 
CDC7 down -2.06 0.24 0.051 
CDC73 down -2.04 0.22 0.048 
CEBPZ down -2.39 0.34 0.054 
CENPC1 down -3.29 0.55 0.054 
CENPE down -3.86 2.55 0.179 
CENPK down -2.36 0.62 0.100 
CENPQ down -2.14 0.47 0.089 
CFI down -2.16 0.02 0.003 
CHD9 down -2.15 0.57 0.107 
COG6 down -3.03 0.07 0.007 
COMMD8 down -2.03 0.37 0.079 
CUL5 down -2.63 0.02 0.002 
CUZD1 down -2.33 0.10 0.017 
 
DCUN1D4 down -2.13 0.53 0.102 
DDX18 down -2.13 0.59 0.112 
DDX6 down -2.05 0.97 0.184 
DLGAP5 down -2.39 0.20 0.033 
DNA2 down -2.51 0.37 0.054 
DNTTIP2 down -2.38 0.35 0.056 
DOPEY1 down -2.17 0.64 0.117 
EEA1 down -2.13 0.31 0.060 
EIF2A down -2.08 0.38 0.077 
EIF3E down -2.21 0.95 0.161 
EIF4A2 down -2,52 0,12 0,018 
ELMOD2 down -2,14 0,14 0,027 
ERBB2IP down -2,04 0,53 0,111 
ERGIC2 down -2,19 0,33 0,062 
ESCO1 down -2,26 0,02 0,004 
ESF1 down -2,13 0,74 0,139 
EXOC6 down -2,05 0,23 0,048 
FAM133B down -2,49 0,10 0,015 
FAM35A down -2,06 0,13 0,027 
FASTKD1 down -2,00 0,07 0,015 
FASTKD3 down -2,03 0,04 0,008 
G2E3 down -2,32 0,04 0,007 
GFM2 down -2,03 0,47 0,099 
GNPDA2 down -2,10 0,19 0,039 
GOLGA4 down -2,53 1,09 0,149 
HLTF down -2,35 0,35 0,058 
HMMR down -2,48 0,50 0,075 
HOOK1 down -2,63 0,54 0,073 
HSP90AA1 down -2,48 0,94 0,134 
IER3IP1 down -2,10 0,10 0,021 
IFIT1 down -2,59 0,46 0,064 
IL6ST down -2,24 0,22 0,040 
ITGB3BP down -2,12 0,84 0,155 
KIAA0528 down -2,53 0,11 0,016 
KIAA0776 down -2,43 0,14 0,022 
KIAA1033 down -2,05 0,14 0,031 
KIAA1524 down -2,18 0,22 0,041 
KIF15 down -2,09 1,01 0,184 
KPNA5 down -2,32 0,65 0,106 
KRR1 down -2,05 0,07 0,014 
KRT37 up 2,53 0,03 0,005 
KTN1 down -2,20 0,55 0,099 
LARP7 down -2,52 0,21 0,031 
LOC401397 down -2,39 0,81 0,125 
LPAR6 down -2,32 0,71 0,115 
LRRC58 down -2,45 0,17 0,027 








































































LTV1 down -2,06 0,17 0,036 
LUC7L3 down -2,00 0,02 0,005 
MAD2L1 down -2,19 0,24 0,044 
MANEA down -2,68 0,05 0,006 
MBNL3 down -2,25 0,71 0,122 
MORC3 down -2,11 0,02 0,003 
MPHOSPH10 down -2,39 0,73 0,114 
MRPL50 down -2,07 0,59 0,119 
MTERF down -2,42 0,10 0,016 
MTTP down -2,18 0,04 0,008 
NARG2 down -2,32 0,33 0,056 
NBEAL1 down -2,05 0,48 0,099 
NCAPG down -2,08 0,49 0,099 
NDC80 down -2,33 0,40 0,066 
NEK7 down -2,45 0,15 0,023 
NOC3L down -2,29 0,47 0,081 
NOL11 down -2,46 0,47 0,072 
NOL8 down -2,25 0,46 0,081 
NOP58 down -2,07 0,10 0,021 
NUDCD1 down -2,00 0,36 0,080 
NUF2 down -2,14 0,53 0,100 
NUP107 down -2,24 0,70 0,122 
NXT2 down -2,21 0,55 0,099 
PAK1IP1 down -2,01 0,05 0,012 
PBK down -2,12 0,08 0,016 
PGM3 down -2,05 0,62 0,126 
PIBF1 down -2,81 0,68 0,083 
PIK3C3 down -2,09 0,59 0,115 
PION down -2,08 0,53 0,107 
PLK4 down -2,30 0,31 0,053 
PLS1 down -2,25 0,52 0,091 
PMS1 down -2,46 0,52 0,079 
PPIG down -2,22 0,04 0,008 
PPWD1 down -2,04 0,01 0,003 
PRKRIR down -2,05 0,39 0,082 
PTAR1 down -2,04 0,09 0,019 
RAC2 up 2,14 0,66 0,123 
RAD51AP1 down -2,35 0,11 0,018 
RAD54B down -2,29 0,07 0,012 
RARS down -2,06 0,87 0,168 
RASD1 up 2,32 0,88 0,140 
RB1CC1 down -2,07 0,17 0,035 
RBM41 down -2,72 1,18 0,143 
RECQL down -2,00 0,27 0,060 
RIF1 down -2,76 0,91 0,112 
RNMT down -2,12 0,63 0,121 
RPAP3 down -2,36 0,09 0,015 
RRAD up 2,86 2,05 0,211 
SAMD9 down -3,93 0,12 0,009 
SCOC down -2,08 0,73 0,142 
SDCCAG1 down -2,29 0,40 0,069 
SEPP1 down -2,22 0,17 0,030 
SEPT7 down -2,05 0,05 0,011 
SFRS12IP1 down -3,18 0,65 0,066 
SGOL2 down -3,56 0,71 0,062 
SHOC2 down -2,08 0,58 0,116 
SLC25A36 down -2,13 0,15 0,030 
SMC2 down -2,34 0,10 0,017 
SMC6 down -2,38 0,05 0,008 
SPP1 down -2,02 0,14 0,031 
SSX2IP down -2,22 0,34 0,062 
STXBP4 down -2,03 0,04 0,008 
TAF1B down -2,29 0,09 0,016 
TANK down -2,13 0,62 0,119 
TAX1BP1 down -2,09 0,56 0,110 
TBC1D23 down -2,29 0,71 0,118 
TBC1D8B down -2,21 0,13 0,024 
TBK1 down -2,50 0,03 0,005 
TBL1XR1 down -2,08 0,08 0,016 
TGDS down -2,15 0,27 0,052 
THUMPD2 down -2,01 0,14 0,030 
TMEM161B down -2,20 0,07 0,013 
TMEM87A down -2,02 0,60 0,125 
TMTC3 down -2,10 0,55 0,109 
TNFAIP2 up 2,11 0,59 0,114 
TNFRSF10D up 2,04 0,16 0,035 
TNPO1 down -2,44 0,39 0,059 
TTC37 down -2,26 0,17 0,030 
TXNDC9 down -2,04 0,60 0,123 
UBA3 down -2,07 0,54 0,109 
UPF3B down -2,02 0,36 0,077 
USP15 down -2,58 0,80 0,110 
WDR36 down -2,17 0,56 0,104 
ZC3H11A down -2,00 0,83 0,169 
ZNF146 down -2,82 0,55 0,066 
ZNF195 down -2,05 0,01 0,003 
ZNF24 down -2,29 0,92 0,148 
ZNF267 down -2,87 0,52 0,062 
ZNF292 down -2,58 0,85 0,116 
ZNF600 down -2,01 0,05 0,011 
ZNF644 down -2,53 0,91 0,127 
ZNF823 down -2,05 0,37 0,077 
ZRANB2 down -2,20 0,09 0,016 
ZRANB3 down -2,21 0,56 0,100 








































































ZWILCH down -2,56 1,07 0,143 

































































































































Supplementary Figure 6. Validation of transcriptome data by quantitative RT-PCR (qRT-PCR).  
Correlation of the relative expression of selected genes determined by transcriptome analysis and 
qRT-PCR. FGFR4-overexpressing clones and vector controls were subjected to the analysis. Each 
data point represents the expression level of a given gene, expressed as fold vector control, and is the 
mean of >2 independent determinations per method applied. Symbols: 1, ACAD10; 2, AFP; 3, CDC7, 
4, CENPE; 5, DUSP26; 6, GAPDH; 7, GNB4; 8, LOXL2, 9, MAPKAP1; 10, MMP11; 11, MMP14; 
12, NDC80; 13, PI4K2A; 14, PIK3IP1; 15, PLCG2; 16, PPP1R3C; 17, PRKAB1; 18; PRKAG2; 19; 














































































Supplementary Table 5. Most significant gene sets in GSEA analysis of hepatoma/hepatocarcinoma 
cells showing FGFR4-overexpression or subjected to interference with FGFR-4 mediated signaling 
by solFGFR4 or kdFGFR4. For further details on GSEA see http://www.broadinstitute.org/gsea/doc 
/GSEAUserGuideFrame.html. Gene sets were considered to be significantly deregulated in case of a 
FDR q-value of less than 0.25 and/or a p-value of less than 0.05. 






FGFR4 Overexpr. reactome  integration of energy metabolism 432 16443998 0,010 0,143 Up 
Bile Acid & Phase I / II Metabolism 
FGFR4 Overexpr. reactome  glutathione conjugation 762 20704389 0,000 0,003 Up 
SolFGFR4 reactome  glutathione conjugation -0, 
391 
-16707102 0,000 0,004 down 
kdFGFR4 reactome  glutathione conjugation -391 -1551765 0,000 0,003 down 
FGFR4 Overexpr. reactome  xenobiotics 737 18618722 0,010 0,029 up 
FGFR4 Overexpr. reactome  phase1 functionalization of 
compounds 
716 25428765 0,000 0,000 up 
FGFR4 Overexpr. reactome  phase ii conjugation 431 14801257 0,039 0,277 up 
FGFR4 Overexpr. kegg  drug metabolism cytochrome 
p450 
604 20455685 0,000 0,003 up 
FGFR4 Overexpr. kegg  primary bile acid biosynthesis 756 19609323 0,000 0,009 up 
FGFR4 Overexpr. reactome  synthesis of bile acids and bile 
salts 
729 19394598 0,000 0,012 up 
Carbohydrate Metabolism 
FGFR4 Overexpr. kegg  glycolysis gluconeogenesis 535 18168197 0,000 0,044 up 
kdFGFR4 reactome  glycolysis -340 -11867602 0,000 0,085 down 
solFGFR4 reactome  regulation of glucokinase by 
glucokinase regulatory protein 
-340 -18091897 0,000 0,002 down 
kdFGFR4 reactome  regulation of glucokinase by 
glucokinase regulatory protein 
-341 -15361433 0,000 0,004 down 
kdFGFR4 kegg  pentose phosphate pathway -246 -13278433 0,000 0,028 down 
FGFR4 Overexpr. reactome  regulation of insulin secretion 381 13782212 0,047 0,342 up 
solFGFR4 signal transduction ke  g alpha s pathway -408 -15892403 0,000 0,007 down 
Lipid Metabolism 
FGFR4 Overexpr. reactome  metabolism of lipids and 
lipoproteins 
408 18155632 0,000 0,044 up 
FGFR4 Overexpr. kegg  ppar signaling pathway 479 16627568 0,006 0,143 up 
FGFR4 Overexpr. kegg  fatty acid metabolism 534 16547354 0,004 0,144 up 
FGFR4 Overexpr. reactome  fatty acid triacylglycerol and 
ketone body metabolism 
374 14658921 0,014 0,276 up 
kdFGFR4 reactome  activated ampk stimulates fatty 
acid oxidation in muscle 
-445 -15405483 0,000 0,003 down 
FGFR4 Overexpr. reactome  lipoprotein metabolism 517 15096359 0,027 0,249 up 
solFGFR4 reactome  cholesterol biosynthesis -0, 
341 
-1348732 0,000 0,045 down 
kdFGFR4 reactome  cholesterol biosynthesis -347 -19267347 0,000 0,000 down 
solFGFR4 kegg  steroid biosynthesis -409 -18535615 0,000 0,001 down 
FGFR4 Overexpr. kegg  steroid biosynthesis 758 19486688 0,000 0,010 up 
kdFGFR4 kegg  steroid biosynthesis -431 -1532288 0,000 0,004 down 
FGFR4 Overexpr. kegg  glycerophospholipid metabolism 422 1476495 0,021 0,279 up 
kdFGFR4 reactome  peroxisomal lipid metabolism -557 -29659848 0,000 0,000 down 
solFGFR4 reactome  peroxisomal lipid metabolism -359 -15086856 0,042 0,014 down 








































































GROWTH FACTORS & SIGNALING 
FGFR4 Overexpr. reactome  signaling by fgfr 372 13992958 0,026 0,328 up 
FGFR4 Overexpr. reactome  signaling by ngf 377 15654117 0,000 0,200 up 
FGFR4 Overexpr. kegg  neurotrophin signaling pathway 342 13113501 0,050 0,380 up 
FGFR4 Overexpr. pathway interaction db  hnf3b pathway 575 185707 0,000 0,030 up 
FGFR4 Overexpr. biocarta  wnt pathway 548 1544899 0,029 0,215 up 
FGFR4 Overexpr. signal transduction ke  wnt ca2 cyclic gmp pathway 677 18498185 0,002 0,030 up 
FGFR4 Overexpr. kegg  vegf signaling pathway 471 16928533 0,000 0,136 up 
FGFR4 Overexpr. kegg  insulin signaling pathway 421 16532453 0,004 0,143 up 
FGFR4 Overexpr. reactome  dag and ip3 signaling 542 16121129 0,006 0,166 up 
FGFR4 Overexpr. pathway interaction db  foxo pathway 455 14477632 0,038 0,283 up 
FGFR4 Overexpr. molecular signature db neighbourhood of egfr 486 18112922 0,000 0,017 up 
FGFR4 Overexpr. kegg  erbb signaling pathway 448 16314427 0,006 0,153 up 
FGFR4 Overexpr. pathway interaction db  erbb1 receptor proximal pathway 535 16491752 0,014 0,139 up 
FGFR4 Overexpr. reactome  pi3k events in erbb2 signaling 473 1462234 0,045 0,277 up 
FGFR4 Overexpr. reactome  signaling by erbb2 457 16867846 0,002 0,134 up 
FGFR4 Overexpr. reactome  grb2 sos provides linkage to 
mapk signaling for intergrins  
619 15648876 0,032 0,198 up 
FGFR4 Overexpr. pathway interaction db  myc represspathway 416 14346324 0,041 0,290 up 
FGFR4 Overexpr. literature8 growth factors 291 15379304 0,000 0,051 up 
FGFR4 Overexpr. molecular signature db neighbourhood of igfbp1 469 18355389 0,003 0,021 up 
solFGFR4 pathway interaction db  smad2, 3 pathway -445 -16881058 0,045 0,004 down 
FGFR4 Overexpr. reactome  regulation of insulin like growth 
factor igf activity by insulin like 
growth factor binding proteins 
igfbps 
755 19594024 0,000 0,009 up 
FGFR4 Overexpr. molecular signature db neighbourhood of igf1 615 22455778 0,000 0,000 up 
FGFR4 Overexpr. biocarta  igf1r pathway 512 14718565 0,043 0,277 up 
FGFR4 Overexpr. pathway interaction db  mtor 4pathway 499 17298361 0,004 0,110 up 
kdFGFR4 biocarta  igf1 mtor pathway -461 -16046475 0,000 0,002 down 
solFGFR4 biocarta  mtor pathway -387 -16303421 0,000 0,005 down 
kdFGFR4 biocarta  mtor pathway -562 -2946386 0,000 0,000 down 
kdFGFR4 pathway interaction db  smad2, 3 pathway -576 -21198254 0,000 0,000 down 
kdFGFR4 reactome  pkb mediated events -499 -21047058 0,000 0,000 down 
solFGFR4 signal transduction ke  erk1 erk2 mapk pathway -250 -13145965 0,000 0,058 down 
kdFGFR4 signal transduction ke  erk1 erk2 mapk pathway -389 -16336486 0,000 0,001 down 
FGFR4 Overexpr. biocarta  erk pathway 547 16009966 0,018 0,165 up 
FGFR4 Overexpr. reactome  p130cas linkage to mapk 
signaling for integrins 
601 15549306 0,047 0,206 up 
FGFR4 Overexpr. pathway interaction db  p53 downstream pathway 364 1408855 0,016 0,314 up 
DNA REPLICATION 
solFGFR4 kegg  dna replication -355 -16250973 0,000 0,005 down 
solFGFR4 reactome  scf skp2 mediated degradation 
of p27 p21 
-328 -17479932 0,000 0,002 down 
kdFGFR4 reactome  e2f mediated regulation of dna 
replication 
-320 -12472445 0,000 0,054 down 
kdFGFR4 biocarta  raccycd pathway -248 -10537288 0,000 0,195 down 
kdFGFR4 gene ontology  regulation of mitotic cell cycle -326 -11982346 0,133 0,040 down 
FGFR4 Overexpr. reactome  deposition of new cenpa 
containing nucleosomes at the 
centromere 
501 1692985 0,000 0,140 up 








































































FGFR4 Overexpr. reactome  meiotic recombination 442 16039301 0,008 0,166 up 
kdFGFR4 gene ontology cytokinesis -277 -14520413 0,000 0,009 down 
CELL ADHESION 
FGFR4 Overexpr. kegg  adherens junction 445 161398 0,004 0,166 up 
FGFR4 Overexpr. reactome  integrin alphaiib beta3 signaling 536 15740358 0,033 0,192 up 
FGFR4 Overexpr. reactome  signal transduction by l1 532 1608842 0,016 0,167 up 
FGFR4 Overexpr. signal transduction ke  integrin signaling pathway 397 14292204 0,036 0,293 up 
FGFR4 Overexpr. kegg  n glycan biosynthesis 455 14559896 0,039 0,280 up 
FGFR4 Overexpr. reactome  formation of fibrin clot clotting 
cascade 
487 14463629 0,046 0,277 up 
FGFR4 Overexpr. reactome  glycosaminoglycan metabolism 391 14483864 0,018 0,286 up 
FGFR4 Overexpr. kegg  cell adhesion molecules cams 334 16972758 0,000 0,031 up 
FGFR4 Overexpr. literature9 cell adhesion 354 14507823 0,031 0,082 up 
FGFR4 Overexpr. reactome  hs gag biosynthesis 518 1536494 0,049 0,221 up 
FGFR4 Overexpr. geneontology  leukocyte cell-cell adhesion 464 16197507 0,013 0,040 up 
FGFR4 Overexpr. reactome  chondroitin sulfate dermatan 
sulfate metabolism 
523 1618145 0,016 0,163 up 
MALIGNANT PHENOTYPE 
FGFR4 Overexpr. kegg  non small cell lung cancer 508 16354848 0,014 0,150 up 
FGFR4 Overexpr. kegg  endometrial cancer 487 15982684 0,014 0,166 up 
FGFR4 Overexpr. kegg  thyroid cancer 506 14910656 0,041 0,259 up 
FGFR4 Overexpr. pathway interaction db  upa upar pathway 527 16548454 0,006 0,147 up 
solFGFR4 biocarta  ndkdynamin pathway -326 -13396149 0,043 0,048 down 
kdFGFR4 molecular signature db breuhahn - growth factor 
signaling in liver cancer 
-237 -0, 922641 0,750 0,195 down 
 
1. The source of the geneset. 
2. The name of the geneset listed in the molecular signature database or gene ontology. 
3. ES: Enrichment score for the gene set is the degree to which this gene set is overrepresented at the top 
or bottom of the ranked list of genes in the expression dataset. 
4. NES: Normalized enrichment score is the enrichment score for the gene set after it has been normalized 
across analyzed gene sets.  
5. p-value: the statistical significance of the enrichment score not adjusted for gene set size or multiple 
hypothesis testing. 
6. FDR q-value: the estimated probability that the normalized enrichment score represents a false positive 
finding. 
7. up/down: whether the geneset is enriched in the up-regulated or the down-regulated portion of the array 
8. This geneset was constructed from literature and encompasses: AGT, AMBN, AMELX, AMH, 
ANGPTL3, AREG, ARTN, BDNF, BMP1, BMP10, BMP15, BMP2, BMP3, BMP4, BMP5, BMP6, 
BMP7, BMP8A, BMP8B, BTC, CD320, CECR1, CLCF1, CLEC11A, CSF1, CSF2, CSF3, CSPG5, 
CTGF, CXCL1, CXCL12, DKK1, EFEMP1, EGF, EREG, ESM1, F2, FGF1, FGF10, FGF11, FGF12, 
FGF13, FGF14, FGF16, FGF17, FGF18, FGF19, FGF2, FGF20, FGF21, FGF22, FGF23, FGF3, FGF4, 
FGF5, FGF6, FGF7, FGF8, FGF9, FIGF, GDF1, GDF10, GDF11, GDF15, GDF2, GDF3, GDF5, 
GDF6, GDF9, GDNF, GFER, GH1, GKN1, GMFB, GMFG, GPI, GRN, HBEGF, HDGF, HDGFRP3, 
HGF, IGF1, IGF2, IL10, IL11, IL12A, IL12B, IL1B, IL2, IL3, IL4, IL5, IL6, IL7, IL9, INHA, INHBA, 
INHBB, INHBC, INHBE, JAG1, JAG2, KGFLP1, KITLG, LACRT, LEFTY1, LEFTY2, LEP, LIF, 
MDK, MIA, NDP, NENF, NODAL, NOV, NRG1, NRG2, NRG4, NRTN, NTF3, NUDT6, OGN, OSM, 
PDGFA, PDGFB, PDGFC, PDGFD, PGF, PPBP, PROK1, PSPN, PTN, RABEP1, RABEP2, REG1A, 
TDGF1, TFF1, TGFA, TGFB1, TGFB2, TGFB3, THPO, VEGFB, VEGFC, VGF and WISP3. 
9. This geneset was manually constructed from literature and consists of: CEACAM6, L1CAM, EFEMP1, 
NCAM1, CHL1, VCAM1, DSCAM, TCAM1, DSCAML1, ECM1, CEACAM4, CEACAM5, SDK1, 








































































OPCML, ECM2, CEACAM7, GLYCAM1, ALCAM, CEACAM8, MATN1, SPON1, MADCAM1, 
CEACAM21, PECAM1, AMBN, NRCAM, COMP, CEACAM3, BSN, EFEMP2, MCAM, FREM1, 
ESAM, CEACAM1, CEACAM20, CEACAM19, SPON. 
 
 








































































Supplementary Table 6. Ingenuity Pathway Analysis of hepatoma/hepatocarcinoma cells showing 
FGFR4-overexpression or subjected to interference with FGFR4-mediated signaling by solFGFR4 
or kdFGFR4. The functional significance of differentially expressed genes was evaluated using 
Ingenuity Pathway analysis software (Ingenuity Systems Version 8.8, Redwood  City, CA; 
www.ingenuity.com). GenBank IDs of all genes with at least a two-fold change and p < 0.05 were 
imputed for network generation and pathway analyses and mapped to canonical pathways and  
functional networks available in the Ingenuity Pathway Knowledge Base. A score was determined for 
each network, reflecting the negative logarithm of the p-value based on the chance that the focus 
genes were grouped in the network by random chance.  Abbreviations: TCP, top canonical pathway; 
TN, top networks.  
 
TREATMENT Cat.  p-value Ratio Score 
METABOLISM 
solFGFR4 TCP 
Superpathway of Methionine 
Degradation                         
4,47E-07      15/65 (0,231)8)  
FGFR4 Overexpr. TCP Protein Ubiquitination Pathway 3,61E-06 99/270 (0,367)  
solFGFR4 TCP Protein Ubiquitination Pathway       7,49E-11      67/270 (0,248)  
kdFGFR4 TCP Protein Ubiquitination Pathway 3,67E-10 65/270 (0,241)  
solFGFR4 TN Small Molecule Biochemistry1)   369) 
kdFGFR4 TN Small Molecule Biochemistry1)   34 
Bile Acid & Phase I / II Metabolism 
FGFR4 Overexpr. TCP LXR/RXR Activation 4,05E-08 60/123 (0,488)  
FGFR4 Overexpr. TCP CAR/RXR Activation 1,93E-04 17/29 (0,586)  
FGFR4 Overexpr. TCP PXR/RXR Activation 1,15E-05 34/67 (0,507)  
FGFR4 Overexpr. TCP LXR/RXR Activation 1,47E-07 58/139 (0,417)  
kdFGFR4 TN Drug Metabolism 2)   34 
Carbohydrate Metabolism 
solFGFR4 TN Carbohydrate Metabolism 2)   36 
kdFGFR4 TN Carbohydrate Metabolism 2)   34 
Lipid Metabolism 
solFGFR4 TCP 
Superpathway of Methionine 
Degradation                         
4,47E-07      15/65 (0,231)  
FGFR4 Overexpr. TN Lipid Metabolism3)   27 
GROWTH FACTORS & SIGNALING 









































































Role of BRCA1 in DNA Damage 
Response                 
5,82E-10      26/71 (0,366)  
kdFGFR4 TCP 
Role of BRCA1 in DNA Damage 
Response 
3,6E-07 22/71 (0,31)  
solFGFR4 TCP 
Hereditary Breast Cancer 
Signaling                                   
6,32E-08      35/134 (0,261)  
solFGFR4 TCP p53 Signaling                                   3,34E-04      24/99  (0,242)  
kdFGFR4 TCP p53 Signaling 3,92E-03 21/99 (0,212)  
kdFGFR4 TCP ATM Signaling 1,6E-06 21/66 (0,318)   
solFGFR4 TCP 
Hypoxia-Inducible Factor 
Signaling                                    
9,56E-05      20/70  (0,286)  
FGFR4 Overexpr. TCP 
Production of Nitric Oxide and 






FGFR4 Overexpr. TN 
Cell-To-Cell Signaling and 
Interaction4) 
  27 
DNA REPLICATION 
solFGFR4 TN Cell Cycle, DNA Replication 5)    36 
kdFGFR4 TN Cell Cycle, DNA Replication 5)   34 
FGFR4 Overexpr. TN Cell Cycle, DNA replication 5)   27 
kdFGFR4 TCP 
Mitotic Roles of Polo-Like 
Kinase 
7,99E-09 26/74 (0,351)  
FGFR4 Overexpr. TCP 
Mitotic Roles of Polo-Like 
Kinase 
3,68E-06 35/74 (0,473)  
solFGFR4 TCP 
Cell Cycle: G1/S Checkpoint 
Regulation                            
7,66E-05      20/69  (0,29)  
kdFGFR4 TCP 
Cell Cycle: G1/S Checkpoint 
Regulation 
1,74E-03 17/69 (0,246)  
solFGFR4 TCP 
Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation     
3,29E-06      18/48  (0,375)  
kdFGFR4 TCP 
Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation 
5,48E-05 16/48 (0,333)  
kdFGFR4 TCP Liver Necrosis/Cell Death 1,56E-03 48/271 (0,177)  
FGFR4 Overexpr. TCP Liver Necrosis/Cell Death 1,25E-05 102/271 (0,376)  
CELL ADHESION 








































































FGFR4 Overexpr. TN 
Connective Tissue Development 
and Function 6) 
  27 
solFGFR4 TCP 
Remodeling of Epithelial 
Adherens Junctions                      
1,43E-08      26/70 (0,371)  
kdFGFR4 TCP 
Remodeling of Epithelial 
Adherens Junctions 
1,03E-06 23/70 (0,329)  
FGFR4 Overexpr.  Cellular Movement 7)   27 
MALIGNANT PHENOTYPE 
solFGFR4 TCP 
Hereditary Breast Cancer 
Signaling                                   
6,32E-08      35/134 (0,261)  
 
F13anonical Pathways 
1) Part of the TN: Carbohydrate Metabolism, Small Molecule Biochemistry, Nephrosis  
2) Part of the TN: Carbohydrate Metabolism, Drug Metabolism, Small Molecule Biochemistry 
3) Part of the TN: Developmental Disorder, Hereditary Disorder, Lipid Metabolism 
4) Part of the TN: Cell-To-Cell Signaling and Interaction, Cellular Assembly and Organization, Cellular 
Function and Maintenance 
5) Cell Cycle, Cellular Assembly and Organization, DNA Replication, Recombination, and Repair 
6) Part of the TN: Organ Morphology, Skeletal and Muscular System Development and Function, 
Connective Tissue Development and Function 
7) Part of the TN:  Dermatological Diseases and Conditions, Cell Cycle, Cellular Movement.  
8) indicates the ratio between deregulated genes to the total number of genes being grouped to a pathway 
given. 
9) A score of 2 corresponds with a 1 in 100 chance that the focus genes are grouped together by random 
chance. As such, scores of 2 or higher indicate at least a 99% confidence that a true molecular 
relationship exists. 









































































Human hepatocellular carcinoma and FGFR4-overepxressing hepatocarcinoma cells 
exhibit similar alterations in signaling cascades 
  
Following ligand binding and FGFR4 dimerization, the kinase domains transphosphorylate 
each other. As a result, several downstream pathways may be activated: RAS–RAF–MAPK, 
PI3K–AKT, signal transducer and activator of transcription (STAT), and phospholipase Cγ 
(PLCG) (Turner et al., Nat Rev Cancer 2010). FGFRs also phosphorylate ribosomal S6 kinase 
(Kang et al., Mol Cell Biol 2009). Signaling can be negatively regulated at several levels, e.g., 
by receptor internalization or the induction of negative regulators, including sproutys or 
MAPK phosphatases, which may interfere through modulation of the MAPK pathway (Turner 
et al., Nat Rev Cancer 2010).  
In FGFR4-overexpressing hepatocarcinoma cells enhanced phosphorylation of PLCG1 and 
ERK became evident, which indicates activation of the PLCG- and RAS-RAF-MAPK-
pathways (suppl.fig.3C and 3D). Interestingly, AKT phosphorylation appeared to be 
somewhat reduced. Analyzing the transcriptome of these cells and the subsequent validation 
of the data by qRT-PCR revealed deregulations of several further genes, involved directly or 
indirectly in FGFR4-mediated signaling, which is outlined in the following.  
In one of the clones we found elevated mRNA levels of 1-phosphatidylinositol-4,5-
bisphosphate phosphodiesterase gamma-2 (PLCG2). Like PLCG1, PLCG2 hydrolyzes 
phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2 or PIP2) to form inositol 1,4,5-
triphosphate and diacylglycerol. The former product promotes the intracellular mobilization 
of calcium, whereas the latter one activates protein kinase C isoforms. Generally, the 
functionality of PLCG isoenzymes is based on the products of phosphoinositide metabolism 
and phosphatidylinositol 4-kinase type 2-alpha (PI4K2A) phosphorylates PtdIns at the D-4 
position, an essential step in the biosynthesis of PtdInsPs (Barylko et al., JBC 2001). This 
indicates that apart from the enhanced phosphorylation of PLCG1 further components of the 
PLCG-pathway were affected occassionally by FGFR4-overexpression.  
With regard to the RAS-RAF-MAPK pathway, we found unchanged levels of the 
serine/threonine kinase, PDZ binding kinase (PBK), and enhanced expression of the target of 
rapamycin complex 2 subunit (MAPKAP1). PBK is related to the dual specific mitogen-
activated protein kinase kinase (MAPKK) family. Evidence suggests that mitotic 
phosphorylation is required for its catalytic activity (Gaudet et al., PNAS 2000). MAPKAP1 








































































binds to both ATF-2 and p38, enhances ATF-2-dependent transcription in the MAPK-
pathway and inhibits RAS-mediated signaling (Makino et al., Genes Cells 2006; Schroder et 
al., Cell Sign 2007). 
The activation of ribosomal S6 kinase by FGFR4 appeared to be active as well, since the 
ribosomal protein S6 kinase polypeptide 5 (RPS6KA5) wase found to be upregulated in two 
of three FGFR4-overexpressing hepatocarcinoma cell clones. As members of the RSK family 
of serine/threonine kinases it phosphorylates various substrates, including members of the 
mitogen-activated kinase (MAPK) signaling pathway. The activity of these proteins has been 
implicated in controlling cell growth and differentiation (Xing et al.,Science 1996). In 
response to growth factors or stress RPS6KA5 is activated by either ERK or SAPK2 proteins, 
which in turn mediates activation of the CREB (cAMP response element-binding protein) and 
ATF1 (Activating Transcription Factor-1). The growth-factor induced activation of RPS6KA5 
can be blocked by inhibitors for the MAPK pathways. Dual specificity protein phosphatase 26 
(DUSP26) inactivates MAPK1 and MAPK3 which leads to dephosphorylation of heat shock 
factor protein 4 and a reduction in its DNA-binding activity. In dependence of the context, 
DUSP26 can also induce activation of MAP kinase p38 and c-Jun N-terminal kinase (Yu et 
al., Oncogene 2007). The level of this gene appeared to be altered by FGFR4-overexpression.  
Also couterregulations appear to be active. Li et al (Mol Cell Biochem 2008) show that zinc 
finger protein 418 (ZNF418) is a transcriptional repressor with the KRAB motif as the basal 
repressive domain. Overexpression of ZNF418 inhibits the transcriptional activity of SRE and 
AP-1 and may act as a negative regulator in MAPK signaling pathway. Phosphoinositide-3-
kinase-interacting protein 1 (PIK3IP1) shares homology with the p85 regulatory PI3K 
subunit.  It directly binds to the p110 catalytic subunit and down modulates PI3K activity 
(Zhu et al., Biochem Biophys Res Commun 2007). The upregulation in clone 4 may explain 
the somewhat reduced phosphorylation of AKT (see suppl.fig. 3C and 3D).  
In samples of human hepatocellular carcinoma (HCC) we studied the expression of genes, 
which were found to be deregulated in FGFR4-overexpressing clones. We discriminated 
between HCC with low and high FGFR4-expression. In the latter group mRNA deregulations 
of PLCG2, PI4K2A, MAPKAP1, DUSP26, ZNF418, and PIK3IP1 were evident. This may be 
indirect evidence that in FGFR4-overexpressing HCC and FGFR4-overexpressing 
hepatocarcinoma cells similar signaling cascades are activated.   
 
Supplementary Table 7. FGFR4-overexpressing hepatocarcinoma cells and human hepatocellular 








































































carcinoma (HCC): Expression of genes related to FGFR4-mediated signaling. Details on FGFR4-
overexpressing clones and vector controls see figure 2. Patients were subjected to surgical resection 
of HCC. Written informed consent was obtained from each patient. The study protocol conformed to 
the ethical guidelines of the 1975 Declaration of Helsinki, as reflected by the approval of the “Ethic 
Committee of the Medical University of Vienna”. Details on age and sex of the patients, 
histopathological grade and pTNM stage of HCCs see below. Abbreviations: m, male; f, female; 
HCC1, HCC grade 1; HCC2, HCC grade 2. The classification of the tumour grade followed the 
criteria published by Edmondson et al. (Cancer 7: 462-503, 1954). For further details see Gauglhofer 
et al. (Hepatology, 2011). Messages were quantified by real time RT-PCR using assay kits (Applied 
Biosystems) according to the manufacturers instructions. For details see Methods. Bold numbers 
indicate message levels in HCC elevated at least 1.5-fold above the levels in the surrounding tissue or 
vector control.   
Expression in FGFR4‐overexpressing clones (x vector control)a) 
  FGFR4  PLCG2  PI4K2A  PBK  MAPKAP1  RPS6KA3  RPS6KA5  DUSP26  ZNF418  PIK3IP1 
Clone 1  10,4  0,13  0,61  0,85  0,83  0,86  0,55  0,64  1,07  0,17 
Clone 3  18,3  0,56  1,32  0,43  2,27  1,27  1,8  1,08  7,27  0,47 
Clone 4  16,5  4,61  2,76  1,33  2,14  1,26  3,56  0,72  8,77  1,59 
Expression in HCC (x surrounding tissue)b)






























3,3  1,85  1,77  1,52  1,85  1,19  1,32  0,08  0,14  1,81 
                         





































































































0,6  2,12  1,15  0,62  0,78  0,62  1,09  3,19  0,29  2,24 
 
a) The expression level in FGFR4-overexpressing clone, relative to that in the vector control, has been 
expressed as 2−deltadeltaCT, which reflects deltaCT of the FGFR4-overexpressing clone minus deltaCT of 
the vector control (normalized to 1). 
b) The expression level in HCC, relative to that in the surrounding liver tissue, has been expressed as 
2−deltadeltaCT, which reflects deltaCT of the HCC minus deltaCT of the surrounding non-tumorous liver 
tissue (normalized to 1).  
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